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ABSTRACT
Triazole Based Peptidomimetics for Mimicking Protein-Protein Hot Spots.
(August 2007)
Yu Li Angell, B.S., Wuhan University
Chair of Advisory Committee: Dr. Kevin Burgess
Copper-mediated alkyne-azide cycloadditions yield 1,4-disubstituted triazoles
with high chemoselectivity that can be used in many ways.  For instance, when alkyne or
azido peptide units combine via this pathway the reaction is relatively insensitive to the
amino acid side-chains.  This serves as an excellent way to produce peptidomimetics,
particularly because there is some stereoelectronic similarity between 1,2,3-triazoles and
amide bonds.
Linear peptidomimetic substrates 60 were used to form the cyclic derivatives 61
via copper catalyzed azide alkyne cycloadditions.  This reaction is fast, simple to perform
and compatible with many solvents and functional groups. A library of eight cyclic
peptidomimetics was prepared in solution and the low yield was mostly due to formation
of dimers.  Computational, NMR, and CD analyses of compounds 61a-c indicate that
their most favorable conformational states include type I and type II β-turn
conformations.
Monovalent triazole mimics were prepared via cycloaddition reactions in solution.
These triazole compounds contain two amino acid chain functionalities at 1- and 4-
positions.  One is derived from a natural amino acid and the other is a functional group
that resembles the side chains of an amino acid.  The 1,3-dipolar cycloaddition reactions
allow quick and efficient generation of the desired peptidomimetics in good yields.
Two monovalent mimics were coupled to the linker scaffold sequentially in
solution by simply manipulating the solvent systems.  This method allows us to prepare
large libraries of bivalent compounds quickly and efficiently.  The two monomers were
iv
combined with each other cleanly, to achieve one-compound-per-well in sufficient purity
for biological testing.
Oxidative coupling to give 5,5’-bistriazoles is discussed.  The bistriazole products
predominate in the copper accelerated “click reaction” of alkynes and azides when
carbonate bases are used as additives (ca 1 – 2 M).  The reaction seems to be more
efficient for propargylic ethers and less hindered substrates.  Use of optically active
azides could afford separable atropisomeric products, providing a convenient access into
optically pure derivatives.
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1CHAPTER I
INTRODUCTION
1.1 Copper-catalyzed Azide-alkyne Cycloadditions
Huisgen 1,3-dipolar cycloaddition reactions of alkynes and organic azides are
well known and have numerous applications in synthetic organic chemistry.1,2  This
transformation has the advantage of high chemoselectivity since few functional groups
react with azides or alkynes in the absence of other reagents.  However, it has the
limitations associated with any process that requires heat, and, more importantly, that
produces two regioisomers (1,4 and 1,5) as illustrated in Figure 1.1a.
a.
R1 + N N
N
R1
R2
N N
N
R1
R2
poor regioselectivity
+N N R2-N
1
1
54ca. 80 °C
+
b.
R1 + +N N R2-N
cat Cu(+1)
N N
N
R1
R2
14
one regioisomer
Figure 1.1.  (a) Huisgen 1,3-dipolar cycloaddition reactions; (b) copper-catalyzed “click
reactions”.
____________
This dissertation follows the style of the Journal of Organic Chemistry.
2It is rare that contemporary science uncovers a very simple modification of a
classical “named reaction” that dramatically improves its value, but in the case of the
Huisgen cycloaddition, this happened. The groups of Meldal3 then Sharpless,4
independently, found copper (I) catalysts dramatically accelerate the reaction and make
it totally regioselective for the 1,4-isomer (Figure 1.1b).
Sharpless and his co-workers have published many high quality papers to alert
the scientific community to the value of copper-catalyzed cycloaddition reactions.  They
coined the term “click chemistry” to describe this and ones like it that proceed in very
high yields and that almost invariably work.  There are, in fact, too few transformations
that fit these criteria in organic chemistry!  Click reactions in general have been
reviewed,5,6 and there is one review specifically on copper-catalyzed azide-alkyne
cycloadditions.7
Here, this introduction approaches the area with one focus: peptidomimetics.  We
are interested in combinatorial and/or high throughput syntheses of peptidomimetics of
potential value in medicinal chemistry.  Reaction in Figure 1.1b has several attributes
that are highly attractive in this regard, specifically it:
• gives the 1,2,3-triazole nucleus that is a likely candidate for small molecule
drugs;
• is compatible with the side chains of all the amino acids, at least in protected
form;
• can potentially give high yields of products with few by-products; and,
• the molecular dimensions of the 1,4-disubstituted 1,2,3-triazoles are somewhat
similar to amide bonds in terms of distance and planarity.
3N
H
COOHH2N
R1
R2O
N
NN
R2
COOH
H2N
R1
3.9 Ao
5.1 A
o
Potential pharmaceuticals based on 1,2,3-triazoles include the anti-cancer
compound CAI8 and the nucleoside derivative known as TSAO,9 a non-nucleoside
reverse transcriptase inhibitor.  Both these compounds are (or have been) in clinical
trials.
O
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Cl
Cl
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H2N
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H2N
O O
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N
N
N
O
NMe2
TSAO
4Meldal and co-workers were the first to begin to address the compatibility of
protected amino acid side-chains with the featured copper-mediated click reaction.
Figure 1.2 illustrates how various solid-supported tripeptides were reacted with an azide
to give high product yields via HPLC analyses.  These purities reflect the efficiencies of
the cycloaddition and the base-mediated cleavage reaction together.  To the best of our
knowledge there has been no such systematic study featuring unprotected side chains,
but research in our lab has indicated most amino acids side chains are compatible.
O
AA Phe Gly
(i) 2-azido-2-methylpropionic acid
CuI, EtiPr2N
(ii) 0.1 M NaOH (aq)
O
AA Phe Gly OHN
N NHO
O
Me Me
AA = Ala, Pro, Thr(tBu), Tyr(tBu), Asp(tBu), Asn(Trt), 
          His(Trt), Cys(Trt), Met, Lys(Boc), Trp(Boc), Arg(Pmc)
HMBA-PEGA800
Pmc = S
O
O
O
Figure 1.2.  Chemoselectivity of “click reactions”.
1.2 Mechanism
The mechanistic interpretation shown in Figure 1.1 is supported by kinetic
studies,10 product distributions for specialized substrates,10 and DFT calculations.11
5N
N
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CuLn-1 N
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R1 H
[LnCu]
R1 CuLn-1
N NN R2
R1 CuLn-2
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Figure 1.3.  Putative mechanism of the copper-mediated click reaction of alkynes and
azides from DFT calculations.
Kinetic studies indicate the reaction is second order in the Cu(1+) source when
present at low concentrations; aggregates of the metal may form at higher
concentrations.  Under typical conditions, the reaction is not precisely first order in
alkyne, but it is in the azide component.  These observations lend support to the assertion
that the reaction may involve rapidly equilibrating copper-alkyne complexes.  Product
inhibition does not tend to be prevalent in these reactions.
Experiments with constrained diazides show the reaction is difficult to stop even
if only one equivalent of alkyne is used.  This implies an intermediate involving only
one triazole unit can be more reactive than the starting diazide.  However, similar
experiments with constrained alkynes do accumulate monotriazole intermediates.  These
observations should not be over-interpreted, but they do imply that monotriazole
intermediates can react significantly faster if an azide is held proximal than in cases
where an alkyne group is.
6Postulated mechanisms have been tested using DFT calculations, and the
theoretical data indicates the reaction pathway shown in Figure 1.3.  It is important to
note that other evidence points to the possible involvement of dicopper (and higher
order) species; this was not tested in the DFT calculations because it is computationally
difficult to do so.   Nevertheless, these calculations provided several valuable insights
into the reaction.  They indicate that π-complexation of terminal alkynes greatly
increases the acidity of the spC-H (“by up to 9.8 units”).  Displacement of water ligands
by alkynes is thermodynamically much more favorable than if an acetonitrile is
liberated.  Finally, theory supports the 6-membered metallocycle intermediate A and its
contraction to the C-ligated triazole B.
1.3 1,2,3-Triazoles in Close Analogs of Peptides
Some molecules have been made wherein a 1,2,3-triazole is a genuine surrogate
for an amide bond, while others have an amide in cyclic structures where the analogy to
a cyclic peptide maybe more tenuous.  Both these types are covered in this section.
1.3.1 Acyclic Compounds
Meldal’s group prepared a huge library of compounds (over 400,000) via a split
and mix approach, then screened them on resin.12  Figure 1.4 shows the basic structure
of the compounds that they produced.  The resin was first masked with two different
protecting groups (Aloc- and Fmoc-based).  It was the Fmoc-protected arm that was
subjected to most of the chemical changes.  This was functionalized with a photolabile
linker (Figure 1.4a), then with a peptide chain “Mis” (Figure 1.4b) designed to enhance
the response of the photocleaved material to MALDI-MS analyses.  Two randomized
amino acids were coupled onto the N-terminus of this chain, the last one to be coupled
being a propiolic acid amide.  Copper-mediated cycloadditions were then performed
using the Fmoc-protected, amino acid derived azides shown in Figure 1.4c.  Finally, two
more randomized amino acids were coupled.  For each coupling step the Fmoc protected
amino acids, and the azide in the click reaction, were doped with 10 % of the
corresponding Boc-protected materials.  These were, of course, not deprotected in the
7piperidine-mediated steps, so a ladder of nested chain-terminated segments was
produced as the synthesis evolved.  Consequently, photocleavage and MS analysis of the
chain revealed the sequence of monomers added via a series of mass differences.  This
so called “MS-laddering” technique13-15 allows peptidomimetics on “active-beads” to be
characterized.  Thus the “Fmoc-arm” of the construct is shown in Figure 1.4d.
a
O2N O
H
N OMe
O
(  )3
b
NH Thr(tBu) Ile Ser(tBu) Arg(Pmc) Thr(tBu) Ile
c
FmocHN
R
N3
H
N NH2
NPmc O
tBu
O
S Ph H
R =
d
H AA1 AA2 N
H
R
N
N N
O
AA3 AA4
H
N
 = PEGA1900
Mis linker
inhibitor
Mis = mass/ionization spacer
Figure 1.4.  Meldal’s split and mix construct, showing the: (a) photolabile linker; (b)
Mis chain for enhanced MS detection; (c) generic structure of the azide components in
the click reaction; (d) “Fmoc-arm”.
8The “Aloc-arm” of the construct was modified using orthogonal protecting group
chemistry to give a peptide substrate for the target enzyme: a protease from the parasite
Leishmania mexicana.  This had an N-terminal 3-nitro-Tyr quencher and a C-terminal
fluorescent group (2-aminobenzoic acid on a Lys side-chain) so that on cleavage by the
protease the beads would fluoresce, ie when the quencher-containing N-terminal part
was cleaved.
The beads in Meldal’s construct function as “microreactors”.  When an inhibitor
of the enzyme is produced in the split synthesis, the substrate is not cleaved, and the
bead does not fluoresce.  Most sequences in the split and mix procedure however give
cleaved substrates and fluorescent beads.  Screening gave a range of “hit” substances,
which were characterized by MS.  Statistical analysis of the structures of these then led
to consensus sequences that were re-prepared and characterized in solution.
Data that emerged from the work shown in Figure 1.4 revealed that the target
protease had an affinity for the Mis sequence; this is unfortunate because the only role of
that sequence was to enhance MS binding.  In retrospect this design weakness could be
avoided, but to rectify the flaw the whole library would have to be prepared again.
Overall this teaches an important lesson: simple encoding strategies tend to be best.  If
the complexity of the encoding molecules rivals that of the probe compound then this
invites experimental difficulties.
One of the motivations for interest in compounds containing triazole and peptide
segments is to prepare synthetic analogs of peptides with perturbed secondary structures.
A straightforward illustration of this idea is shown in Figure 1.5.16  In that work click
chemistry was used to combine azido- and alkyne-functionalized peptides to give
putative β-turn mimics.  The secondary structures of these compounds were examined in
chloroform, and showed NOE crosspeaks, temperature/concentration variations of NH
chemical shifts, and FTIR data that are consistent with a small sheet-like structure.  Of
course, hydrogen-bonding effects are accentuated in non-protic media, so it remains to
be established that these constructs are secondary structure mimics in aqueous solutions.
9N3
+
"click chemistry" N
N N
N
N N
N
N
O
H
N
N
O
H
OH
O
H NOE crosspeaks
Figure 1.5.  Construction of a β-sheet mimic.
Proline-derived triazoles like 1 have been synthesized via click reactions.  These
molecules were of interest as surrogates for dipeptide segments to see how the triazole
impacts cis/trans proline-amide bond ratios.17
N
OO
N
NN
O
OEt
1
Access to triazole-based peptidomimetics is greatly facilitated by a relatively
convenient azo-transfer reaction18 that generates 2-azido acids from α-amino acids19 or
protected derivatives of these (Figure 1.6). This azo-transfer reaction tends to proceed
without racemization of the amino acid chirality, even for peptide segments with one
10
free amine group.  Further azido acids can be activated and coupled to the N-terminus of
a peptide without significant racemization.19
Fmoc Pro
(i) 20% piperidine, DMF
(ii) N3-Tyr, DCC, HOBt, DMF
Tyr ProN3
Wang
(i) trimethylphosphine 
Fmoc-Val-OSu, dioxane
(ii) TFA/CH2Cl2 (1;1)
Tyr ProValFmoc OH
Figure 1.6.  Solid phase peptide synthesis by azo-transfer reactions.
Using this azo-transfer reaction, Ghadiri and coworkers20 explored click-
combinations of C-terminal propargyl peptides with α-azido-acids to give dipeptide
surrogates (Figure 1.7).   Thus the L-Leu-derived triazole ε2 - amino acid was substituted
to give sequences in the pLI-GCN4 sequence to test if the mimics retained the native α-
helical character.  Mimic 2 in the solid state had a disordered structure about the triazole
segment (X-ray), but 3 and 4 had helical structures in the peptide region.  Like GCN4,
peptide-mimics 2 and 4 formed tetramers in solution (as seen via gel permeation
chromatography; presumably these are a four-helix-bundles), whereas 3 self-assembled
into structures with two helices packed against each other.
11
N
H
H
N
O
OR
N
O
N N
N
H
Ac-RMKQIEDKLEEILSKLYHIENELARIKKLLGER-OH (pLI-GCN4)
Ac-RMKQIED-XEEILSKLYHIENELARIKKLLGER-OH  2
Ac-RMKQIEDKLEEILS-XYHIENELARIKKLLGER-OH  3
Ac-RMKQIEDKLEEILSKLYHIEN-XARIKKLLGER-OH  4
X
Figure 1.7.  Triazole-based dipeptide surrogates in GCN4 mimics.
The research described above investigates the effect of placing single triazole-
based amino acid surrogates in large peptides.  At the other extreme is the use of several
triazole-based residues in series.  Trimeric molecules of this kind have been made
wherein both the alkyne and azide fragments are derived from amino acids (Figure
1.8).21  This is unlike the work above where the alkyne fragment was propargyl amine, ie
did not have an amino acid side chain.  It was recognized that the triazole units have
distinct dipole moments, and conformers of oligomers containing them could be termed
syn or anti based on the orientation of these dipoles.  In fact the tripeptide derivatives
prefer “zig-zag” conformations in the solid state (X-ray) and in DMSO solution (NMR)
wherein the dipoles are opposite.
12
a
N N
N
H
N
N
N
H
RH
N N
N
H
N N
N
RH
anti 1 syn 1
H
N N
N
H
N
N
N
H
R
N N
N
H
N N
N
R
anti 2 syn 2
H
HH
b
N
N
N
N
N
N
BocHN
N
NN
H
NHCbz
H H
COOMe
H
H
Ph
H
H
Ph
NHCbz
w
s
w
s
w
s
Figure 1.8.  Trimers of triazole-based amino acid surrogates: (a) must accommodate
dipole moments of the triazole units; and, (b) appear to do this in zig-zag conformations
that keep the dipoles anti (W = weak, S = strong).
In between the two extremes of isolated triazole-based residues and several in
series, are molecules with alternating triazole and amide linkages: these have also been
investigated, to some degree.22  Using solid phase syntheses to connect pentynoic acid 5
and the Fmoc protected amino-acid azides 6 it proved possible to prepare systems like 7.
Copper(1+) iodide and ascorbic acid combinations (DMF/piperidine) were found to be
the most effective for formation of the triazole units.
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1.3.2 Formation of Peptide-peptide Linkages
Orthogonal chemoselectivities for amino acid coupling reactions and the copper-
catalyzed click-reaction can be useful for joining two peptide fragments.23   Figure 1.9
shows a simple illustration where a supported alkyne was joined to a peptide with an N-
terminal azide fragment.  A more elaborate example of this ligation method is given in
Figure 1.10.  Here the cyclic protected peptide 8 has peripheral nitro, NHivDde, and
14
NHAloc groups.  These were selectively converted to free amines under different
conditions, coupled with alkyne-containing acid fragments, then “clicked” with N-
terminal azidopeptides.  Deprotection of the amino acid side chains and cleavage from
the trityl-based resin gave the multimeric peptide 9.  The exact application of this
particular product was not revealed.
O
XAFK
(ii) cleavage
N
N
N
O
O
TSKYREG-OH
XAFK-NH2
X = C, D, E, G, H, M, N, Q, R, S, T, W, Y
N3 TSKYREG-OH
O
(i) CuI,
Figure 1.9.  Triazoles serve as linkages between peptides.
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Figure 1.10.  Supported alkynes were joined to a cyclic peptide with N-terminal azide
fragments.
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1.3.3 Cyclic Compounds
One compelling advantage of the orthogonal nature of the Cu-mediated
alkyne/azide couplings is that they can be used to prepare cyclic peptides.  Meldal and
coworkers have done this to make an analog 10 of a disulfide-containing cyclic
peptide.24  They used their poly(ethylene glycol)-based amino polymer resins, which
have excellent swelling characteristics in water. Cyclic product 10 was obtained with
high purity and yield via two methods.  In the first, the side-chains were deprotected and
the supported peptide was cyclized via the Cu-mediated reaction, then cleaved from the
resin.  In the alternative procedure, the side-chain protection was removed after the
cyclization.  Both approaches gave over 70 % yield of HPLC-purified product.  No
mention of any dimerization products was made, even though such products can be
prevalent, as described in the next section.
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Compound 10 was the expected product (type A) from a click-mediated
macrocyclization reaction.  However, a surprising number of papers have reported
macrocyclic dimers B as prevalent products in similar processes.  This sub-section
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discusses those examples and the possible origins of this anomaly.
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A spectacular demonstration of this macrocyclodimerization effect featured two
resin-bound 19-amino acid peptide molecules 11 combining into a 38-residue cyclic
peptide 12 where 36 amino acid residues are in the ring.25 (Figure 1.11)  This cyclization
required a certain density of molecules on the resin; if the supported concentration was
too dilute then it failed.  Attempts to form a similar ring system but via closure with
amide bond formation also were largely unsuccessful, indicating the peptide sequence
itself is not predisposed to cyclize.  Yields of the cyclodimer were reduced when more
than 0.5 equivalents of copper were used, and the process was completely interrupted if
an excess of a simple alkyne (but not of an azide) were included.  Thus the
cyclodimerization seems to be favored by low catalyst concentrations, and bringing
alkyne units into proximity was more important than it was for the azides.  In 11 the
azide and alkyne are on the N- and C-termini, respectively, but this did not seem to be
critical because a model peptide with reversed orientation also cyclodimerized well
18
(though some more monomer was formed, data not shown).  On the basis of these
observations it was proposed that the reaction proceeds via two alkynes bound to a
dicopper intermediate where the azide units interact with the Cu-atom that is not
attached to the alkyne of the same substrate.
GEARTAFTDGRIAHDNMK
HN
NHP
O N3
(i) CuI, Na ascorbate
2,6-lutidine
(ii) TFA, triisopropylsilane
1,2-ethanedithiol
F CO2
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NH F
O
N
N
N
G E A R T A F T D G R I A H D N M
HN O
N
N
N
F
COOH
HOOC
11
12  10 - 15 %
Wang
resin
K
Figure 1.11.  Preparation of a 38-residue cyclic peptide from cyclodimerization reaction.
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Another surprisingly efficient macrocyclodimerization reaction occurred in
syntheses of carbohydrate/amino acid hybrids as artificial receptors for small
biomolecules.  This time the click reactions were solution phase ones.26 Various
conditions were evaluated, and CuI combined with N,N-diisopropylethylamine in
acetonitrile was best.  Two similar substrates were investigated.  These only differed by
one amino acid residue, and both cyclized well (64 and 33 % before deprotection);
Figure 1.12 shows the most efficient (the yield for the other was 33 %).
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OMe (i) CuI, EtiPr2N
(ii) NaOMe
HN Tyr Tyr
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N
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O OMe
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Figure 1.12.  Syntheses of carbohydrate/amino acid hybrids.
Cyclic ditriazole 14 forms nicely organized nanotube structures in the solid state
in which these doughnut-shaped molecules pack on top of each other via H-bonds.
Originally monomers 14 were prepared via an amide bond forming reaction from linear
peptidomimetic 13 (the yield for that step was 65 %).27  Conversion of the alkyne/azide
15 into that same product was vulnerable to simple cyclization and to formation of
20
polymeric products.  However, in the event, the macrocyclodimerization of the N-
protected substrate 15 was shown to be quite efficient.  A 94:6 mixture of the desired
product 14 and the corresponding cyclotrimer was formed in this process, from which 14
was isolated in 80 % yield.28
Another solution-phase illustration of macrocyclodimerization in this area
featured eight different azidoalkyne dipeptide substrates 16, prepared via solution phase
methods.29  Mixtures of the monomeric and dimeric products 17 and 18 formed when
these substrates were subjected to the copper-mediated bis-triazole formation reaction.
The ratios of monomer-to-dimer ranged from 54:46 to 18:82, and the dimeric product
was prevalent in all but one case.
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Based on the examples given above, formation of macrocyclodimers can be
expected, but it will not always occur.  For example, compound 19 was one of four
similar compounds prepared via Cu-mediated triazole formation to close 12- to 17-
membered rings.   No macrocyclodimers were observed in these cases, even though the
researchers looked for them.  Compound 20 is a 1,5-disubstituted triazole formed via the
Cu-mediated process.30  This is highly unusual for this type of reaction.  It is tempting to
assume that this product formed because of some particular constraint that prevented
formation of the expected 11-membered ring.  However, if that is the case, then a similar
stereoelectronic constraint prevented formation of the macrocyclodimer from 1,4-
triazoles.  Clearly there are some unresolved issues surrounding this work.
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Another anomaly is the synthesis of the cyclic triazole tetrapeptide 21 (a
potential tyrosinase inhibitor).31  Attempted cyclization by peptide bond formation at
room temperature failed to provide the desired product: mixtures of dimers and higher
oligomers were obtained.  The copper (I) catalyzed azide-alkyne coupling was
successful but only at 110 oC; the triazole tetrapeptide 21 was isolated in 70 % yield
under these conditions.  It is surprising to us that the reaction took such a high
temperature (intermediate temperatures were also studied), and that no macrocyclodimer
was observed.
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At least one other example of a macrocyclization reactions that gives only cyclic
monomers has been reported.  This did not involve peptides or peptidomimetics.32
1.4 Compounds With Triazole Links to Other Functionalities
1.4.1 Carbohydrate- peptide
Glycopeptides are important compounds with a range of biological functions.
Native O- and N-linked glycopeptides are relatively unstable to hydrolysis, but C-linked
isosteres are far more robust to chemical and enzymatic degradation.  They have
potential as probes for glycopeptide biological activities and as drug candidates for
diseases involving carbohydrate-based metabolic disorders.
C-Linked glycopeptide analogs like 23 can be formed very conveniently via Cu-
mediated cycloadditions to carbohydrates with anomeric alkyne groups, eg 22.  This
type of chemistry has been investigated by at least two groups using glucose- (Figure
1.13) and galactose-based starting materials.33-35
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Figure 1.13.  Synthesis of C-linked glycopeptide analogs.
N-Linked glycopeptides 25, where the N-atom is part of the triazole, can be
formed by reversing the orientation of the two functional groups in the Cu-mediated
reaction.  Thus, glycosidic azides, like 24, can be coupled with alkyne-containing amino
acids to give carbohydrates where the triazole is attached to the anomeric position
(Figure 1.14).
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X = Ala, 51 %; Pro, 92 %
X NHBoc
Figure 1.14.  Synthesis of N-linked glycopeptide analogs.
Anomeric azides36-40 and unsaturated amino acid derivatives41 are readily
accessible so this chemistry has quite a wide scope.  Indeed, one of the easiest ways to
prepare unsaturated amino acids is to add an N-propargyl group; such substrates have
also been investigated as click partners to make glycopeptide analogs like 26.42
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N N
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26  77 %
Mono- and disaccharide alkylating agents 27 and 28 have been prepared via the
Cu-mediated click process, and used to couple with cysteine residues in a peptide.
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Glycopeptide analogs produced in this way are compatible with native ligation methods
involving C-terminal thioesters and N-terminal Cys-residues.  Large peptides containing
several unnatural S-linkages to carbohydrates have been prepared in this way.43
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One of the most elaborate routes to glycopeptide analogs has been reported by
Lin and Walsh.44  They were motivated to prepare glycosylated forms of the cyclic
peptide antibiotic known as tyrocidine or “Tyc”.  To do this, about 17 linear
decapeptides were prepared on a solid phase having the Tyc sequence except that one,
two or three propargyl glycine residues had been substituted at select positions.  These
linear peptides were derivatized as N-acetyl cysteamine esters to facilitate
chemoenzymatic cyclization using the excised thioesterase domain of tyrocidine
synthetase.  This afforded a small library of cyclic peptides containing one to three
propargyl side chains.  These were reacted with 21 different azidomonosaccharide
derivatives to give a range of glycosidated Tyc analogs having triazole-based linkages to
the sugar parts (Figure 1.15).
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Figure 1.15.  (a) Tyrocidine; and (b) some of the analogs prepared.
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Another way to take advantage of the exquisite chemoselectivity of the copper-
mediated cycloaddition reaction is to conjugate carbohydrate based antigens onto
peptide substrates.  The Danishefsky group has done this for a model peptide system,
and infer that the same approach will work for proteins.45  In this study, the model
peptide system 29 was coupled with a trisaccharide antigen to provide the immunogenic
conjugate 30.  If this approach is to be applied to proteins, it requires chemoselective
introduction of alkyne or azide groups otherwise the labeling is non-uniform.
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Carbohydrates can also form the basis of macrocyclic molecules for molecular
recognition.  Compound 31 is representative of a molecule prepared for this purpose.46
It has a fluorescent reporter group (anthracene-based) which forms a hydrophilic face
with the two triazole units.  No specific target was suggested for this potential host
molecule, though clearly the amino acid and sugar units might be varied to
accommodate different hosts.
31
N
N
N
NH
NH
O
O
NH
HNN
N N O
OtBu
O
O
OtBu
O
O
HO
HO OMe
Finally, less peptidic peptidomimetics can also be fused to carbohydrate residues
using the Cu-mediated reaction.  An illustrative example is compound 32 wherein a
conformationally restricted analog of the Ala-Pro dipeptide was joined with a glucose-
based azide (and with fluorescein and biotin in other experiments, not shown).47
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1.4.2 Organic- peptide
Alkyne- or azide-modified peptides can be transformed into a variety of
structures beyond glycopetide analogs.  The last section briefly mentioned cases in
which Cu-mediated cycloadditions were used to add biotin and fluorescein: these are
clearly two very useful types of molecular probes for bioconjugation.  The Cu-promoted
process also provides convenient access to structural diversification for medicinal
chemistry.  For instance, cis-4-azidoproline was substituted for the Pro6 residue in the
dodecapeptide RINNIPWSEAMM to allow for preparation of a range of analogs via the
Cu-promoted reactions with azides.  Routine peptide synthesis methods were used to
incorporate this azido-residue.  The parent sequence was discovered via phage display; it
binds to the gp120 protein of HIV-1 and prevents the HIV virus docking with CD4 cells.
Preparation of over 20 derivatives via Cu-mediated click chemistry, and testing these for
gp120 binding revealed addition of phenyl acetylene as shown in Figure 1.16 gave
approximately a 500-fold increase in binding.48
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Figure 1.16.  Preparation of triazole derivative of dodecapetide.
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Incorporation of azidoproline residues is quite a specialized modification; it is
essentially only valuable for parent peptides containing proline and for modifications at
that position.  On the other hand, one of the simplest and most general approach to
peptidomimetics of extended peptides is to couple propiolic acid to either the N-terminus
or the to the side chains of Lys or Orn residues, then make modifications via the Cu-
mediated cycloaddition process.  This was done, for example, to peptide chains
containing the SIINFEKL sequence (a major histocompatiblity {MHC} class 1 epitope)
to access derivatives 33 and 34 with conjugated 2-alkoxy-8-hydroxyadenine entities.49
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1.4.3 Polymer- and Dendrimer- peptide
Most amphiphilic molecules are relatively small structures, like detergents.
However, it is possible to make “amphiphilic-nanostructures” containing large, water-
soluble, biomolecules attached to lypophilic polymers of a comparable size.  Copper-
mediated cycloaddition reactions provide a convenient way to do this.  In the example
shown in Figure 1.17, bovine serum albumin was attached to a polystyrene fragment via
this approach.  Aggregates of the product molecules 35 were visualized via various
microscopy techniques (SEM and TEM).50
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Figure 1.17.  Bovine serum albumin was attached to a polystyrene fragment.
Polyesters are less chemically stable than polystyrene derivatives, but the
conditions for Cu-mediated cycloadditions are sufficiently mild for their elaboration.
Consequently, the polyester 36 from e-caprolactone was efficiently grafted with the
RGD-containing azidopeptide G peptide to give the biomaterial 37 without a significant
change in the polydispersity.51
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Click reactions can be used to elaborate dendrimers.  Sharpless, Fréchet and co-
workers used alternating Cu-mediated cycloadditions and SN2 substitutions to build up
dendrimer cores.52  So far, in the area of peptidomimetics, the Cu-mediated
cycloadditions have only been used to add peptide residues to dendrimer surfaces.  Thus,
multivalent dendrimeric peptides like 38 were synthesized.  The coupling reactions were
slow and not high yielding under the regular conditions.  However, microwave
irradiation for 10 min to generate a temperature of 100 °C greatly accelerated the process
and yields as high as 94 % for a fourth generation system elaborated with eight end
35
groups.  Azide derived amino acids, linear- and cyclic peptides were coupled.53
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Chloromethylpolystyrene and similar supports are easily transformed into the
corresponding azides via simple nucleophilic displacement reactions.  The azido resins
so produced can be further functionalized by click reactions to add linkers.  Figure 1.18
shows how this approach was used to prepare a indole-based backbone amide linker 39
(BAL).54,55
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Figure 1.18.  Indole-based backbone amide linker.
1.4.3 Conjugates of Metal Complexes for Radiolabeling
Triazoles are good ligands for transition metals.  Peptides (or other
biolmolecules, in fact) can be C- or N-terminated with an amino acid derived alkyne or
azide, then “clicked” with the complement in a copper catalyzed cycloaddition.  This
procedure fulfills two objectives simultaneously.  First, it introduces a metal binding site
onto the peptide.  Second, the triazole linkage is itself part of the metal-ligand.  The
obvious application of this approach is in labeling bio-active peptides for imaging in
cells or in vivo.  Thus, complexes of the type 40 and 41 have been prepared, where the
triazole units have different orientations but are still disposed to coordinate with metals.
Technetium complexes of the derivatized peptide 42 have been prepared for this
purpose.56
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1.5 1,2,3-Triazoles in Less Peptidic Compounds
1.5.1 Peptoids
Peptoids (N-alkyl oligoglycines) are in some ways representative of molecules
that bridge the gap between peptidic molecules and more organic based structures.  The
attractive feature of peptoids is that they are formed from primary amines, and a large
selection of these is commercially available.  If amines that are also functionalized with
terminal alkynes are used, then Cu-promoted cycloadditions of azides can be used to
increase the diversity even further.  This elaboration could be done on each addition of
an alkyne, or globally to every alkyne in the sequence prepared.  The latter approach was
38
taken in the one paper that has appeared so far on combining peptoids and catalyzed
azide/alkyne cycloadditions.57  In fact, the peptoids were derivatized while supported on
a resin, then cleaved.  Fluorophores, nucleobases and other peptoids were conjugated
and yields of up 96 % were obtained, eg Figure 1.19.
HN
O
O O
N3
OH
N
O
N N
O
Ph
O O
O
O
H
3
N
O
N N
O
Ph
O O
O
O
H
NN
N
HN
O
O O
OH
CuI, EtiPr2N
 ascorbic acid
3
88 %
Figure 1.19.  Peptoids were derivatized with triazoles while supported on a resin.
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1.5.2 Non-peptidic Mimics Where Triazoles Replace Amides
In medicinal chemistry, Cu-promoted cycloaddition reactions can be valuable in
cases where a particular structural element is almost invariably required, but others are
to be joined to it to promote high affinity, potency, and/or selectivity.  A good example
of this is in design of analogs of the matrix metalloprotease inhibitor type H where the
hydroxamate dipeptide mimic (shown in blue) is essential for binding metals in these
enzymes, and the other part can be varied.  Thus a library of mimics including
compounds 43 and 44 were conveniently produced and tested.  These two molecules
were selected from the library on the basis of selective binding to, and inhibition of, the
MMP-7 enzyme relative to thermolysin and collagenase.58
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In a sequel to the work above, 12 compounds I were prepared to test the effects
of the P1’ substituents on binding and selectivity.59  To this the Eastern portion of the
molecule was engineered to include a photoaffinity tag and a fluorescent label.
Irradiation of the compounds with the enzymes anchored the photoaffinity tag, and the
extent of the bound fluorescence was taken as a measure of the affinity.  This approach
assumes that all the enzymes have identical affinities for the Eastern segment, and that
the extent of photobleaching is uniform for all the substrates.  If these are valid
assumptions, then the method facilitates rapid assay of binding and selectivity.
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1,2,3-Triazoles with small 4-substituents can be useful as replacements for
acetamide groups.  A simple illustration of this is the lead structure 45 that was
mimicked with triazole 46.  This was done to find analogs that would not display
undesirable monoamine oxidase A side-effects but maintain the antibacterial properties.
In the event, this was part of a much more extensive study and the compound formed by
removal of TMS 46 emerged as an interesting lead.
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Amprenavir is one of the commercially available HIV-1 protease inhibitors.  A
library of 100 mimics of this structure was produced from the two starting azides 47 and
48 (accessible via diazo transfer chemistry to the amine, and via epoxide opening,
respectively).  These segments were joined with alkynes via Cu-mediated
cycloadditions, and triazoles 49 and 50 emerged as potent inhibitors of both the wild
type protease, and of three different mutants.60  Intriguingly, when these compounds
were cocrystallized with HIV-1 protease, the triazole unit revealed itself as an effective
surrogate for the amide bond.61  It has a large dipole moment (bisecting the ring plane
near atoms N3 and C5) and the N2 and N3 electron lone pairs can function as hydrogen
bond acceptors.  In the specific case of 49, the N2 atom serves as a H-bond acceptor
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surrogate for the amide carbonyl of substrates in the protease.  Further, the C5H serves
as a hydrogen bond donor effectively mimicking the substrate amide NH.
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Sharpless and co-workers have prepared a series of compounds as potential HIV-
1 protease inhibitors.62  Molecular modeling indicated that triazole sub-units based on
1,2-amino azides, derived from amino acids, would be useful.  Consequently, successive
iterations of synthesis and testing led to the development of compounds 51 and 52,
which are nanomolar inhibitors.  The latter compound was formed via a copper-mediated
cycloaddition, followed by directed metalation and quenching with formaldehyde.
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1.5.3 Other Non-peptidic Peptidomimetics
In many other branches of medicinal chemistry, triazoles from the click reaction
have been used to extend molecules or replace similar functional groups.63  This review
focuses on peptidomimetics, so the discussion in this sub-section is restricted to
compounds where the native substrate is a peptide, even if the synthetic analogs are not
peptidic at all.
Inhibitors of tyrosine phosphatases may act via the active site or they may bind
the enzyme peripherally.  Moreover, some inhibitors have poor pharmacokinetic
properties.  Therefore, a logical approach to discovery of new inhibitors is to join two
active segments into one molecule, and Cu-mediated cycloadditions are ideal for this.64
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Compound 53 emerged from a library of 66 “bivalent” compounds prepared in this way;
it inhibits protein tyrosine phosphatase 1B with an IC50 of 4.7 mm.
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Compound 54 is one of 16 triazole-based zanamivir analogues that were formed
via Cu-mediated cycloadditions.  Zanamivir is a licensed pharmaceutical that acts via
inhibition of neuramidases.   In the analog, the triazole is acting as a mimic of the
guanidine functionality.  Compound 54 showed moderate inhibition against avian
influenza virus (subtype H5N1) in a cellular assay.65
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Resveratrol is a phytoalexin (antibiotic produced by plants under attack)
displaying an array of biological activities.  The problem with this compound is that it
has a diverse array of activities at high concentrations.  This has motivated research to
find analogs by replacing the alkene with a triazole functionality, formed by the copper-
mediated cycloaddition (and by other small heterocycles).66  Compounds 55 were thus
found to be more potent than the lead compound in cytotoxicity/antiproliferative assays.
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The lead compound NGD94-1 is a selective ligand for the D4 dopamine receptor.
As part of a larger study, three compounds were prepared in which the triazole unit
replaces the pyrazole part.  The N-phenyl compound 56 had a Ki value of 3.2 nM for
dopamine D4 receptor.67
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A library of 85 GDP-triazole compounds has been synthesized and screened for
inhibition of fucosyltransferase activity.68,69  It is known that the most important binding
determinant was in the GDP part of inhibitors, but the azide function was added to
screen for increased binding.  Compound 57 was identified as a promising hit (IC50 0.15
- 1.00 mM) depending on the enzyme used.
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Ellman and coworkers have used a substrate-based screening method to identify
key segments of inhibitors of the cysteine protease cathepsin S, which is implicated in
autoimmune diseases.70  In the first step, acylated amino coumarins were screened to
find the most appropriate functionality at the N-terminus via the method indicated in
Figure 1.20.  The preferred acyl groups contained some triazoles derived from click
products.  It was later shown that simple replacement of the coumarin with a hydrogen
gave potent inhibitors, including compounds 58 and 59.
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Figure 1.20.  Triazole derived inhibitors of cysteine protease cathepsin S.
Copper-mediated cycloadditions can be used to elaborate selected parts of
libraries that contain terminal alkyne or azide functionalities.  For instance, split
syntheses were recently used to produce a 10,000-membered library of which 78
compounds contained triazoles.71  Such applications are beyond the focus of our
research.
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1.6 Conclusion
Copper-mediated cycloadditions proceed via pathways that feature activation of
the alkyne part via coordination, then non-concerted cycloaddition of the azide
component.  This pathway is relatively unique, accounting for the superb
chemoselectivity of the reaction.  That chemoselectivity can be used in many ways.  For
instance, when alkyne or azido peptide units combine via this pathway the reaction is
relatively insensitive to the amino acid side-chains.  This serves as an excellent way to
make peptidomimetics, particularly because there is some stereoelectronic similarity
between 1,2,3-triazoles and amide bonds.  Research on the three dimensional
consequences of incorporating triazoles into peptides is at an early stage, and this is an
exciting area for future studies.  Further, Cu-mediated click processes can be used to
conjugate peptides to carbohydrates, organic molecules, polymers, dendrimers, and
labeling agents.  Finally, 1,2,3-triazole cores may form the basis of small molecule
pharmaceutical leads in which they fulfill some binding function of peptides, even
though the molecular resemblance of these compounds to peptides is obscure.
There are some disadvantages of copper-mediated click reactions.  They use azides and
copper, both of which pose safety- and environmental-hazards.  Further,
macrocyclization reactions can be complicated by somewhat mysterious
macrodimerization events.  Nevertheless, the fact that there are convenient routes to
amino-acid-derived azides and alkynes, and the lack of practical obstacles to executing
these Cu-mediated reactions, both point to a strong future for the peptidomimetics
formed via this route.
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CHAPTER II
RING CLOSURE TO BETA–TURN MIMICS VIA COPPER
CATALYZED AZIDE ALKYNE CYCLOADDITIONS
2.1 Introduction
β-Turn motifs are important targets for mimicry, both because they allow a
protein chain to fold back upon itself to form a compact structure and because they are
important recognition sites in peptides and proteins and often involved in protein-protein
interactions. A wide variety of β-turn types are observed based on their topological
features.  Unlike α-helixes and β-sheets, the backbone conformation of β-turns is highly
variable and any tetrapeptide sequence in which the αCi-αCi+3 distance is less than 7 Å
is a β-turn.72 The turn conformation can be stabilized by chelation of a cation, such as
Ca2+, or intramolecular hydrogen bonds.  Kahn et al reported the very first β-turn mimic
synthesis in 1986.73  This indolizidinone mimic of the tuftsin tetrapeptide exhibited some
bioactivity in a dose dependent manner.
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In the past two decades, many groups have been interested in syntheses of β-turn
peptidomimetics that have potential applications in medicinal chemistry.74,75  Cyclic
structures were first synthesized as turn mimics in the mid-1980s and continue to be
used for this purpose.  Hruby et al76 reported the synthesis of 6,5-bicyclic lactams that
incorporate amino acid side chains in the appropriate position. Kelly et al77 have used
dibenzofuran unites as turn mimics to align two peptide strands into a parallel β-sheet
like structure.  More recently, alkenes containing acyclic compounds have been
developed and the alkene units in these compounds mimic the amide bonds that would
be present in natural turns.  Allylic strains and other acyclic conformational effects were
explored in these turn mimics.  Gardner et al78 have reported the synthesis and
conformational analyses for molecules containing trans-5-amino-3,4-dimethylpent-3-
enoic acid residue (ADPA).  A combination of NMR and IR data for the ADPA
containing peptide analogues reveals that β-turn and β-hairpin-like folding is promoted
in dichloromethane solution.
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In our laboratory we have focused on constraining dipeptide fragments in
appropriate conformations by using macrocyclizations, particularly to form 14-
membered rings.79,80  That ring size facilitates conformational arrangements of edge
shared C10 systems, one featuring the dipeptide and the other comprising of a non-
peptidic fragment (Figure 2.1).  Previous work from our laboratory has focused on β-
turn mimics J and K via solid-phase, SNAr macrocyclization reactions.  It is evident that
compounds J and K can disrupt some protein-protein interactions. 81,82,83  Small libraries
of mimics J and K were prepared based on the i + 1 and i + 2 residues of the turn
regions of the nerve growth factor (NGF).  The turn regions of NGF are considered as
the relevant hot spots for the interaction of this protein with its high affinity receptor
TrkA.  Several lead compounds such as D384 and MPT1885 were identified based on
pharmacological tests, implying that the combination of peptidic and nonpeptidic
fragments in structures J and K might be especially favorable for mimicry of hot spots in
protein-protein interactions that involve β-turn i + 1 and i + 2 regions.
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Figure 2.1.  Some β-turn nomenclature, semi-peptidic mimics J and K usually prepared
via solid phase reactions, and the identified lead compounds D3 and MPT18.
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Figure 2.1.  Continued.
Many non-peptidic fragments can be used in the peptidomimetics featured above.
This is a means to incorporate diversity and to use different chemical reactions in the
ring-closure step.  Our bias is to avoid reactions that make the macrocycles more
peptidic (ie amide bond formation) and to favor ones that give the small heterocyclic
fragments found in pharmaceuticals.  Moreover, we are currently interested in scalable
solution phase methods to do this.  Solid phase syntheses were used in all our previous
syntheses of dipeptide containing peptidomimetics.86,83,82,87,88,89 ,90,91,92,80  These have the
advantage of pseudo-dilution caused by reactive site isolation on solid supports at
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moderate to low loading.  Solution phase methods, on the other hand, require ring
closure via efficient reactions.  Copper catalyzed azide alkyne cycloadditions, a “click
reaction”,5 were therefore an obvious choice.  Consequently, this chapter features the
concept depicted in Figure 2.2.
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Figure 2.2.  Substrate and product structures in this study.  R1’ and R2’ denote protected
side chains, R1 and R2 are deprotected ones.
A simple molecular modeling experiment was performed on compounds 61,
which was represented with a molecule containing Ala-Ala sequence.  The dihedral
angles around Ala-Ala residues were constrained and the energy was minimized.  The
resulting molecule was overlaid with the ideal type I β-turn as illustrated in Figure 2.3.
The backbone of the cyclic mimic fit that of the β-turn fairly well and the side chains of
the Ala-Ala residues were oriented in the appropriate region in space. This simple
molecular modeling indicated that the triazole induced cyclic mimic could successfully
sample β-turn conformation.
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Figure 2.3.  General structure of compounds 61 and the overlaid structure with ideal
type I   β-turn.
2.2 Solution Phase Synthesis of the Linear Peptidomimetics
Scheme 2.1 outlines the preparation of the starting materials 60.  Side chain
protection was necessary for the Lys (Cbz), Glu (Bn), Thr (Bn), Ser (Bn), Tyr (Bn)
amino acids.  These protecting groups render the intermediates relatively lypophilic,
hence use of a water soluble diimide reagent in the coupling steps facilitated separation
of the products via aqueous extractions.  Finally, the linear precursors 60 were
recrystallized and isolated in an overall average yield of 70 %. Thus the substrates 60
were conveniently accessible in gram amounts via syntheses that could be performed in
parallel.93
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a, 99%; b, 85%; c, 93%; d, 97%
e, 88%; f, 50%; g, 83%; h, 92%
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Scheme 2.1.  Preparation of the linear substrates 60.  R1’ and R2’ denote protected side
chains, R1 and R2 are unprotected ones (see Table 2.1 for a – h definitions).
2.3 Copper Catalyzed  Azide Alkyne Cycloadditions
Cyclization of the linear precursors gave the “monomeric” and “dimeric”
products 64 and 65.  Two measures were taken to favor formation of the protected 14-
membered ring products 64: THF solutions of the azides 60 were added to the copper
catalyst over 10 – 14 h via a syringe pump, and the final concentration was kept low
(approximately 0.001 M).  Nevertheless, dimeric products tend to predominate; data for
the cyclization reactions are shown in Table 2.1.
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Table 2.1.  Copper catalyzed cyclization reactions of compounds 60.
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64 Amino Acids 64:65
(monomer/dimer)a
Isolated
Yield 64
(%)b
i + 1 i + 2
a Ile Lys 39 : 61 12
b Glu Lys 54 : 46 11
c Thr Gly 29 : 71 8
d Gly Lys 23 : 77 14
e Lys Gly 23 : 76 9
f Gly Ser 39 : 61 9
g Ser Gly 20 : 79 8
h Tyr Ser 18 : 82 12
a Monomer/dimer ratio was based on the UV peak area of HPLC traces at 254 nm.
b Calculated on the basis of the mass after preparative HPLC separation.
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Even though the crude purities of the monomer/dimer mixtures are high after the
cyclization described above, relatively low yields were isolated after purification via
HPLC.  This is mainly because of the limited solubility of the products in organic and in
aqueous solvents.  For example, the crude yield of compounds 64a and 65a together
(39:61) was 92 %, but the isolated yield of 64a was only 12 %.
Deprotection of the products 64 (Pd/C, H2, MeOH or EtOH) proceeded cleanly to
give the unmasked products 61; any losses of material at this stage probably were
attributable to these relatively insoluble materials sticking to the catalyst.  Lysine side
chains of the peptidomimetics 64d and 64e were converted entirely to N,N-dimethyl and
N-ethyl derivatives, respectively, under these conditions.  Alkylation of amino groups
during hydrogenolysis in methanol and ethanol is well-known.94,95  However, it is curious
that this was only observed for the two peptidomimetics containing Gly/Lys amino
acids.
2.4 Conformational Analyses
Extensive conformational analyses were carried out for compounds 61a-c.  Full
details of analyses data are given out in Appendix A.  Sequential assignments for all
compounds were made from analyses of one-dimensional 1H NMR, gCOSY, TOSCY,
and ROESY spectra of samples in DMSO-d6 at 275 K.96  DMSO was used as the solvent
for the solubility problems and also because it has a dipole moment (ε=45) in between
water and a lipophilic binding pocket which resembles biologically relevant media.
Proton close contacts were obtained from ROESY spectra.  Hydrogen bonding
information was accessed from the measurements of the temperature coefficients97,98 and
deuterium exchange rates99 of backbone amide protons.  Molecular simulations were
made via the quenched molecular dynamics technique (QMD)100,101 without any
constrain from the spectra measurements.  Data obtained from 1D and 2D NMR
experiments were then compared with the families of low energy conformations derived
from QMD calculation. Good agreements of the parameters provided by the simulated
physical model and the experimentally observed data are indicative of a realistic model.
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Table 2.2.  QMD results for the lowest energy conformer of compound 61a.
Amino acid residue Dihedral angle (°) Lowest energyconformer of 61a
Ile (R1) φ -84.44
ψ -121,20
Lys (R2) φ -77.74
ψ -92.39
Distance (Å)COi – NH i + 3 5.114
Type of beta-turn Type I
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M
M
S
W
S
WS
Hydrogen ROE QMD distance (Å)
Ile NH - Lys NH medium 3.822
Ile CαH - Lys NH medium 3.313
Lys NH - PPA NH weak 4.108
triazole CH - PPA NH strong 2.943
Figure 2.4.  Correlations between ROE cross-peaks and distances from QMD (PPA =
propargyl amine residue).
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To access if compounds 61 adopt β-turn conformation, QMD, NMR and CD
experiments were performed on 61a-c.  Table 2.2 shows the QMD analysis of compound
61a.  The lowest energy conformers from four different families were generated.  The
lowest energy conformer that best fit the physical data was chosen as the most
representative structure of compound 61a. (Figure 2.4)  The dihedral angles around the
Ile and Lys residues have some correlation with the type I β-turn (-60o, -30o, -90o and
0o).72  However the distance between the oxygen of the carbonyl (C=O) of the i residue
and the NH hydrogen of the i + 3 residue is not very indicative of hydrogen bond
formation.
Table 2.3  QMD results for the lowest energy conformer of compound 61b.
Amino acid residue Dihedral angle (°) Lowest energyconformer of 61b
Glu (R1) φ -65.35
ψ -74.63
Lys (R2) φ -96.95
ψ 94.64
Distance (Å)COi – NH i + 3 4.441
Type of beta-turn Type I
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Hydrogen ROE QMD distance (Å)
Glu NH - Lys NH srong 3.026
Glu CαH - Lys NH medium 3.583
Lys NH - PPA NH weak 4.101
triazole CH - PPA NH medium 3.274
Figure 2.5.  Correlations between ROE cross-peaks of 61b and distances from QMD
(PPA = propargyl amine residue)
For compound 61b, four families were also generated and the physical data of
lowest energy conformers were compared with the experimental data. (Figure 2.5)  The
dihedral angles around Glu and Lys residues indicated that compound 61b was a type I
β-turn analogue. (Table 2.3) Again, the distance between the oxygen of the carbonyl
(C=O) of the i residue and the NH hydrogen of the i + 3 residue is not very indicative for
the hydrogen bond formation.
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Table 2.4.  QMD results for the lowest energy conformer of compound 61c.
Amino acid residue Dihedral angle (°) Lowest energyconformer of 61c
Thr (R1) φ -71.12
ψ 117.60
Gly (R2) φ -87.73
ψ -106.60
Distance (Å)COi – NH i + 3 4.979
Type of beta-turn Type II
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Hydrogen ROE QMD distance (Å)
Thr NH - Gly NH weak 4.462
Thr CαH - Gly NH strong 2.104
Gly NH - PPA NH weak 4.299
triazole CH - PPA NH medium 2.999
Figure 2.6. Correlations between ROE cross-peaks of 61c and distances from QMD
(PPA = propargyl amine residue).
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As for compound 61c, only three families were generated and the physical data
of lowest energy conformers were compared with the experimental data. (Figure 2.6)
The dihedral angels around Thr and Gly residues indicated that compound 61c was a
type II β-turn analogue. (Table 2.4)  The distance between the oxygen of the carbonyl
(C=O) of the i residue and the NH hydrogen of the i + 3 residue is not very indicative for
the hydrogen bond formation.
Table 2.5. Temperature coefficinces and H/D exchange data of compounds 61a-c.
Comp’d -Δδ/K[ppb/K]/H-D
AA i+1 AA i+2 AA i+3
61a 3.8/M 4.6/F 5.3/F
61b 1.5/S 3.8/F 6.6/F
61c 7.0/M 6.0/M 6.4/M
The temperature dependence and the H/D exchange rate of the i + 3 residue are
indicative of the presence of 10-membered ring intramolecular hydrogen bonding.  From
the data showed in Table 2.5, the relatively high temperature dependence and fast to
medium H/D exchange rates indicated that the intramolecular hydrogen bonding were
not present, which correlated well with the data obtained from the best fit lowest energy
conformers.
Circular dichroism (CD) spectra102,103 were also recorded.  Compounds 61a-c
were dissolved in 20% MeOH/H2O, the ratio of which approximates the dielectric
constant of DMSO used in the NMR studies.  Overlaid CD spectra of the three
compounds are shown in Figure 2.7.  While there is a maxima around 190 nm for
compound 61a and 61b, the negative minima band at 205 nm is absent.  Typical type I
and type II turns have minima around 205 nm and 225 nm, respectively; and maxima
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around 190 and 205 nm, respectively. Clearly, the CD data do not closely fit the shape
spectra commonly associated with type I and II turn conformations,104,105,106 indicating
non-ideal matches and/or other important contributions to the conformational ensemble.
Figure 2.7.  CD spectra of compounds 61a - c in 4:1 water/methanol at 0.1 mg/ml.
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2.5 Monomer/Dimer Selectivity Discussion
The studies described above successfully generated monomeric β-turn mimics:
the original goal of this work.  However, it was surprisingly difficult to do this.  Dimers
65 were preferred for seven of the eight cases cited in Table 2.1.  Further, azidoalkynes
similar to the linear substrates 60 were also tested as cyclization precursors, but without
success.  For instance, when substrates 66 and 67 were subjected to the copper-catalyzed
conditions described above there was no evidence of the monomeric cyclized product in
the ESI-MS of the crude reaction material; instead, complex mixtures of compounds
formed.
The literature reveals that at least three groups have attempted to use copper-
mediated azide/alkyne cycloaddition reactions to form macrocyclic rings, but “dimers’
were formed in each case.25-28  Finn et al.25 described dramatic examples in which 76-
and 124-membered rings were formed in preference to the corresponding monomeric
ones.  This result was unexpected particularly since solid phase syntheses were used, ie
conditions in which there is an inherent dilution effect.
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Finn and co-workers hypothesized that preferential formation of dimeric products
could be due to coordination of two alkynes prior to the cycloaddition, and/or to
coordination of the catalyst to the peptidic part of the molecule.  The immediate
precursor to cycloaddition in the copper-mediated transformations is not known, but the
kinetic studies10 suggest it contains two copper atoms and possibly two alkynes.
Intermediates L  and M , are possible candidates (Figure 2.8).  For the following
discussion, intermediates M is assumed to be the important ones (though this is not
critical).
In a simple elaboration of the hypothesis presented by Finn et al, we suggest that
selectivity for dimers in these copper mediated cyclizations may be explained as follows.
The perfect regioselectivity of the copper mediated cycloaddition processes for 1,4-
disubstituted triazoles would require that the azido alkyne coils in an endo-like
conformation to form a monomeric cyclization product.  In the absence of extenuating
circumstances, this conformational state would be less populated than exo-like ones that
are intrinsically less ordered.  The effects in question are small, but so are the rate
differences leading to mixtures of monomeric and dimeric products.  We suggest the
preference for the exo-like orientation M prevails over the conformational biases of the
peptide part, or secondary copper coordination effects, that might sometimes favor
reactions via endo-like conformations.
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Figure 2.8.  Formation of dimeric products in copper-mediated azide/alkyne
cycloadditions may be associated with less populated “endo-like” conformations relative
to less well ordered, more populated, exo-like ones.
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2.6 Biological Assays
Biological assays for compounds 61 were conducted by Dr. Uri Saragovi and his
coworkers at McGill University in Canada.  Cell survival assays were performed to
access the compounds’ activities as neurotrophin mimics.  One of the functions of NGF
is to control cell survival.  Untreated E25 cells (NIH cells that express TrkA receptor) in
serum-free media (SFM) generally die without addition of NGF (0 % survival).  Cells
can be rescued by adding NGF or functional mimic ligands.  Untreated E25 cells were
cultured with SFM supplemented with NGF control (low and high) and peptidomimetics
(1 or 10 µm) with and without addition of low NGF.  The effect of peptides 61a, b, d, e,
g, h on the survival rate of E25 cells were evaluated through MTT assays.  In this test,
the MTT is captured and metabolized only by living cells, producing a change in the
color of media that can be measured with a spectrophotometer.  Different concentrations
of DMSO were used as negative controls.
Data from the cell survival assay is given in Figure 2.9.  Peptides 61a, 61b and
61d displayed only a marginal increase in survival with or without NGF.  On the other
hand, peptides 61e and 61h showed an increase of approximately a 5 % in the rate of
survival of E25 cells in SFM and 13 % with NGF.  The only exception was 61g (10 mm)
that brought a relative survival of more than 20 % in the presence of NGF.  However, it
is important to consider that the negative controls (DMSO) also increase the survival of
E25 cells.  So probably this value is not very significant.
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a.
Comp'd 61 Comp'd 61% survival of E25
cells
% survival of E25 cells
 SFM low NGF  SFM low NGF
 
untreated 0.00 0.00 untreated 0.00 0.00
a (10 uM) 10.26 6.41 e (10 uM) 6.45 13.36
b (10 uM) 3.85 4.27 g (10 uM) 8.29 21.66
d (10 uM) 2.99 3.85 h (10 uM) 5.99 14.75
a (1 uM) 1.28 1.28 e (1 uM) 5.99 11.06
b (1 uM) 1.28 0.00 g (1 uM) 4.15 6.91
d (1 uM) 0.00 0.00 h (1 uM) 3.23 13.36
50% DMSO -1.71 2.14 40% DMSO 1.84 13.36
10% DMSO 2.56 5.56 30% DMSO 1.38 5.99
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Figure 2.9.  Cell Survival Data and Graphic Representation for Compounds 61.
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2.7 Summary
Copper catalyzed azide alkyne cycloadditions of the linear substrates 60 were
used to form the cyclic derivatives 61.  This 1,3-dipolar cycloaddition reaction is fast,
simple to perform and compatible with many solvents and functional groups. A library
of eight cyclic peptidomimetics was prepared in solution and the low yield was mostly
due to formation of dimers.
Computational, NMR, and CD analyses of compounds 61a-c indicate that their
most favorable conformational states include type I and type II β-turn conformations.
The low energy conformers that best fit with the observed physical data were identified
for compounds 61a – c.  These conformations of compounds 61a and 61b resemble type
I β-turns, and for 61c a type II β-turn is most relevant.  These data indicate the
compounds can sample turn conformations.  However, the CD data do not closely fit the
shape spectra commonly associated with type I and II turn conformations, indicating
non-ideal matches and/or other important contributions to the conformational ensemble.
Selectivity for the dimeric products 65 in these cyclisation reactions is discussed.
We suggest that the perfect regioselectivity of the copper mediated cycloaddition
processes for 1,4-disubstituted triazoles would require that the azido alkyne coils in an
endo-like conformation to form a monomeric cyclization product.
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CHAPTER III
A COMBINATORIAL METHOD TO SOLUTION-PHASE
SYNTHESIS OF LABELED BIVALENT BETA-TURN MIMICS
3.1 Introduction
Peptides and proteins play a crucial role in many biological systems.  However,
their intrinsic instability limits their potential as reagents in drug discovery.
Replacement of the amide bond with surrogates in potential drug candidates has been a
continual strategy in medicinal chemistry.  Successful replacements provide improved
oral bioavailability via increased lipophilicity and stability.  Many amide bond
surrogates have been used,107-112 but some of these compounds are not very easily
accessible from amino acid derivatives. 109,112  Therefore, discovery of new peptide
surrogates more compatible with amino acid side-chains is highly desirable.  Meanwhile,
such innovations have to allow the rapid synthesis of peptidomimetics in large numbers
for high throughput screening.
Meldal and Sharpless reported independently the efficient synthesis of 1,2,3-
triazoles by Cu(I)-catalyzed azide-alkyne cycloaddition reactions in 2002.3,4  This 1,3-
dipolar cycloaddtion reaction is fast, simple to perform, and compatible with many
solvents and functional groups.  In our search of convergent syntheses of β-turn mimics,
this regioselective formation of triazole motifs attracted our attention.16  As shown in
Figure 3.1, the molecular modeling indicated that the triazole moiety has topological
similarities with the amide bond and pharmacophores could be placed around the
triazole core with limited degrees of freedom,25,24  but enough to find the appropriate
region of space for docking to occur.113 (Figure 3.1)
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Figure 3.1.  (a)  The key distance of Cb-separations of the i + 1 to i + 2 residues of a
type 1 β-turn and of the monovalent turn mimics 70 featured here; (b) an overlay of the
mimics onto a type 1 β-turn; and, (c) a comparison of their electrostatic charge
separations for these two entities.
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In screening random libraries of small molecules against targets involving
protein-protein interactions114,115, hit rates for screening are usually low for the following
two reasons: (i) small molecules may bind at one hot-spot, but rarely bind two or more
simultaneously; and (ii) weakly binding molecules are difficult to identified when
screened against natural ligands which usually have extremely high affinities.116,117
Thus, it is possible to join two small molecules together to impact two hot-spots
simultaneously, ie to combine monovalent ones to form bivalent ligands that bind
protein surfaces more strongly.118,119  Fesik and co-workers proposed that two small
molecules that each weakly binds a protein, can be linked to form higher affinity
bifunctional ligands.120,118  Thus weakly binding ligands could be identified via an
NMR-based screen of a combinatorial library.121,119  “Bivalent analogs”, which are two
of these ligands linked together, should have much higher affinity than their monovalent
components.122,123  We propose that two mimics that bind a single receptor molecule
should be more potent antagonists than their monovalent constituents.  They can be
called “superantagonists”.  Moreover, coupling of two mimics that bind two different
receptor molecules simultaneously could provide optimal agonists with much higher
affinity. (Figure 3.2)
monovalent       
antagonist
bivalent 
“superantagonist”
bivalent
agonist
Figure 3.2.  Weakly binding molecules could be jointed together to form bivalent
molecules with higher binding affinity.
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Our “linker scaffold” strategy124,125 to form bivalent compounds is shown in
Figure 3.3. If n monovalent compounds are combined with themselves in all possible
ways, then n(n + 1)/2 bivalent compounds could be formed.  Bivalent molecules are
ideal targets for combinatorial libraries directed at protein-protein interactions for two
reasons.  First, combining two monovalent ligands into a bivalent system can increase
the affinity of the molecule.  Secondly, small additions to the monomer pool lead to
dramatic increases in the number of permutations available.126
linker scaffold
couple
n monovalent
compounds
linker scaffold
active site A
n(n + 1)/2 bivalent compounds
couple
n monovalent
compounds
linker scaffold
active site Bactive site A
Figure 3.3.  “Linker scaffold” strategy.
Cyanuric chloride is more reactive to nucleophiles than 2-amino-4,6-
dichlorotriazines, and both of them are more reactive than 2,4-diamino-6-
chlorotriazines.127,128  In the search of linker scaffolds for dimerization, the
aminofluorescein labeled triazine derivative (DTAF) has proven an excellent scaffold in
our research group based on this type of selectivity.129  Scheme 3.1 shows our initial
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“semi-solution phase” strategy to dimers.  In the reactions shown, one monomer was
coupled to the DTAF linker on solid phase and the other was later combined to give
heterodimers selectively in solution.  Only potassium carbonate was required to affect
the coupling, and no protecting groups were involved.  The final product does not have
to be purified from protecting group residues and scavenger material, and the bivalent
materials were obtained in high purities.
N
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(i)
(ii) 90 % TFA, CH2Cl2
K2CO3, DMSO, 25 ˚C
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N
N
Cl
Cl
unprotected
peptidomimeticHN
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peptidomimetic N
N N
N
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peptidomimeticN
solution phase recombination
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does not react with
most nucleophilic
amino acid side-chains
unprotected
peptidomimetic N
N N
N Cl
HN fluorescein
unprotected
peptidomimetic
HN
O
N
H
5-([4,6-Dichlorotriazin-2-yl]
amino)-fluorescein (DTAF)
Scheme 3.1.  “Semi-solution phase” reactions illustrate the sequential addition of
monomers and the surprising selective coupling of a piperidine over most nucleophilic
amino acid side-chains.
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The observations in Scheme 3.1 were exploited to make 78 dimeric, unprotected
peptidomimetics.129  The triazine scaffold can therefore be used as a scaffold to
transform unprotected peptidomimetic monomers into dimers.  However, several issues
have to be overcome before this method could be suitable for preparing much bigger
libraries.  First, the monomers had to be made in solution to get the quantities required
since solid phase methods are intended for small amounts and HPLC purification is
sometimes necessary.  Second, dimerization conditions have to be devised so that both
components could be reacted in solution, and meanwhile the monovalent components
have to be accessible and usable without protecting groups.  Finally, monomers have to
combine with each other cleanly, to give one-compound-per-well with sufficient purity
for testing. (Scheme 3.2)  This chapter focuses on the rapid synthesis of small molecule
mimics in large scale and their efficient assembly to dimers in solution.
peptidomimeticpeptidomimetic
N
N N
N N
tag
peptidomimetic peptidomimetic
+
N
N
N
N
Cltag
N
H
K2CO3, DMSO
neither peptidomimetic is protected
but both may contain
reactive functional groups
Scheme 3.2.  Solution phase dimer assembly.
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3.2 Preparation of Monovalent Triazole Peptidomimetics
Two methods were used to prepare the monovalent building blocks 70.  The most
economical and direct route (Scheme 3.3a) begins with amino acids that were converted
to the corresponding azides via known azo-transfer reactions, coupled with Boc-
piperazine, and combined with appropriately substituted alkynes via copper-mediated
cycloadditon processes.  Only the final products 74 were purified via flash
chromatography; the intermediates were isolated via aqueous work-up (crude yields of
73 are shown) and used in the next step without further purification.  This route was
successful for all the amino acid/alkyne combinations tested, ie those shown in Table
3.1.  Scheme 3.3a uses R1’ and R2’ to denote protected side chains (and R1 and R2 to
indicate deprotected ones).  In fact, the only side-chain of the amino acid starting
materials (R1 shown in Table 3.1) that had to be protected was the amino group of Lys
(Boc-protected to mask it during the azo-transfer step).
Method B in Scheme 3.3b is a more conservative approach that begins with Cbz-
protected amino acids, and requires an additional deprotection step.  This was our
original approach, but as the work evolved it was found that this route had no advantages
over Method A for the amino acids shown in Table 3.1.  However, Method B is shown
here just in case the work is later expanded to other amino acids for which it might have
some merit.
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Scheme 3.3.  Two methods for preparing the monovalent mimics 70.  Generally the least
expensive and most direct route uses is: (a) featuring unprotected amino acid starting
materials (except for Lys which was side-chain protected).  Route (b) uses protected
amino acids.
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Table 3.1.  Peptidomimetics 74 prepared via method A.
compound
74 R
1’ R2’ yield (%)a
a NHBOC 78
b H NHBOC 79
c COOH 80
d H OH 94
e H
OH
96
f OH 80
g
OH
NHBOC 71
h NHBOC
OH
92
i Me N
H
NBoc
NHBoc 77
j NHBOC 94
k NHBOC COOH 87
l Me COOH 87
m H N
H
NBoc
NHBoc 86
n
OH
OH 89
o N
H
NBoc
NHBoc 96
a From intermediate 5 after flash chromatography.
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3.3 Adaptation of the Dimerization Method to Solution Phase   
After considerable optimization studies, the solution-phase method for assembly
of the bivalent compounds shown in Scheme 3.4 was developed.  The protected
compounds 74 were unmasked to give mimics 70 then reacted with a dichlorotriazine
derivative of aminofluorescein (ie DTAF) to give the electrophiles 76.  These were then
reacted with second aliquots of the mimics 70, in all permutations, to give the library of
bivalent mimics 71.  Morpholine was also used in the second couplings.  This resulted in
syntheses of the specific mimics 71a’-o’ that represent controls for testing which contain
only one mimic, triazine with the fluorescein label, and the morpholine part which
represents the linker.
Some attributes of the method in Scheme 3.4 are follows.  Our goal was to
prepare compounds 71 in over 85 % purity, so the threshold of acceptable purity applied
to the intermediates 76 had to be above this.  The crude intermediates (chlorotriazines
76) were assayed by reverse phase HPLC (UV and SEDEX detection) and found to be
above 85 % purity, so no chromatographic isolation was necessary.  In the first coupling,
THF facilitated addition of just one monomer, giving monochloro-intermediates 76 in
satisfactory purities for use in the next stage without further purification.  Removal of
THF after the synthesis of the intermediates 76 is convenient because it is volatile
relative to some other solvents.  It seems that DMSO facilitates faster coupling of
nucleophiles to triazines than THF.  Indeed, we found that DMSO as solvent for
coupling the second monovalent compounds was critical; other solvents tested gave
unsatisfactory results.  The bivalent molecules formed in good overall purities, even
though the monovalent building blocks used to assemble them were completely
unprotected.  The reactions were typically performed on a small scale to form a few
milligrams of product.  However, no problems were encountered scaling-up syntheses of
some selected bivalent compounds to give 100 mg of product.
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Scheme 3.4.  Solution phase method for the preparation of the library of compounds 71.
Briefly, the exploratory work that led to the method shown above illustrated
several valuable conclusions.  The solvents tested for the coupling reactions were THF,
MeCN, MeOH, DMF, and DMSO); THF proved to be best for the first addition and
DMSO for the second (see above).  When DMF or DMSO was used for the first
coupling reaction, the major products tended to be homobivalent molecules.  Methanol
was unsuitable for the first coupling because it tends to react with the DTAF.
Acetonitrile gave similar results to THF in the first coupling, but it is more toxic and
slightly harder to remove.  For the second addition, the reaction went very slow in THF,
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MeCN and MeOH at 25 °C and could not be completed in a reasonable time period.  It
was harder to remove DMF than DMSO, but it seems to be an equally good solvent for
the second coupling in all other respects.  Use of (NH4)2CO3 as a based was investigated
but it gave incomplete complete coupling reactions.  This is particularly unfortunate
because ammonium salt residues are volatile, whereas sodium chloride residues are not
and have to be removed via using differential solubilities.
3.4 Application of the Solution-phase Procedure to Make a Library of
Fluorescently Labeled Bivalent Mimics
The method outlined in Scheme 3.4 was applied to synthesis of a library of 135
fluorescently-labeled bivalent mimics.  Thus the monovalent compounds 74 were
deprotected with TFA; no scavenger was required.  The resulting unmasked
intermediates 70 dissolved in THF were reacted with equimolar amounts of DTAF and
excess K2CO3 for 4 h to give the intermediates 76.  The THF was removed, then these
intermediates were dissolved in DMSO, split into small portions, then coupled with
another equivalent of the deprotected monomers 70 to give the bivalent compounds 71.
Alternatively, to generate a set of control compounds, mophorline was used instead of
the deprotected monomers as a capping group giving compounds 71a’ – o’.
The purities of intermediates 76 were monitored by analytical HPLC, and they
were judged to be high enough to use in the next step without purification.  After the
second coupling, a major practical issue was removal of inorganic salts; two procedures
were developed for this.  Most of the bivalent products were not very water soluble so
they could be precipitated from the basic solutions by adding 5 % HCl; presumably the
acid protonates the fluorecein labels transforming them into their less soluble, ring-
closed forms.  However, some of the bivalent molecules have side chains that promote
solubilities in slightly acidic aqueous media (eg those in the g, h, and k series).  Bivalent
molecules in this second category were separated from most of the inorganic salts by
removing the solvent and extracting them into methanol.  After these procedures, more
than 80% of the bivalent compounds 71 were produced with a minimum of 85% purity.
It appears that the other 20 % were not as pure due to pipetting errors because all gave
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purities above 85 % when they were re-prepared.  HPLC and MALDI analyses were
performed on all the compounds.  Both UV and SEDEX detectors were used to
determine the purities shown in Figure 3.4, which includes the ones that were
reprepared.  Purity data before and after the re-preparation procedures is given in the
supporting material. In summary, this new methodology allows the monovalent
compounds to combine with each other cleanly in a one-compound-per-well format.
a.
a 100 100
b 93 86 91
c 100 86 85 100
d 85 86 92 90 92
e 86 92 100 94 100 100
f 100 100 90 100 91 89 100 purities (%)
g 88 86 100 96 87 94 96 86 below 85
h 98 89 93 93 93 93 87 96 91 85 – 90
i 92 93 100 91 90 100 100 98 92 89 90  and up
j 100 100 87 100 87 90 100 90 89 89 100
k 87 88 100 97 100 100 87 100 100 100 90 95
l 92 92 86 97 100 89 100 88 88 100 100 100 100
m 94 90 100 94 100 100 86 93 100 100 88 100 100 86
n 100 100 100 100 100 100 100 86 92 100 100 100 100 100 100
o 100 100 100 100 100 100 100 96 96 100 100 100 100 100 100 100
cap a b c d e f g h i j k l m n o
Figure 3.4.  Purities of the library of compounds 71 where the detection method was: (a)
UV set at 254 nm; and, (b) SEDEX detection.  The term “cap” is used for morpholine.
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b.
a 100 100
b 100 100 100
c 100 92 92 100
d 92 100 100 100 100
e 90 94 100 100 100 100
f 100 100 100 100 100 100 94 purities (%)
g 98 92 100 98 100 100 100 100 below 85
h 100 93 100 100 100 100 94 98 100 85 – 90
i 87 91 100 100 100 100 100 97 100 96 90  and up
j 100 93 93 100 86 92 100 94 93 95 91
k 100 94 100 100 100 100 100 100 100 100 90 100
l 97 100 92 100 100 100 100 96 87 100 100 100 100
m 99 95 100 100 100 100 93 90 100 100 93 100 100 100
n 100 96 100 100 100 100 98 100 100 100 100 100 100 100 100
o 100 100 100 100 100 100 100 100 100 100 98 100 100 100 100 100
cap a b c d e f g h i j k l m n o
Figure 3.4.  Continued.
3.5 Preparation of Biotin Labeled Bivalent Compounds
A library of 135 compounds 72 labeled with biotin was also prepared from
monovalent compounds 74a-o.  The preparation procedure is similar to that used to
prepare fluorescent labeled compounds 71.  As shown in Scheme 3.5, the difference is
that DMSO was used as the solvent in the first monomer addition and the lower
concentration was necessary due to reduced solubility of the Biotin-containing linker 77.
Purities of the crude materials of compounds 72 were evaluated by analytical HPLC,
monitored by UV and SEDEX detectors.  Figure 3.5 shows the final purities of bivalent
compounds 72.  Initially, about 10 bivalent compounds gave unsatisfactory purity by UV
and/or SEDEX but this was remedied upon resynthesis.
Twenty percent of bivalent compounds were characterized by one-dimensional
and two-dimensional NMR experiments. (See Appendix B)  All the compounds gave
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satisfactory molecular ions in MALDI-MS analyses.  The product yields were not
determined either due to the small scale of the synthesis.
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Scheme 3.5.  Preparation of biotin-labeled bivalent library 72.
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h 89 87
g 100 100 89
j 100 88 85 90
k 96 87 86 94 91
c 100 88 89 90 88 100 UV
a 100 89 87 92 99 91 93 Purities(%)
d 100 92 89 100 86 97 100 100 below 85
e 100 89 85 85 86 86 100 87 100 85 – 90
f 100 100 100 87 86 87 90 89 89 100 90  and up
l 100 89 90 87 92 86 86 87 96 86 91
b 100 90 91 86 90 86 90 87 89 98 100 97
i 100 93 100 95 89 97 95 91 92 96 100 98 91
m 100 94 100 94 87 96 95 92 97 90 94 100 87 98
n 100 97 85 91 87 93 89 92 90 100 86 85 87 85 96
o 100 95 100 100 88 93 100 87 87 100 89 95 90 91 87 96
cap h g j k c a d e f l b i m n o
b.
h 87 89
g 100 100 97
j 98 93 92 92
k 100 87 86 100 96
c 100 91 94 85 86 87 Sedex
a 98 91 90 87 100 91 100 purities (%)
d 100 89 100 100 85 100 100 100 below 85
e 100 90 89 100 89 92 100 100 100 85 – 90
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l 100 88 90 97 92 100 86 94 100 85 89
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cap h g j k c a d e f l b i m n o
Figure 3.5.  Purities of the library of compounds 72 where the detection method was: (a)
UV set at 254 nm; and, (b) SEDEX detection.  The term “cap” is used for morpholine.
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3.6 Direct Binding to Trk and p75 Transfected Cells
Direct binding assays were performed to assess the ability of peptidomimetics 71
to bind Trk and p75 receptors. 130,129,85,131  The library of 135 bivalent compounds was
tested for binding to transfected TrkC-expressing, TrkA-expressing or p75-expressing
cells in a fluorescence activated cell sorting (FACScan) assay.  Live cells expressing the
indicated receptors were incubated with ligands (20 µM), washed, and immeditely
studied by FACScan. Data was acquired and analyzed CellQuest software.  Mean
channel fluorescence (MCF) ± sem, n =5 independent experiments, in each 3,000 to
6,000 cells were acquired.  In all cases cellular controls and antibody controls were used
(not shown).  The NIH-IGFR-1 cells which do not express any neurotrophin receptor
served as a negative control.  Each compound was tested three times and the mean
channel fluorescence was determined.
 From the preliminary screening data, four bivalent compounds exhibited
relatively high binding affinity and better selectivity against TrkA-expressing cells.
These compounds were purified by preparative HPLC and their direct binding data has
been confirmed.  The structures of the four compounds are illustrated in Figure 3.6.  As
shown in Figure 3.7, compounds 71gj, 71gm, 71gn bind to TrkA, and to a lower degree
they also bind to TrkC and p75, and 71gi binds to TrkA, but it does not bind
significantly to TrkC or p75.  Interestingly, four “hits” all contain Thr-Lys sequences.
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Figure 3.6.  Structures of compounds 71 that bind to TrkA from the preliminary FACS
assay.
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NIHTrkA NIHTrkC p75
Comp'd
71 Mean Stdev Sem Mean Stdev Sem Mean Stdev Sem
gj 805.26 318.52 142.45 319.57 145.71 65.16 560.89 459.18 205.35
gm 1152.98 3378.26 150.83 586.24 195.28 87.33 628.95 198.75 88.88
gn 880.04 256.37 114.65 349.78 159.02 71.12 585.71 414.53 185.39
gi 482.23 228.37 102.13 101.33 99.83 44.64 295.81 369.1 165.07
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Figure 3.7.  Direct binding assay data and the graph presentation of the four “hits”.
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3.7 Summary
Copper(I)-catalyzed azide/alkyne cycloaddition reactions can be used to make
1,2,3-triazoles that serve as amide bond surrogates.  These reactions are mild, easy to
work-up and compatible with many functional groups and solvent systems.  A library of
15 monovalent triazole mimics is prepared via “click” reactions in solution.  These
triazoles compounds contain two amino acid chain functionalities at 1- and 4- positions.
One is derived from a natural amino acid and the other is functional group that
assembles the side chains of an amino acid.  “Click” reactions allow quick and efficient
generation of the desired peptidomimetics in good yields.
Initially, our dimers syntheses are achieved via addition of one monomer on solid
phase and the other in solution. This “semi-solution phase” methodology requires
expensive resins and HPLC purification, and tends to give small amount of materials.  In
our new strategy, both monomers are coupled to the linker scaffold sequentially in
solution by simply manipulating the solvent systems.  This method allowed us to prepare
large libraries of bivalent compounds quickly and efficiently.  The two monomers are
combined with each other cleanly, to achieve one-compound-per-well in sufficient purity
for biological testing.
The fluorescence activated cell sorting (FACScan) assay has performed on the
fluorescently labeled compounds for binding to transfected TrkC-expressing, TrkA-
expressing or p75-expressing cells.  Four bivalent compounds 71gi, 71gj, 71gm and
71gn have exhibited relatively high binding affinity and better selectivity against TrkA-
expressing cells.  All of these molecules contain Thr-Lys sequence.  The assay has been
repeated on the purified compounds and the binding data is confirmed.
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CHAPTER IV
SOLUTION PHASE SYNTHESIS OF NON-PEPTIDIC MIMETICS
USING ARYLALKYNE AS AMIDE BOND SURROGATES AND
THEIR ASSEMBLY TO BIVALENT MOLECULES
4.1 Introduction
Peptidomimetic synthesis has benefited greatly from the rapid development of
combinatorial chemistry.  Fast generation of molecular diversity libraries, followed by
their evaluation using highthroughput screening, has produced many potential drug
candidates.132,133,134  About a decade ago, many new approaches were discovered and
applied to the generation of non-peptidic, “drug-like” small molecule libraries.135,136
Peptides and proteins play a crucial role in many biological systems.  However,
their utility as therapeutic agents is limited due to their low metabolic stability and poor
absorption after oral ingestion.137,138  Efforts to alleviate these problems have fueled the
rapid growth of non-peptidic small molecule peptidomimetics.  In general there are two
ways to generate this type of mimics.  One is to install a unit that can replace the amide
bond139; the other is to use scaffolds that contain sites for attachment140.  The purpose of
these modifications is to increase the selectivity and potency of drug candidates at the
target binding sites and decrease their possibility of degradation.  Further, the
lipophilicity can be increased and the compounds will be more easily absorbed into the
biological systems.
Backbond modifications generally involve the isosteric or isoelectronic
replacement of the amide moiety in the peptide chain and /or introduction of additional
groups.141  Although a number of amide bond replacements have been reported in the
literature142-145, the most widely used surrogates are illustrated in Figure 4.1.
Incorporation of peptide side chains may be varied due to the unique physicochemical
properties of each surrogate.
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Figure 4.1.  Structures of the common peptide backbone replacements.
Rigid scaffolds have been utilized to attach amino acid side chain moieties and
display them in the appropriate region of space.146-148  As shown in Figure 4.2, some of
these mimics hardly resemble peptides, with the exception that side chain-like motifs are
attached to the rigid core structure.149,150  The conformation of the peptide
pharmacophore can be locked or strongly influenced by the rigidity of the core structure.
Combinatorial libraries were prepared on solid support since some scaffolds are suitable
for solid phase synthesis. 151,152
O
SO O
H2N COOH
phenoxathiin S-dioxide
H
N NH2
NH
HO2C
RGD mimics based on 
steroidal structure
Figure 4.2.  Examples of non-peptidic scaffolds.
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Our efforts to development small molecules with less peptide character include
using a simple substituted iodobenzene153 that will serve as a scaffold to attach
functional groups that analogue side chains found in the amino acids in the loop region
of the neurotrophins.  As shown in Figure 4.3, the big advantage of this design is that the
monovalent compounds are easy to make on a large scale, and the molecular fragments
that correspond to protein amino acids are highly accessible.  Also, turn analogs of this
type are “non-directional” so that the side-chains can mimic i+1 and i+2 or i+2 and i+1.
N
H
O
HNHN
R1 O
R2
O
HN
R2
R1
5.2 A
o 4.7 A
o
β−turn aryl alkyne mimic overlay
84
Figure 4.3.  Generic structure of aryl-alkyne library.
In the attempt to mimic neurotrophins function, one of our goals is to develop
simple methodologies to assemble bivalent libraries.  Neurotrophins exist and function
as dimers, and the distances of the relevant loop region are varied.154,155,156   It is
expected that bivalent turn mimics with optimal-length linkage should be more selective
and bind to neurotrophin receptors with higher affinity.  We call this simple idea as “mix
and match” linker design presented in Figure 4.4.  It involves matching short and long
linkers in all three possible ways and the diversity of the molecules will be greatly
increased.  The approach is a general one for all dimeric ligands docking with dimeric
receptors, even when the ideal linker dimensions are unknown.  Thus, if 50 monovalent
peptidomimetics were to be transformed into dimers, then they could each be coupled
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with the linker molecules to give a library of 100 monovalent species.  If 50 compounds
are combined with themselves then the total maximum library size would be 1275, but
for 100 it is 5050, and the latter library would be far more interesting because it would
cover a range of linker geometries.
peptidomimetic
long linker
peptidomimetic
short linker
+
N N
N
NHF*
peptidomimetic
short linker
peptidomimetic
short linker
+
N N
N
NHF*
peptidomimetic
short linker
peptidomimetic
long linker
N N
N
NHF*
peptidomimetic
long linker
peptidomimetic
long linker
+
Figure 4.4.  “Mix and match” linker design.
4.2 Preparation of Non-Peptidic Aryl-Alkyne Mimetics
In our laboratory, a library of 14 non-peptidic aryl-alkyne mimetics was prepared
in solution.  Substituted iodobenzene served as a scaffold and a simple Sonogashira
coupling157 reaction afforded the aryl-alkyne core structure.  The solution phase
approach featured in Figure 4.5-a is my part of a group effort. Other people in our group
prepared the alternative similar monomers. The general synthesis route begins with a
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Sonogashira coupling followed by an SNAr step to give another side-chain variety.  In
my part of work, the compounds that mimic glycine, serine and/or valine side chains
simply start from a iodonitrobenzene to prepare mimics only with Sonogashira coupling
reactions.  A set of three linkers was used in this work.  Both N and O are short linkers.
They were picked from different synthetic strategies.  Linker P is a long linker that was
prepared from N and diglycolic anhydride.
R1 R
2
NO2
reduce nitro
couple
N-deprotect
R1 R
2
HN linker
84a-n
I
R2
NO2
Sonogashira
a.
R1 and R2 are functional groups that mimic side chains 
of Gly, Ser, Val, Thr, Lys, Glu, Gln, Asn
N
NBocCO
OHOOC
P
HN
NBoc NBoc
HOOC
N O
b.
Figure 4.5.  (a) General synthetic scheme and the short/long linkers; (b) Short/long
linkers.
The library of 14 monovalent peptidomimetics is listed below (Table 4.1).
Compounds 84a-g were functionalized with short linkers N or O and the long linker P
was attached to the compounds 84h-n.  Most compounds were prepared following the
route shown in Figure 4.5-a except that 84a, 84b, 84f and 84g were prepared from
substituted benzoic acids. Urea (84a, 84b, 84f) or amide (84g) formation led to the
desired molecules for the synthetic convenience.
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Table 4.1.  Aryl-alkyne library 84.
I
III IV
IIR
1 R2
H
N
C
O
N
NBoc
H
N
C
O NBoc
O
C
N
NBoc
H
N
C
O
O C
O
N
NBoc
Comp’d
84
Scaffold R1 R2
Overall
Yield
(%)
a I H
OH
61
b I H OH 56
c II OH H 92
d II CH3 CONH2 49
e II CH3 CONH2 45
f I H NHBoc 48
g III CH3 COOH 72
h IV H
OH
56
i IV H OH 52
j IV OH H 65
k IV CH3 CONH2 42
l IV CH3 CONH2 37
m IV H NHBoc 42
n IV CH3 COOtBu 32
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4.3 Preparation of Bivalent Compounds 85
The preparation of the bivalent library of compounds 85 is similar to that
discussed in Chapter III.  As shown in Scheme 4.1, the Boc protecting groups of the
monovalent compounds from Table 4.1 were removed by TFA and treated with DTAF
and K2CO3 in THF for 4 h at 25 oC.  The resulting intermediate was concentrated and
redissolved in DMSO and split into small portions.  An equimolar of the deprotected
monomer was added to each portion followed with the addition of excess of K2CO3.
The resulting mixture was placed on a shaker and reacted for 72 h to afford compounds
85.
Purities of the crude materials of compounds 85 were evaluated by analytical
HPLC, monitored at 254 nm by a UV detector.  Figure 4.6 shows the crude purities of
bivalent compounds 85.  Among the 105 compounds, 81% were obtained with the purity
above 85%.  The compounds with less than 85% purity were resynthesized by the same
method shown in Scheme 4.8 and the purities were shown in Figure 4.7.  Most of the
compounds gave satisfactory purities after they were prepared again.  The only
exception was that the purities of compounds 85ml and 85mh were still below 85% but
they were significantly improved.  This reveals that the impurities were mainly caused
by the pipetting errors and the dimerization method is fairly efficient.
One-dimensional and two-dimensional NMR experiments were conducted on
20% compounds that were randomly picked (See Appendix C).  All the compounds gave
satisfactory molecular ions in MALDI-MS analyses.  The product yields were not
determined because of the small scale of the synthesis.
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Scheme 4.1.  Preparation of bivalent mimetics 85.
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N N
N
HN F*
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mimic 2
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B and C
mimic 1
linker A
B and C
85
n 85
m 93 95 purities (%)
l 87 77 80 below 85
k 89 86 86 86 85-90
j 72 87 75 70 86 90 and up
i 79 86 88 81 86 87
h 68 62 59 85 85 86 86
g 92 91 93 85 88 86 89 97
f 74 89 89 90 83 85 92 94 90
e 87 85 87 89 87 85 90 93 89 92
d 84 86 80 85 70 85 91 91 93 85 85
c 88 87 89 86 89 85 87 100 100 81 81 93
b 87 87 90 92 80 94 94 93 89 94 87 84 85
a 94 90 86 92 87 84 88 96 95 87 85 93 89 88
n m l k j i h g f e d c b a
Figure 4.6.  HPLC purities of the bivalent turn mimics 85.
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n 92
m 93 95 purities (%)
l 87 81 87 below 85
k 89 86 86 86 85-90
j 98 87 85 86 86 90 and up
i 95 86 88 89 86 87
h 90 77 89 85 85 86 86
g 92 91 93 85 88 86 89 97
f 90 89 89 90 99 85 92 94 90
e 87 85 87 89 87 85 90 93 89 92
d 95 86 85 85 99 85 91 91 93 85 85
c 88 87 89 86 89 85 87 100 100 94 99 93
b 87 87 90 92 88 94 94 93 89 94 87 99 85
a 94 90 86 92 87 99 88 96 95 87 85 93 89 88
n m l k j i h g f e d c b a
Figure 4.7.  HPLC purities of 85 after resynthesis.
4.4 Biological Assays
Direct binding assays were performed in a fluorescence activated cell sorting
(FACScan) as previously discussed in Chapter III.  The library of 105 bivalent
molecules was screened for binding to Jurakat and NIH cells.  The histograms were
analyzed on the compounds that exhibited high mean channel fluorescence (MCF) on
the assays performed with Jurkat or NIH cells.
The histograms are curves that show the relation between the amount of cells
(events) and their fluorescence level.  If there is binding of the peptide to the cells it is
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expected a shift in the curve to the right (i.e. more event with higher fluorescence).  Cells
IGF1-R do not express any neurotropin receptor served as negative control.  The
majority of the evaluated peptides displayed a higher tropism toward NIH-Trk-C and
NIH-p75 cells.  The most promising peptides were 85gn, 85hn, 85jn and 85kn (Figure
4.7), which binded preferentially to Trk-C, with a lower binding to Trk-A expressing
cells.  However, we did not find any peptide with higher tropism by TNF receptor,
which is over-expressed in Jurkat cells cultivated in SFM.
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Figure 4.8.  Structures of 85gn, 85hn, 85jn and 85kn that bind TrkC from the
preliminary FASC assay.
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A FACS competition test was preformed with peptide mimics 85gn, 85hn, 85jn
and 85kn , using 2B7 (anti-Trk C monoclonal antibody) or NT-3 at saturating
concentrations as competitors. The mIgG was used as an irrelevant competitor, so these
values reflect the standard binding of the peptides to the cells.  The presence of
competitors, especially 2B7, reduces the MCF of the peptide mimics 85gn to 85kn,
without reaching the background level.  Thus, it seems (Table 4.2) that unspecific union
exists while the peptide mimics join to TrkC receptor near to the antibody binding site,
as well as other places all over the cell surface.
Table 4.2.  FACS Competition Assay.
 NIH TrkC cells
 Comp’d mIgG NT-3 2B7
85gn 207.34 189.49 165.67
85hn 274.88 255.35 233.38
85jn 248.77 241.48 213.43
85kn 306.83 314.52 282
    
To determine if these four compounds were bioactive, a MTT assay was
performed using a concentration of 10 µM (see Chapter II for the details of MTT assay).
None of the compounds induces survival on NIH-Trk C cells (Table 4.3); this seems to
confirm lack of specific binding to TrkC receptors.
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Table 4.3.  Cell Survival Data for Compounds 85.
Comp'd NIH-TrkA cells NIH-TrkC-C1 cells NIH-IGF1-R cells
 SFM NGF low SFM NT-3 low SFM IGF low
untreated 0 0 0 0 0 0
85gn 0.88 6.11 -0.07 -3.84 -0.75 3.3
85hn -1.19 5.44 -0.91 -0.06 -0.75 2.98
85jn 0.31 8.21 -0.78 2.61 -4.05 -2.24
85kn 0.17 4.32 -1.8 -2.8 -4.58 -7.35
       
4.5 Summary
Syntheses of rationally designed non-peptidic mimics normally involve peptide
bond surrogates or scaffolds wherein the critical side-chains are retained and presented
in the proper region of space to maintain the desired biological properties. Our efforts
toward the synthesis of non-peptide mimetics have utilized an aryl-alkyne scaffold that
retains some properties of the amide bond.  Also, the functionalized amide acid side
chains can be sequentially introduced via Sonogashira coupling reactions.
This method produced a library of non-peptide mimics 84.  These compounds
contain variable side-chain analogs, ca. norleucine, isoleucine, arginine and lysine.
Short or long linkers were attached to the mimetics by amide or urea formation
reactions.  After removal of the Boc protecting groups, the monovalent compounds were
introduced onto the fluorescent-labeled triazine scaffold sequentially.  The bivalent
library of 105 compounds 85 was obtained in satisfactory analytical HPLC purity.
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CHAPTER V
BASE DEPENDENCE IN COPPER CATALYZED HUISGEN
REACTIONS: EFFICIENT FORMATION OF BISTRIAZOLS*
5.1 Introduction
“Click chemistry” has offered a pool of potential active compounds of lead
optimization and drug discovery.158  Reactions defined as “click” reactions take place
with high yields, mild conditions, and using reagents that have no impact on most other
functional groups.  Sharpless and coworkers have identified a number of reactions that
meet these criteria,5,6 the most powerful of which is the copper-accelerated3,4 Huisgen
additions1,159 of azides to alkynes.  They are undeniably useful in contemporary organic
chemistry for two reasons.  The first is that they are highly chemoselective; the
conditions of the reaction tend not to influence functional groups other than azides and
alkynes.  The second is that this type of click reaction is very robust.  They are
experimentally simple to run, and the conditions seem tolerant of many minor changes.
It has often been claimed that the copper mediated alkyne/azide cycloaddition reaction is
not sensitive to pH11,10.  However, we find that the course of the reaction can be altered
dramatically by adding carbonate bases, and that discovery is the basis of this chapter.
In our laboratory, a minor impurity was often observed via analytical HPLC
when preparing libraries of triazoles via these copper-mediated reactions.  LC-MS
analyses indicated these were oxidative dimers of the desired product (ie twice the
desired M+, less 2H).  Sharpless et al have previously noticed such minor by-products,
without reporting their characterization, and attributed them to direct use of CuI species.4
____________
* Reproduced in part with permission from “Base Dependence of Copper Catalyzed
Huisgen Reactions: Efficient Formation of Bistriazoles” by Angell Y. and Burgess K.
Angew. Chem. Int. Ed., 2007, 46, 3649-3651.  Copyright © 2007 WILEY-VCH Verlag
GmbH & Co. KGaA, Weinheim
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However, we observed significant amounts of these products when attempting
azide-alkyne couplings of crude substrates, even with a CuSO4/Cu powder system.  Here
we report that these oxidative dimers have the structure 88 and that, under basic
conditions, they can be the major products.
R1 -N
+N N R2+
copper catalysis
carbonate base
MeCN/H2O, air N
N
N N
NN
R2 R1
R1 R2
88
major product
Several groups have attempted to prepare bistriazoles by the 1,3-diploar
cycloaddition reactions.  All of them were conducted under thermal conditions and
elevated temperatures were required.  These cycloaddtion reactions are not
regioselective and the isomers have to be isolated with column chromatography.
Meanwhile, the scaffolds were rarely functionalized.  Huisgen 1,3-dipolar cycloaddition
reactions have been utilized to the syntheses of bistriazoles from diacetylene derivatives
with azides. 160,161   The cycloaddition between azides and alkynes is typically carried
out refluxing xylene, benzene or toluene.  Figure 5.1 shows the sequential cycloaddition
of diacetylene derivatives with azides.160  Bistriazoles Q, R, S and T were generated
when azides refluxed with triazole derivatives A and B in xylene.
In this chapter, oxidative “click” coupling to give 5,5’-bistriazoles is discussed.
The bistriazole products predominate in the copper accelerated “click reaction” of
alkynes and azides when carbonate bases are used as additives (ca 1 – 2 M).  The
reaction seems to be more facile for propargylic ethers and less hindered substrates.  Use
of an optically active azide gave separable atropisomeric products, providing a
convenient access into optically pure derivatives.
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Figure 5.1.  Bistriazole formation in thermal conditions.
5.2 Base Screening for the Formation of the Bistriazole Compounds
Variation of the reaction conditions was attempted to optimize the yield of
compound 88a in this Cu-mediated process; most of the data collected were negative
(see Appendix D).  For instance, triazole 89 was the main product when the reaction was
performed under nitrogen with Cu/CuSO4 as catalyst, but the catalyst was rapidly
deactivated and the starting materials remained when that reaction was performed under
pure oxygen.  Attempts were made to increase the amounts of oxidative dimer by adding
palladium catalysts, but these had little effect. Finally, pH was identified as the key
variable.  The model transformation in Table 5.1 was chosen because the oxidative
dimerization product 88a was fully characterized at an early stage in the work.
Compound 88a was a by-product in the presence of 1.5 M NaHCO3, and it was the
major one when K2CO3 was used.  The optimal base strength was 1 – 2 M; at higher
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concentrations the alkyne 90 became more prevalent.  Ammonium carbonate (entry 6)
gave only the normal click product 90 implying that Cu-NH3 coordination prevents
oxidative dimerization.  Entries 7 – 9 show that hydroxide or phosphate bases give
mixed results; this could mean that ligation of the carbonate to the copper assists
formation of oxidative dimer.  Other experiments with K2CO3 additive indicate that
oxidative dimerization is more prevalent in 1:1 MeCN/H2O than THF/H2O or
MeOH/H2O, but the differences were relatively small.  The extent of oxidative
dimerization was less when an inert atmosphere was used, but under pure oxygen the
reaction gave mostly starting materials.
Table 5.1.   Effects of bases on the oxidative dimerization process.
N
NN
N N
N
Bn
O
O
Bn
1.0 eq Cu powder
0.1 eq CuSO4
3 ml 1:1 MeCN/base(aq)
air, 25 oC, 18 h
88a
O
Br
O2N
+
Br
Br
O2N
O2N
N3 Bn
1 mmol 1 mmol
N N
NO
Bn
Br
O2N
N N
NO
Bn
Br
O2N
89 90
O
Br
O2N
+ +
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Table 5.1.  Continued.
product
distribution (%)aentry base
base(aq)
(M)
88a 89 90
1 NaHCO3 1.5 12 88 0
2 K2CO3 1.5 95 2 3
3 K2CO3 2.0 93 3 4
4 K2CO3 4.0 84 2 13
5 Na2CO3 2.0 95 3 2
6 (NH4)2CO3 2.0 0 100 0
7 LiOH 1.5 33 57 10
8 KOH 5.0 50 0 50
9 K3PO4 4.0 56 38 6
a Determined via analytical HPLC on a C18 column (MeCN, H2O).
5.3 Control Experiments
Figure 5.2 illustrates some control experiments performed to elucidate the origin
of the oxidative dimer 88a.  None of this material formed when the triazole 89 was
isolated then exposed to the conditions in Table 5.1, entry 2.  Similarly, isolated
compound 90 did not give any detectable amount of the oxidative dimer 88a when it was
mixed with benzyl azide then subjected to those reaction conditions.  Compounds 89 and
90 are therefore not intermediates in the formation of the oxidative dimer 88a.
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Figure 5.2. Control experiments.
5.4 Syntheses of Compounds 88a-g
Table 5.2 shows examples where the oxidative dimerization methodology was
extrapolated to other substrates.  In all cases the oxidative dimerization products 88 were
conveniently separated from the other materials via a simple flash chromatography.
Compounds 88a – d all gave propargylic O-atoms: this seems to enhance the yields
relative to compounds 88e – g.  The reaction did not work when the reactants were
hindered and, in such cases, the triazole forms but this requires more reaction time than
under neutral conditions (data not shown).
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Table 5.2.  Syntheses of bistriazole product 88.
N
N
N N
NN
R2 R1
R1 R21.0 Cu powder/0.1 CuSO4
1:1 MeCN/2M Na2CO3 (aq)
air, 25 oC, 18 h
R1 + N3 R2
88
comp’d R1 R2 isol’d yield (%)
88a O
O2N
Br
87
88b O
O2N
Br
O
N
NBoc 72
88c Ph O O
O tBu 47
88d Ph O Ph 69
88e Ph Ph 37
88f Ph O
O tBu 23
88g HO Ph 34
5.5 Synthesis of Compounds 88h-i via Convergent Desilyation
Many researchers using the Cu-mediated cycloaddition reactions access their
alkyne starting materials via Sonogashira157 reactions of trimethylsilylethyne, then
desilylation.  Trimethylsilyl protecting groups could also be deprotected with Ag(I) and
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“click” in one pot.162  In our research, the oxidative dimerization products 88 are the
desired end-point and we thought the basic conditions of the reaction might facilitate
deprotection of 1-trimethylsilyl alkynes in situ, saving a step.  Reactions in Figure 5.3
show how this idea was validated.
TMS N3 Bn+
N
N N
N
N N
Bn Bn
1.0 Cu powder/0.1 CuSO4
1:1 MeCN/2M Na2CO3 (aq)
air, 25 oC, 18 h
88h  25 %
1 eq 1 eq
S TMS N3 Bn
+
1.0 Cu powder/0.1 CuSO4
1:1 MeCN/2M Na2CO3 (aq)
air, 25 oC, 18 h
N
N
N
N N
N Bn
BnS
S
11 %
N
N
N
Bn
S
88i  38 %
+
Figure 5.3. Bistriazole formation from TMS protected precursors via convergent
desilyation.
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5.6 Physical Properties of Bistriazoles
The bistriazole core of molecules 88 has not previously been reported with this
substitution pattern (though regioisomeric materials have been made).160  Figure 5.4
shows a molecular representation from a single crystal X-ray diffraction analysis of
compound 88e.   Rotation around the C-C bond that connects the two rings is highly
hindered, hence the molecules are chiral and the enantiomeric forms do not interconvert
under ambient conditions.  Consistent with this, the AB quartet pattern observed for the
benzylic protons of compound 88e at ambient temperature did not coalesce into a singlet
when the sample was heated to 115 °C in DMSO.
 
N
N N
NN
N
88e
Figure 5.4.  Representation of 88e from single crystal X-ray diffraction.
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5.7 Asymmetric Synthesis of Bistriazoles
Production of optically active 5,5’-bistriazoles is likely to be of most interest for
syntheses of new chiral ligands and auxiliaries.  In such compounds the heterocyclic
core is a stereoelectronic variation, and a patentable modification, of chiral biaryl cores,
very frequently encountered in ligands.163  Two reactions were performed to explore this
concept.  Reactions shown in Figure 5.5 and Figure 5.6 gave unexceptional
diastereoinductions, but the products were easily separated via flash chromatography, so
the approach is extremely practical. In the case of the chiral bipyridyl product, the
stereochemistry of the atropisomeric chiral center of the minor product was proven via
single crystal X-ray crystallographic analysis. (Figure 5.7)
N3
O
N NBoc
PhO +
1.0 Cu powder/0.1 CuSO4
1:1 MeCN/2M Na2CO3 (aq)
air, 25 oC, 18 h
N
N
N
N N
N
N
O
N
O NBoc
NBocPhO
PhO
88j
dr  of crude material  3:2
isol'd yields: major 42 %, minor 14 %
N
N
N
N
O
NBocPhO
12 %
N
N
N
N
O
NBocPhO
OPh
7%
+
+
Figure 5.5.  Synthesis of the optically active bistriazole from propargyl phenyl ether.
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Figure 5.6.  Synthesis of the chiral bipyridyl product.
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Figure 5.7.  The stereochemistry of the bistriazole atropisomeric chiral center in the
minor diastereomer 88k.
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The fact that compounds 89 and 90 (Table 5.1) do not react to form the 5,5’-
bistriazole 88a rules out these as intermediates for the reaction, and the possible
involvement of diynes.  It seems highly likely that the reaction therefore proceeds via
coupling of two organocopper species.  Sodium or potassium carbonate is favorable for
the dimerization process.  It could be that carbonate bridged copper dimers are
particularly well suited to the process, and these do not form efficiently from sodium
bicarbonate (entry 1). Ammonia from ammonium bicarbonate may inhibit formation of
this carbonate complex or its mode of action (entry 6).   Dicopper species have been
implicated in copper-mediated additions of azide to alkyne,4,10 and carbonate bridged
dicopper complexes are known.164-166  A plausible mechanism for the reaction therefore
features two σ-bonded triazole units coming together in oxidative coupling reaction, for
which carbonate is a particularly favorable bridging ligand. However, we have no direct
evidence to implicate dicopper species or the bridging carbonate ligand at this time.
5.8 Summary
In summary, oxidative coupling can be the prevalent pathway in copper-mediated
Huisgen reactions of azides and terminal alkynes.  This is surprising because it has been
stated several times in the literature that pH is relatively unimportant for copper-
mediated cycloadditions to give triazoles.4,10  5,5’-Bistriazoles are an under-explored
heterocyclic backbone.  However, the reactions described here allow ready access to
these compounds and should provide a foundation for further studies.   In particular, use
of optically active constituents provides a way to make and isolate diastereomerically
pure derivatives representing different atropisomeric forms.  Overall, these findings may
impact ligand syntheses and development of libraries to screen for pharmaceutical lead
compounds; it should influence the strategies used by researchers to design conditions
for formation of triazole or bistriazole products.
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CHAPTER VI
CONCLUSIONS
Strategies in design and synthesis of triazole based β-turn peptidomimetics have
been discussed.  The approaches involve preparation of new type of triazole mimics and
bivalent turn analogs to enhance the probability of finding bioactive molecules.  Copper-
mediated Huisgen 1,3-dipolar cycloaddition reaction has been used to synthesis small
molecule peptidomimetics in solution phase.  The cycloaddition reaction is fast, simple
to perform, and compatible with many solvents and functional groups.  This serves as an
excellent way to make peptidomimetics, particularly because there is some
stereoelectronic and topological similarity between 1,2,3-triazoles and amide bonds.  It
is expected that 1,2,3-triazole cores could form the basis of small molecule
pharmaceutical leads in which they fulfill some binding function of peptides, even
though the molecular resemblance of these compounds to peptides is obscure.
Chapter II has illustrated the approach to β-turn conformations using copper-
medicated cycloaddition reaction as macrocyclization method.  In solution, linear
peptidomimetic substrates were used to form the cyclic derivatives.  A library of eight
cyclic peptidomimetics was prepared and the low yield was mostly due to formation of
dimers.  Computational and NMR analyses of the cyclic compounds 61a-c indicate that
their most favorable conformational states include type I and type II β-turn
conformations.  However, the CD data do not closely fit the spectra commonly
associated with type I and II turn conformations, indicating non-ideal matches and/or
other important contributions to the conformational ensemble.  Selectivity for the
dimeric products 65 in these cyclisation reactions is discussed.  We suggest that the
perfect regioselectivity of the copper mediated cycloaddition processes for 1,4-
disubstituted triazoles would require that the azido alkyne coils in an endo-like
conformation to form a monomeric cyclization product.
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In our search of more reliable models that can be used to prepare later generation
of therapeutic candidates, second generation peptidomimetics with less peptidic structure
and more convergent synthesis were developed.  Our molecular modeling indicated that
the triazole moiety shares very close topological similarities with the amide bond.  The
pharmacophores placed around the triazole core are allowed to rotate freely to find the
appropriate region of space for docking to occur.  As described in Chapter III, a library
of small-molecule triazole mimics was prepared via “click” reactions in solution.
Compared to the traditional solid phase synthesis, the new design is far more convergent
and low cost.  The “click” reactions allow quick and efficient generation of the desired
peptidomimetics in good yields.  One major drawback in this design is that one of the
functionalities placed around the triazole core is not derived from a nature amino acid.
This might lower the similarity of the designed molecule to the natural β-turn.  Another
group member has prepared a library of triazole mimics with both side-chains derived
from natural amino acids.  The biological assay of the new library is in progress.
The more challenging approach in our turn analog synthesis involves the
development of the methodology for the formation of bivalent mimics in solution.  Both
Chapter III and IV have described the approach that monovalent mimics are coupled to
the linker scaffold sequentially in solution by simply manipulating the solvent systems.
Libraries of simple bivalent systems containing guanidine, primary amine, alcohol and
carboxylic acid functionalities have been prepared to demonstrate this principle.  In the
attempt to mimic neurotrophins function, the “mix and match” linker design was
developed in Chapter IV.  Bivalent turn mimics with optimal-length linkage have been
prepared. The new solution-phase combinatorial method allows us to prepare large
libraries of bivalent compounds quickly and efficiently.  The two monovalent
components were combined with each other to achieve one-compound-per-well in
sufficient purity for biological testing.
As shown in Chapter V, Oxidative coupling to give 5,5’-bistriazoles has been
discussed.  The bistriazoles become the predominant products in the copper accelerated
“click reaction” of alkynes and azides when manipulating the bases in the reaction.
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Conditions with carbonate bases as additives (ca 1 – 2 M) have been found to be the
most effective.  Starting materials like propargylic ethers and less hindered substrates
could give higher yields.  Use of optically active azides has afforded separable
atropisomeric products, providing a convenient access to optically pure derivatives.
Copper-catalyzed 1,3-dipolar cycloaddition reactions are undeniably useful in
contemporary organic chemistry, but disadvantages still exist in these reactions.  Azides
and copper used in the reactions are both possible safety- and environmental-hazards.
Further, macrocyclization reactions can be complicated by somewhat mysterious
macrodimerization events.  Nevertheless, the fact that there are convenient routes to
amino-acid-derived azides and alkynes, and the lack of practical obstacles to executing
these Cu-mediated reactions, both exhibit a promising future for the peptidomimetics
formed via this route.
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APPENDIX A
EXPERIMENTAL FOR CHAPTER II
General Methods.  All the amino acids used had the L-configuration and they
were purchased from NovaBiochem, Advance BioTech or Chem-Impex.  All chemicals
were obtained from commercial suppliers and used without further purification.  N-
Hydroxybenzotriazole (HOBt), N-methylmorpholine, N,N-diisopropylethylamine, acetyl
chloride (AcCl) were purchased from Aldrich. Ethyl-(N’,N’-
dimethylamino)propylcarbodiimide (EDC) was obtained from Advanced ChemTech.
Dichloromethane was obtained anhydrous by distillation over calcium hydride and THF
was distilled over sodium metal and benzophenone.  Reverse phase high performance
liquid chromatography (RP-HPLC) was carried out on Vydac C-18 column with the
dimension of 25 x 0.46 cm for analytical studies, and on XTerra C – 18 column with the
dimension of 10 x 1.9 cm for preparative work.  All HPLC experiments were performed
using gradient conditions.  The eluents used were: solvent A (H2O with 0.1% TFA) and
solvent B (CH3CN with 0.1% TFA).  The flow rate used was 1.0 mL/min for analytical,
and 10 ml/min for preparative HPLC.  NMR spectra of compounds 62a-c, 63a-h, 61a-h,
66 and 67 were recorded on Inova instruments at 300 MHz and at 500 MHz for
compounds 64a-h and 61a-h.  NMR chemical shifts were expressed in ppm relative to
internal solvent peaks, and coupling constants were measured in Hz.
General Procedure for Preparation of 62a-c.  Propargyl amine (1.0 equiv) was added
to a suspension of Boc protected amino acid (1.1 equiv) (0.2 M) in dry CH2Cl2.  N-
methylmorpholine (1.1 equiv) was added to the above suspension followed with HOBt
(1.1 equiv) and EDC (1.1 equiv).  The resulting solution was stirred at room temperature
for 4h.  Ethyl acetate (40 ml) was added to the reaction mixture, and the resulting
suspension was washed with 5% HCl (30 ml), H2O (30 ml), 5% Na2CO3 (30 ml) and
brine (30 ml).  The organic layer was separated and dried with Na2SO4 and concentrated
to dryness.  Recrystallization with EtOAc and hexanes afforded 62a-c.
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Lysine Derivative 62a
BocHN
H
N
O
NHCbz
62a
Compound 62a was prepared from Boc-Lys(Cbz)-OH (5.50 mmol, 2.09 g).
Recrystallization afforded 62a (1.94 g, 93%) as a white solid.
1H NMR (CDCl3) 7.32 (m, 5H), 5.54 (s, 1H), 5.28 (d, 1H, J = 4.8 Hz), 5.07 (s, 2H), 4.16
(d, 1H, J = 5.4 Hz), 3.98 (dd, 2H, J = 5.4 Hz, 2.7 Hz), 3.15 (m, 2H), 2.21 (t, 1H, J = 2.1
Hz), 1.77 (m, 1H), 1.63 (m, 1H), 1.48 (m, 2H), 1.42 (s, 9H), 1.36 (m, 2H)
13C NMR (CDCl3) 172.5, 156.9, 156.1, 136.9, 128.7, 128.3, 128.1, 80.2, 79.8, 71.8,
66.8, 54.4, 40.8, 32.4, 29.7, 29.2, 28.6, 22.8
MS (ESI, m/z) 440 (M+Na)+
132
1H NMR of 62a
13C NMR of 62a
133
Glycine Derivative 62b
BocHN
H
N
O
62b
Compound 62b was prepared from Boc-Gly-OH (5.50 mmol, 0.88 g). Recrystallization
afforded 62b (1.0 g, 94%) as a white solid.
1H NMR (CDCl3) 7.29 (s, 1H), 5.41 (s, 1H), 4.08 (dd, 2H, J = 5.4 Hz, 2.7 Hz), 3.84 (d,
2H, J = 5.7 Hz), 2.25 (t, 1H, J = 2.7 Hz), 1.47 (s, 9H)
13C NMR (CDCl3) 169.6, 156.4, 80.7, 79.5, 71.9, 44.5, 29.3, 28.6
MS (ESI, m/z) 213 (M+H)+
1H NMR of 62b
134
13C NMR of 62b
Serine Derivative 62c
BocHN
H
N
O
62c
OBn
Compound 62c was prepared from Boc-Ser(Bn)-OH (5.5 mmol, 1.48 g).
Recrystallization afforded 62c (1.61 g, 97%) as a white solid.
1H NMR (CDCl3) 7.38-7.27 (m, 5H), 6.76 (s, 1H), 5.41 (s, 1H), 4.55 (dd, 2H, J = 21.3
Hz, 9.3 Hz), 4.30 (s, 1H), 4.06 (d, 2H, J = 2.4 Hz), 3.90 (dd, 1H, J = 9.0 Hz, 5.4 Hz),
3.58 (dd, 1H, J = 9.3 Hz, 6.3 Hz), 2.23 (t, 1H, J = 2.6 Hz), 1.45 (s, 9H)
13C NMR (CDCl3) 170.4, 156.4, 137.6, 128.8, 128.2, 128.1, 80.7, 79.5, 73.7, 72.0, 70.0,
54.1, 29.5, 28.6
MS (ESI, m/z) 339 (M+Li)+
135
1H NMR of 62c
13C NMR of 62c
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General Procedure for Preparation of 63a-h. To a solution of 62a-c in 20:1
EtOAc/MeOH (0.15 M) was added AcCl (5 equiv) dropwise and the resulting mixture
was stirred at 0 °C for 2 h in a sealed flask, then warmed to room temperature for
another 2h.  Solvent was removed and the residue was used without further purification.
To a suspension of the above residue (1 equiv) in dry CH2Cl2 was added Boc protected
amino acid (1.1 equiv) followed by addition of NEt3 (2.5 equiv), HOBt (1.1 equiv) and
EDC (1.1 equiv).  The resulting suspension (0.075 M) was stirred at room temperature
for 4 h. EtOAc was added to the reaction and extracted with 5% HCl, H2O, 5% Na2CO3
and brine. The organic layer was dried with Na2SO4 and concentrated to dryness.
Recrystallization with EtOAc and hexanes provided 63a-h.
Isoleucine – Lysine Derivative 63a
N
H
H
N
O
O
BocHN
NHCbz
63a
Compound 63a was prepared from 62a (3.0 mmol, 1.25 g) and Boc-Ile-OH·0.5 H2O (3.3
mmol, 0.79 g). Recrystallization afforded 1.60 g (99%) 63a as a white solid
1H NMR (CD3OD) 7.19-7.07 (m, 5H), 4.85 (s, 2H), 4.11 (dd, 1H, J = 8.4 Hz, 2.7 Hz),
3.73 (dd, 2H, J = 7.5 Hz, 2.4 Hz), 3.68 (t, 1H, J = 6.3 Hz), 2.89 (t, 2H, J = 6.6 Hz), 2.36
(t, 1H, J = 2.1 Hz), 1.57 (m, 2H), 1.48 (m, 1H), 1.28 (m, 3H), 1.23 (s, 9H), 1.18 (m, 2H),
0.96 (m, 1H), 0.72-0.66 (m, 6H)
13C NMR (CDCl3) 172.5, 171.6, 156.9, 156.3, 136.9, 128.7, 128.3, 128.1, 80.3, 79.7,
71.8, 66.8, 59.7, 53.0, 40.7, 37.5, 31.8, 29.6, 29.3, 28.6, 25.0, 22.7, 15.9,11.6
MS (ESI, m/z) 553 (M+Na)+
137
1H NMR of 63a
13C NMR of 63a
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Glumatic Acid – Lysine Derivative 63b
N
H
H
N
O
O
BocHN
NHCbz
63b
COOBn
Compound 63b was prepared from 62a (3.0 mmol, 1.25 g) and Boc-Glu(Bn)-OH (3.3
mmol, 1.10 g). Recrystallization with EtOAc and hexanes afforded 1.45 g (85%) 63b as
a white solid.
 1H NMR (CD3OD) 7.22-7.17 (m, 10H), 5.00 (s, 2H), 4.98 (s, 2H), 4.18 (dd, 1H, J = 8.4
Hz, 3.0 Hz); 3.95 (m, 2H), 2.98 (t, 2H, J = 6.6 Hz ), 2.43 (t, 1H, J = 2.4 Hz), 2.35 (t, 2H,
J = 7.5 Hz), 1.95 (m, 1H), 1.79(m, 1H), 1.71 (m, 1H), 1.67 (m, 1H), 1.53-1.18 (m, 13H)
13C NMR (CDCl3) 173.4, 172.4, 171.6, 157.0, 156.2, 136.9, 136.0, 128.8, 128.7, 128.5,
128.4, 128.3, 128.1, 80.4, 79.8, 71.9, 66.8, 54.2, 53.1, 40.8, 32.2, 30.7, 29.6, 29.3, 28.6,
28.0, 22.7
MS (ESI, m/z) 659 (M+K)+
1H NMR of 63b
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13C NMR of 63b
Threonine – Glycine Derivative 63c
N
H
H
N
O
O
BocHN
63c
OBn
Compound 63c was prepared from 62b (2.7 mmol, 0.57 g) and Boc-Thr(Bnl)-OH (3.0
mmol, 0.93 g). Recrystallization afforded 1.01 g (93%) 63c as a white solid.
1H NMR (CDCl3) 7.39-7.23 (m, 5H), 7.13 (s, 1H), 7.01 (s, 1H), 5.52 (d, 1H, J = 6.6
Hz), 5.23 (d, 1H), 4.58 (q, 2H, J = 36 Hz, 11.4 Hz), 4.26 (dd, 1H, J = 6.6 Hz, 3.0 Hz),
4.17 (dd, 1H, J = 6.3 Hz, 3.0 Hz), 3.95 (m, 2H), 2.21 (t, 1H, J = 2.4 Hz), 1.48 (s, 9H),
1.25 (d, 3H, J = 6.3 Hz)
13C NMR (CDCl3) 171.2, 168.7, 156.3, 137.9, 128.8, 128.2, 128.0, 80.9, 79.6, 74.8,
71.8, 66.8, 59.0, 43.4, 29.3, 28.6, 16.1
MS (ESI, m/z) 410 (M+Li)+
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1H NMR of 63c
13C NMR of 63c
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Glycine – Lysine Derivative 63d
N
H
H
N
O
O
BocHN
NHCbz
63d
Compound 63d was prepared from 62a (3.0 mmol, 1.25 g) and Boc-Gly-OH (3.3 mmol,
0.58 g). Recrystallization afforded 1.38 g (97%) 63d as a white solid.
1H NMR (CD3OD) 7.34-7.27 (m, 5H), 5.05 (s, 2H), 4.32 (dd, 1H, J = 7.5 Hz, 3.3 Hz),
3.94 (d, 2H, J = 2.4 Hz), 3.70 (s, 2H), 3.10 (t, 2H, J = 6.9 Hz), 2.56 (t, 1H, J = 2.4 Hz),
1.67 (m, 1H), 1.61 (m, 1H), 1.49 (m, 2H), 1.44 (s, 9H), 1.35(m, 2H)
13C NMR (CDCl3) 171.8, 170.4, 157.0, 156.6, 136.9, 128.8, 128.3, 128.1, 80.6, 79.7,
71.8, 66.8, 53.1, 44.5, 40.7, 32.1, 29.6, 29.3, 28.6, 22.7
MS (ESI, m/z) 475 (M+H)+
1H NMR of 63d
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13C NMR of 63d
Lysine – Glycine Derivative 63e
N
H
H
N
O
O
BocHN
63e
NHCbz
Compound 63e was prepared from 62b (3.0 mmol, 0.63 g) and Boc-Lys(Cbz)-OH (3.3
mmol, 1.26 g). Recrystallization afforded 1.25 g (88%) 63e as a white solid.
1H NMR (CDCl3) 7.37-7.29 (m, 5H), 5.68 (d, 1H, J = 5.4 Hz), 5.29 (s, 1H), 5.08 (s,
2H), 4.02 (m, 3H), 3.94 (d, 2H, J= 5.4 Hz), 3.15 (t, 2H, J= 6.3 Hz), 2.20 (t, 1H, J = 2.4
Hz), 1.80 (m, 1H), 1.65 (m, 1H), 1.50 (m, 2H), 1.42 (s, 9H), 1.36 (m, 2H)
13C NMR (CDCl3) 173.5, 169.3, 157.1, 156.6, 136.8, 128.8, 128.4, 128.1, 80.7, 79.7,
71.7, 66.9, 55.5, 43.2, 40.4, 31.5, 29.7, 29.3, 28.6, 22.7
MS (ESI, m/z) 475 (M+H)+
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1H NMR of 63e
13C NMR of 63e
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Glycine – Serine Derivative 63f
N
H
H
N
O
O
BocHN
63f
OBn
Compound 63f was prepared from 62c (1.5 mmol, 0.50 g) and Boc-Gly-OH (1.64 mmol,
0.29 g). Recrystallization with EtOAc and hexanes afforded 0.23 g (50%) 63f as a white
solid.
1H NMR (CDCl3) 7.49 (s, 1H), 7.37-7.25 (m, 5H), 5.70 (t, 1H, J = 5.4 Hz), 4.65 (t, 1H,
J = 3.6 Hz), 4.50 (dd, 2H, J = 14.4 Hz, 12.0 Hz), 4.05-3.91 (m, 3H), 3.77 (d, 1H, J = 5.1
Hz), 3.59 (dd, 1H, J = 9.6 Hz, 5.4 Hz), 2.21 (t, 1H, J = 2.4 Hz), 1.44 (s, 9H)
13C NMR (CDCl3) 170.2, 170.0, 156.8, 137.7, 128.7, 128.1, 128.0, 80.7, 79.7, 73.6,
71.7, 69.7, 53.1, 44.7, 29.5, 28.6
MS (ESI, m/z) 390 (M+H)+
1H NMR of 63f
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13C NMR of 63f
Serine – Glycine Derivative 63g
N
H
H
N
O
O
BocHN
63g
BnO
Compound 63g was prepared from 62a (3.0 mmol, 1.25 g) and Boc-Ser(Bn)-OH (3.3
mmol, 0.97 g). Recrystallization afforded 0.97 g (83%) 63g as a white solid.
1H NMR (CDCl3) 7.60 (s, 1H), 7.41 (s, 1H), 7.31-7.25 (m, 5H), 5.76 (t, 1H, J = 6.3 Hz),
4.52 (s, 2H), 4.35 (t, 1H, J = 3.6 Hz), 4.96-3.81 (m, 5H), 3.63 (dd, 1H, J = 15.3 Hz, 5.4
Hz), 2.18 (t, 1H, J = 2.4 Hz), 1.42 (s, 9H)
13C NMR (CDCl3) 171.3, 169.1, 156.1, 137.5, 128.8, 128.2, 128.0, 80.7, 79.8, 73.6,
71.7, 70.1, 55.1, 43.2, 29.1, 28.6
MS (ESI, m/z) 412 (M+Na)+
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1H NMR of 63g
13C NMR of 63g
147
Tyrosine – Serine Derivative 63h
N
H
H
N
O
O
BocHN
63h
OBn
BnO
Compound 63h was prepared from 63c (1.5 mmol, 0.50 g) and Boc-Tyr(Bn)-OH (1.64
mmol, 0.61 g). Recrystallization with EtOAc and hexanes afforded 0.80 g (92%) 63h as
a white solid.
1H NMR (CDCl3) 7.47-7.27 (m, 10H), 7.15 (d, 2H, J = 8.4 Hz), 7.08 (s, 1H), 6.96 (d,
2H, J = 8.4 Hz), 6.80 (d, 1H, J = 7.8 Hz), 5.06 (s, 1H), 4.96 (d, 1H, J = 5.1 Hz), 4.60-
4.44 (m, 3H), 4.31 (dd, 1H, J = 7.2 Hz, 5.7 Hz), 4.14-3.97 (m, 3H), 3.54 ( dd, 1H, J = 9.3
Hz, 5.1 Hz), 3.12 (dd, 1H, J = 14.3 Hz, 8.7 Hz), 2.96 (dd, 1H, J = 14.1 Hz, 7.8 Hz), 2.21
(t, 1H, J = 2.4 Hz), 1.41 (s, 9H)
13C NMR (CDCl3) 171.5, 169.7, 158.3, 137.8, 137.1, 130.5, 128.9, 128.7, 128.4, 128.3,
128.2, 128.0, 127.8, 115.5, 81.3, 79.9, 73.6, 71.5, 70.3, 69.4, 56.8, 53.1, 37.1, 29.5, 28.5
MS (ESI, m/z) 586 (M+H)+
1H NMR of 63h
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13C NMR of 63h
General Procedure for preparation of 60a-h. To a solution of 63a-h in 20:1
EtOAc/MeOH (0.15 M) was added AcCl (5 equiv) dropwise and the resulting mixture
was stirred at 0 °C for 2 h in a sealed flask and warmed to room temperature for another
2h.  Solvent was removed and the residue was used without further purification.
Triethylamine (2.5 equiv) was added to a solution of the above residue (1 equiv) in dry
THF (0.1-0.2 M). The resulting mixture was stirred for 10 min and treated with DMAP
(0.7 equiv). Freshly prepared 2-azido-benzoyl chloride (from 1 equiv.of 2-azidobenzoic
acid, See Takeuchi, H.; Hagiwara, Eguchi, S. Tetrahedron 1989, 45, 6375-6386) in dry
THF (0.5 M) was added dropwise to the solution and the resulting mixture was stirred
for 2h at room temperature. The reaction mixture was poured into ice water and the
white precipitate was filtered with a fine frit funnel and rinsed with small portions of
water three times. The precipitate was dried under vacuum and recystallized with EtOAc
and hexanes afforded 60a-h as white or slightly yellow solid.
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Linear Isoleucine – Lysine Derivative 60a
N
H
H
N
O
OH
N
NHCbz
60a
O
N3
Compound 60a was prepared from (1.9 mmol, 0.98 g) of 63a. Crystallization afforded
0.76 g (88%) 60a as a white solid.
1H NMR (CD3OD) 7.62 (d, 1H, J = 7.8Hz), 7.47 (t, 1H, 7.8 Hz), 7.21-7.10 (m, 7H),
4.93 (s, 2H), 4.36 (d, 1H, J = 7.5 Hz), 4.25 (t, 1H, J = 6.6 Hz), 3.85 (m, 2H), 2.99 (t, 2H,
J = 5.6 Hz), 2.47 (t, 1H, J = 2.6 Hz), 1.86-1.23 (m, 9H), 0.90 (d, 3H, J = 4.8 Hz), 0.83 (t,
3H, J = 7.2 Hz)
13C NMR (CD3OD) 173.6, 173.5, 168.4, 158.9, 139.0, 138.4, 133.5, 131.5, 129.5,
128.9, 128.8, 127.6, 126.1, 120.1, 80.4, 72.4, 67.3, 59.9, 54.5, 41.5, 38.3, 32.8, 30.4,
29.5, 26.2, 24.0, 16.1, 11.5
MS (ESI, m/z) 576 (M+H)+
1H NMR of 60a
150
13C NMR of 60a
Linear Glutamic Acid – Lysine Derivative 60b
N
H
H
N
O
OH
N
NHCbz
COOBn
60b
O
N3
Compound 60b was prepared from (1.0 mmol, 0.64 g) of 63b.  Crystallization afforded
0.52 g (70%) 60b as a white solid.
1H NMR (CD3OD) 7.62 (d, 1H, J = 8.1 Hz), 7.46 (t, 1H, 7.8 Hz), 7.24-7.11 (m, 7H),
5.06 (s, 2H), 5.02 (s, 2H), 4.55 (t, 1H, J = 6.8 Hz), 4.26 (t, 1H, J = 6.8 Hz), 3.85 (dd, 2H,
J = 17.4, 25.2), 3.01 (t, 2H, J = 7.8 Hz), 2.48 (m, 3H), 2.20 (m, 1H), 2.00 (m, 1H), 1.72,
(m, 1H), 1.62 (m, 1H), 1.43-1.33 (m, 4H)
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13C NMR (CD3OD) 171.6, 170.9, 170.6, 165.7, 158.9, 136.3, 125.9, 134.8, 130.8,
128.7, 126.8, 126.7, 126.5, 126.2, 126.0, 124.8, 123.3, 117.3, 77.7, 69.6, 64.7, 64.6,
51.9, 51.8, 38.7, 30.2, 28.6, 27.7, 26.8, 25.4, 21.2
MS (ESI, m/z) 704 (M+Na)+
1H NMR of 60b
13C NMR of 60b
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Linear Threonine – Glycine Derivative 60c
N
H
H
N
O
OH
N
60c
O
N3
OBn
Compound 60c was prepared from (1.0 mmol, 0.40 g) of 63c. Crystallization afforded
0.35 g (70%) 60c as a slightly yellowish solid.
1H NMR (CDCl3) 8.41 (d, 1H, J = 6.6 Hz), 8.10 (dd, 1H, 7.8 Hz, 1.5 Hz), 7.50 (m, 2H),
7.36-7.27 (m, 5H), 7.20 (m, 2H), 4.72-4.56 (m, 3H), 4.29 (dd, 1H, J = 6.3Hz, 3.0 Hz),
3.98 (t, 2H, J = 5.9 Hz), 2.18 (t, 1H, 2.4 Hz), 1.31 (d, 6.3 Hz)
13C NMR (CDCl3) 170.71, 168.8, 165.6, 138.1, 137.9, 133.2, 132.4, 128.8, 128.2,
127.8, 125.4, 124.3, 118.7, 79.7, 74.4, 71.7, 71.6, 58.9, 43.4, 29.2, 16.6
MS (ESI, m/z) 471 (M+Na)+
1H NMR of 60c
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13C NMR of 60c
Linear Glycine – Lysine Derivative 60d
N
H
H
N
O
OH
N
NHCbz
60d
O
N3
Compound 60d was prepared from (1.1 mmol, 0.52 g) of 63d. Crystallization afforded
0.49 g (85%) 60d as a white solid.
1H NMR (CD3OD) 7.67 (d, 1H, J = 7.8 Hz), 7.44 (t, 1H, J = 8.1 Hz), 7.24-7.10 (m, 7H),
4.95 (s, 2H), 4.34 (q, 5.4 Hz, 8.7 Hz, 3.3 Hz), 4.02 (dd, 2H, 21.0 Hz, 5.2H), 3.88 (d, 2H,
2.1 Hz), 3.01 (t, 1H, J = 6.6 Hz), 2.51 (t, 1H, 2.6 Hz), 1.74 (m, 1H), 160 (m, 1H), 1.43-
1.30 (m, 4H)
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13C NMR (CD3OD) 171.0, 168.7, 165.7, 156.2, 136.3, 135.8, 131.0, 129.1, 126.9,
126.3, 126.1, 124.3, 123.4, 117.4, 77.9, 69.9, 64.7, 51.8, 41.6, 38.9, 30.4, 27.8, 26.9,
21.2
MS (ESI, m/z) 526 (M+Li)+
1H NMR of 60d
13C NMR of 60d
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Linear Lysine – Glycine Derivative 60e
N
H
H
N
O
OH
N
60e
O
N3
NHCbz
Compound 60e was prepared from (1.0 mmol, 0.47 g) of 63e. Crystallization afforded
0.42 g (80%) 60e as a white solid.
1H NMR (CD3OD) 7.67 (d, 1H, J = 7.5 Hz), 7.44 (t, 1H, J = 7.5 Hz), 7.21-7.10 (m, 7H),
4.92 (s, 2H), 4.40 (dd, 1H, 5.4 Hz, 3 Hz), 3.80 (m, 4H), 3.04 (t, 2H, 6.2 Hz), 2.49 (t, 1H,
J = 2.4 Hz), 1.83 (m, 1H), 1.73 (m, 1H), 1.43 (m, 4H)
13C NMR (CD3OD) 172.1, 168.3, 166.0, 156.2, 136.4, 130.8, 128.9, 126.8, 126.2,
126.1, 124.7, 123.3, 117.3, 77.8, 69.6, 64.6, 53.1, 40.9, 38.7, 29.7, 27.7, 26.9, 26.8, 21.3
MS (ESI, m/z) 520 (M+H)+
1H NMR of 60e
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13C NMR of 60e
Linear Glycine – Serine Derivative 60f
N
H
H
N
O
OH
N
60f
O
N3 OBn
Compound 60f was prepared from (0.7 mmol, 0.27 g) of 63f. Crystallization afforded
0.17 g (52%) 60f as a slightly yellowish solid.
1H NMR (CDCl3) 8.24 (t, 1H, J = 5.1 Hz), 7.96 (q, 1H, 7.8 Hz, 1.2 Hz), 7.55 (m, 2H),
7.42 (m, 1H), 7.20 (m, 5H), 7.16 (d, 1H, J = 7.5 Hz), 7.08 (m, 1H), 4.69 (dd, 1H, J = 8.4
Hz, 4.8 Hz)), 4.43 (dd, 1H, 18 Hz, 6 Hz), 4.20 (dd, 1H, 11.4 Hz, 5.7 Hz), 4.06 (dd, 1H,
11.4 Hz, 5.7 Hz), 4.03 (dd, 1H, J = 5.4 Hz, 2.7 Hz), 3.96 (dd, 1H, 5.4 Hz, 2.7 Hz), 3.92
(dd, 1H, J = 4.8 Hz, 2.4 Hz), 3.87 (dd, 1H, 9.6Hz, 5.4Hz), 3.56 (dd, 1H, 9.3 Hz, 5.4 Hz),
2.16 (t, 1H, J = 2.1 Hz)
13C NMR (CDCl3) 169.9, 169.6, 165.9, 137.7, 137.7, 132.9, 132.0, 128.6, 128.0, 127.9,
125.2, 124.6, 118.7, 79.8, 73.5, 71.7, 69.7, 53.3, 44.3, 29.5
MS (ESI, m/z) 441 (M+Li)+
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1H NMR of 60f
1H NMR of 60f
158
Linear Serine – Glycine Derivative 60g
N
H
H
N
O
OH
N
60g
O
N3
OBn
Compound 60g was prepared from (1.0 mmol, 0.39 g) of 63g. Crystallization afforded
0.35 g (81%) 60g as a yellowish solid.
1H NMR (CD3OD) 7.55 (d, 1H, J = 7.8 Hz), 7.42 (d, 1H, J = 7.8 Hz), 7.18-7.03 (m,
7H), 4.54 (t, 1H, J =4.8 Hz), 4.41 (s, 2H), 3.76-3.62 (m, 6H), 2.37 (t, 1H, J = 2.4 Hz)
13C NMR (CD3OD) 169.9, 168.3, 165.3, 136.6, 136.4, 131.3, 129.4, 126.8, 126.2,
125.2, 123.6, 123.3, 117.4, 77.7, 71.6, 69.7, 67.8, 53.2, 40.9, 26.7
MS (ESI, m/z) 457 (M+Na)+
1H NMR of 60g
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13C NMR of 60g
Linear Tyrosine – Serine Derivative 60h
N
H
H
N
O
OH
N
60h
O
N3 OBn
OBn
Compound 60h was prepared from (1.0 mmol, 0.59 g) of 63h. Crystallization afforded
0.52 g (83%) 60h as a yellowish solid.   
1H NMR (CDCl3) 8.16 (d, 1H, J = 7.8 Hz), 8.04 (t, 1H, J = 4.5 Hz), 7.54 (t, 1H, J = 7.8
Hz), 7.46-7.35 (m, 6H), 7.29-7.10 (m, 13H), 6.99 (d, 2H, J = 8.4 Hz), 6.89 (d, 1H, J =
4.8 Hz), 5.05 (s, 2H), 4.78 (dd, 1H, J = 12 Hz, 6 Hz), 4.66 (dd, 1H, J = 8.4 Hz, 4.2 Hz),
4.48 (dd, 2H, J = 24.6 Hz, 12.6 Hz), 4.18-3.95 (m, 3H), 3.59 (dd, 1H, J = 9.6 Hz, 4.2
Hz), 3.27 (dd, 1H, J = 13.8 Hz, 7.8 Hz), 3.15 (dd, 1H, J = 14.1 Hz, 6.6 Hz), 2.21 (t, 1H, J
= 2.4 Hz)
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13C NMR (CDCl3) 171.1, 169.7, 166.1, 158.5, 137.7, 137.7, 137.0, 133.4, 132.7, 130.8,
128.9, 128.6, 128.4, 128.3, 128.0, 127.8, 127.7, 125.5, 123.8, 118.8, 115.4, 79.8, 73.5,
71.5, 70.3, 69.5, 57.1, 53.2, 36.9, 29.5
MS (ESI, m/z) 653 (M+Na)+
1H NMR of 60h
1H NMR of 60h
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General Procedure for Cyclization
N,N-diisopropylethylamine (4.0 mmol, 0.70 ml, 20 equiv) was added to a suspension of
CuI (0.4 mmol, 76 mg, 2 equiv) in 200 ml dry THF.  A solution of 60a-h (0.2 mmol, 1.0
equiv) in 20 ml dry THF was added to the suspension slowly at for 10 h and stirred for
another 4 h under nitrogen. The suspension was filtered with a pad of celite and
concentrated. Flash chromatography on silica gel (3% MeOH in CH2Cl2) gave a mixture
of monomeric and dimeric compounds.  Preparative HPLC (20-90% B in 30 min) was
carried out to provide 64a-h as white powder.
Cyclic Isoleucine – Lysine Mimic 64a
CO
HN
HN
CO
N
HNO
N
N
64a
NHCbz
1H NMR (DMSO-d6) 8.62 (d, 1H, J = 8.5 Hz), 8.32 (s, 1H), 8.01 (d, 1H, J = 8.5 Hz),
7.85 (s, 1H), 7.79 (d, 1H, J = 7.5 Hz), 7.69 (m, 1H), 7.61 (t, 1H, J = 7.5 Hz), 7.53 (d, 1H,
J = 6.0 Hz), 7.38-7.31 (m, 5H), 7.24 (t, 1H, J = 6.0 Hz), 5.00 (s, 2H), 4.67 (dd, 1H, J =
15.5 Hz, 8.0 Hz), 4.06 (m, 3H), 2.97 (dd, 2H, J = 12.5 Hz, 6.0 Hz), 1.77 (m, 1H), 1.59
(m, 1H), 1.40 (m, 2H), 1.24 (m, 5H), 0.87 (m, 6H)
MS (ESI, m/z) 576 (M+H)+
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1H NMR of 64a
Cyclic Glutamic Acid – Lysine Mimic 64b
CO
HN
HN
CO
N
HNO
N
N
64b
NHCbz
BnOOC
 1H NMR (DMSO-d6) 8.59 (d, 1H, J = 8.0 Hz), 8.38 (dd, 1H, J = 7.5 Hz, 4.5 Hz), 8.11
(d, 1H, J = 8.5 Hz), 7.85 (s, 1H), 7.84 (d, 1H, J = 8.0 Hz), 7.69 (m, 1H), 7.59 (m, 2H),
7.38-7.30 (m, 5H), 7.22 (t, 1H, J = 5.5 Hz), 5.12 (s, 2H), 5.00 (s, 2H), 4.70 (dd, 1H, J =
15.5 Hz, 8.0 Hz), 4.21 (dd, 1H, J = 15.0 Hz, 7.0 Hz), 4.11 (dd, 1H, J = 16.0 Hz, 8.0 Hz),
4.00 (dd, 1H, J = 10.0 Hz, 4.0 Hz), 2.96 (dd, 2H, J = 13.0 Hz, 6.5 Hz), 2.55 (m, 2H),
1.99 (m, 2H), 1.75 (m, 1H), 1.57 (m, 1H), 1.41 (m, 2H), 1.21 (m, 2H)
MS (ESI, m/z) 682 (M+H)+
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1H NMR of 64b
COSY of 64b
164
Cyclic Threonine – Glycine Mimic 64c
CO
HN
HN
CO
N
HNO
N
N
64c
OBn
1H NMR (DMSO-d6) 9.32 (d, 1H, J = 8.5 Hz), 8.99 (t, 1H, J = 6.0), 7.95 (d, 1H, J = 7.0
Hz), 7.79 (s, 1H), 7.78 (d, 1H, J = 7.5 Hz), 7.66 (t, 1H, J = 7.5 Hz), 7.59 (t, 1H, J = 7.5
Hz), 7.40-7.29 (m, 6H), 4.56 (dd, 1H, J = 28.0 Hz, 12.0 Hz), 4.47 (t, 1H, J = 8.5 Hz),
4.42 (dd, 1H, J = 15.0 Hz, 7.0 Hz), 4.32 (dd, 1H, J = 15.0 Hz, 7.0 Hz), 3.92 (dd, 1H, J =
13.0 Hz, 6.5 Hz), 4.82 (m, 1H), 1.15 (d, 3H, J = 5.5 Hz)
MS (ESI, m/z) 449 (M+H)+
1H NMR of 64c
165
COSY of 64c
Cyclic Glycine – Lysine Mimic 64d
CO
HN
HN
CO
N
HNO
N
N
64d
NHCbz
1H NMR (DMSO-d6) 9.32 (t, 1H, J = 7.5 Hz), 8.65 (d, 1H, J = 8.0), 7.95 (dd, 1H, J =8.0
Hz, 5.0 Hz), 7.81 (s, 1H), 7.78 (dd, 1H, J = 8.0 Hz, 1.0 Hz), 7.67 (m, 1H ), 7.56 (m, 2H),
7.37-7.26 (m, 5H), 7.26 (t, 1H, J = 6.0 Hz), 5.01 (s, 2H), 4.63 (dd, 1H, J = 15.5 Hz, 8.0
Hz), 4.15 (m, 2H), 4.06 (dd, 1H, J = 15.5 Hz, 4.0 Hz), 3.44 (dd, 1H, J = 14.5 Hz, 5.0
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Hz), 2.98 (q, 2H, J = 13.5 Hz, 7.0 Hz), 1.69 (m, 1H), 1.54 (m, 1H), 1.41 (m, 2H), 1.23
(m, 2H)
MS (ESI, m/z) 520 (M+H)+
1H NMR of 64d
COSY of 64d
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Cyclic Lysine – Glycine Mimic 64e
CO
HN
HN
CO
N
HNO
N
N
CbzHN
64e
1H NMR (DMSO-d6) 9.20 (d, 1H, J = 8.0 Hz), 8.93 (t, 1H, J = 6.0), 7.93 (t, 1H, J =6.0),
7.79 (d, 1H, J = 8.0 Hz), 7.77 (s, 1H), 7.67 (m, 1H), 7.56 (t, 1H, J = 8.0 Hz ), 7.52 (d,
1H, J = 6.5 Hz), 7.38-7.27 (m, 5H), 7.27 (t, 1H, J = 6.0 Hz), 5.01 (s, 2H), 4.43 (dd, 1H, J
= 15.5 Hz, 6.5 Hz), 4.35 (dd, 1H, J = 15.5 Hz, 9.0 Hz), 4.30 (dd, 1H, J = 15.5 Hz, 5.5
Hz), 3.93 (dd, 1H, J = 13.5 Hz, 7.0 Hz), 3.27 (dd, 1H, J = 13.5 Hz, 5.0 Hz), 3.01 (m,
2H), 1.63 (m, 2H), 1.42 (m, 2H), 1.28 (m, 2H);
MS (ESI, m/z) 520 (M+H)+
1H NMR of 64e
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COSY of 64e
Cyclic Glycine – Serine Mimic 64f
CO
HN
HN
CO
N
HNO
N
N
64f
OBn
1H NMR (DMSO-d6) 8.81 (t, 1H, J = 6.0 Hz), 8.51 (d, 1H, J = 8.5), 8.38 (s, 1H), 8.16 (t,
1H, J =5.5), 7.68 (d, 1H, J = 8.0 Hz), 7.65 (m, 1H), 7.57 (m, 1H), 7.28-7.20 (m, 6H),
4.81 (dd, 1H, J = 12.0 Hz, 6.0 Hz), 4.41 (m, 4H), 3.93 (m, 2H), 3.65 (d, 2H, J = 6.0 Hz)
MS (ESI, m/z) 457 (M+H)+
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1H NMR of 64f
COSY of 64f
170
Cyclic Serine – Glycine Mimic 64g
CO
HN
HN
CO
N
HNO
N
N
64g
BnO
1H NMR (DMSO-d6) 9.04 (t, 1H, J = 7.5 Hz), 8.34 (t, 1H, J = 6.0 Hz), 8.24 (s, 1H),
8.10 (t, 1H, J =6.0), 7.63 (m, 1H), 7.61 (m, 1H), 7.56 (m, 1H), 7.51 (m, 1H), 7.37-7.34
(m, 5H), 7.29 (m, 1H), 4.59 (dd, 1H, J = 12.5 Hz, 7.0 Hz), 4.53 (s, 2H), 4.41 (dd, 1H, J =
14.5 Hz, 5.0 Hz), 4.34 (dd, 1H, J = 16.0 Hz, 5.0 Hz), 3.89 (dd, 1H, J = 16.5, 6.0 Hz),
3.78 (dd, 1H, J = 16.5 Hz, 6.0 Hz), 3.72 (m, 2H)
MS (ESI, m/z) 457 (M+Na)+
1H NMR of 64g
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COSY of 64g
Cyclic Tyrosine – Serine Mimic 64h
64h
CO
HN
HN
CO
N
HNO
N
N
OBn
OBn
1H NMR (DMSO-d6) 8.73 (d, 1H, J = 8.5 Hz), 8.36 (t, 1H, J = 4.5 Hz), 8.33 (d, 1H, J =
8.0 Hz), 7.88 (s, 1H), 7.76 (m, 1H), 7.66 (m, 1H), 7.55 (m, 1H), 7.44 (d, 2H, J= 7.0),
7.37 (t, 3H, J = 7.0 Hz), 7.36-7.31 (m, 5H), 7.27 (m, 1H), 7.21 (d, 2H, J = .5 Hz), 6.94
(d, 2H, J = 8.5 Hz), 5.07 (s, 2H), 4.76 (dd, 1H, J = 16.0 Hz, 8.0 Hz), 4.51 (dd, 2H, J =
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24.0 Hz, 7.0 Hz), 4.38 (m, 1H), 4.23 (dd, 1H, J = 15.5 Hz, 7.5 Hz), 3.97 (dd, 1H, J =
15.5, 4.0 Hz), 3.83 (dd, 1H, J = 9.5 Hz, 8.0 Hz), 3.56 (dd, 1H, J = 9.5 Hz, 7.5 Hz), 2.89
(m, 2H)
MS (ESI, m/z) 631(M+H)+
1H NMR of 64h
COSY of 64h
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General Procedure for Side Chain Deprotection
One molar equivalent of 10% Pd/C was added to a 10 ml methanol or ethanol solution of
5-10 mg cyclic compounds 64a-h. The resulting suspension was stirred under 1atm H2
for 24 h and filtered with a pad of Celite. The solution was concentrated and dried under
vacuum overnight to give 61a-h as a white solid.
Deprotected Cyclic Isoleucine – Lysine Mimic 61a.
CO
HN
HN
CO
N
HNO
N
N
61a
NH2
1H NMR (DMSO-d6) 8.65 (d, 1H, J = 8.5 Hz), 8.35 (t, 1H, J = 7.0 Hz), 8.04 (d, 1H, J =
8.5 Hz), 7.85 (s, 1H), 7.78 (d, 1H, J = 7.5 Hz), 7.70 (b, 2H), 7.69 (m, 1H), 7.61 (m, 1H),
7.52 (dd, 1H, J = 7.5 Hz, 1.5 Hz), 4.67 (dd, 1H, J = 15.0 Hz, 7.5 Hz), 4.06 (m, 3H), 2.75
(m, 2H), 1.82 (m, 2H), 1.56 (m, 4H), 1.27 (m, 3H), 0.89 (m, 6H)
MS (ESI, m/z) 442 (M+H)+
1H NMR of 61a
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ROESY of 61a
Deprotected Cyclic Glutamic Acid – Lysine Mimic 61b
CO
HN
HN
CO
N
HNO
N
N
61b
NH2
HOOC
1H NMR (DMSO-d6) 12.28 (s, 1H), 8.69 (d, 1H, J = 8.0 Hz), 8.60 (b, 1H), 8.41 (q, 1H,
J = 8.0 Hz, 4.5 Hz), 8.24 (d, 1H, J = 8.5 Hz), 7.89 (s, 1H), 7.81 (b, 1H), 7.78 (d, 1H, J =
8.0 Hz), 7.69 (m, 1H), 7.61 (d, 2H, J = 4.0 Hz), 4.70 (dd, 1H, J = 15.0 Hz, 8.0 Hz), 4.21
(dd, 1H, J = 15.0 Hz, 8.0 Hz), 4.16 (dd, 1H, J = 15.0 Hz, 8.5 Hz), 4.02 (dd, 1H, J = 15.5
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Hz, 4.5 Hz), 2.73 (m, 2H), 2.41 (m, 2H), 1.96 (m, 2H), 1.78 (m, 1H), 1.61(m, 3H), 1.25
(m, 2H)
MS (ESI, m/z) 458 (M+H)+
1H NMR of 61b
TOCSY of 61b
176
ROESY of 61b
Deprotected Cyclic Threonine – Glycine Mimic 61c
CO
HN
HN
CO
N
HNO
N
N
61c
OH
1H NMR(DMSO-d6) 9.64 (d, 1H, J = 7.5 Hz), 9.20 (t, 1H, J = 6.0), 8.05 (t, 1H, J = 6.0
Hz), 7.84 (s, 1H), 7.75 (d, 1H, J = 7.5 Hz), 7.66 (m, 1H), 7.56 (m, 2H), 4.36 (m, 2H),
4.19 (t, 1H, J = 7.5 Hz), 3.88 (dd, 1H, J = 14.0 Hz, 6.5 Hz), 3.35 (dd, 1H, J = 14.0 Hz,
6.5 Hz), 1.07 (d, 3H, J = 6.5 Hz)
MS (ESI, m/z) 381 (M+Na)+
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1H NMR of 61c
TOCSY of 61c
178
ROESY of 61c
Deprotected Cyclic Glysine – Lysine Mimic 61d
CO
HN
HN
CO
N
HNO
N
N
61d
N
1H NMR (DMSO-d6) 9.20 (d, 1H, J = 9.0 Hz), 8.96 (t, 1H, J = 6.0), 7.92 (t, 1H, J = 6.0
Hz), 7.79 (d, 1H, J = 8.0 Hz), 7.77 (s, 1H), 7.67 (m, 1H), 7.57 (m, 1H), 7.51 (dd, 1H, J =
7.5 Hz, 1.5 Hz), 4.44 (dd, 1H, J = 15.5 Hz, 6.5 Hz), 4.36 (dd, 1H, J =  16.0 Hz, 8.0 Hz),
4.30 (dd, 1H, J = 15.5 Hz, 6.0 Hz), 3.93 (dd, 1H, J = 13.5 Hz, 7.0 Hz), 3.28 (dd,1H, J =
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13.5 Hz, 4.5 Hz), 2.18 (t, 2H, J = 7.0 Hz), 2.10 (s, 6H), 1.64 (m, 2H), 1.41 (m, 2H), 1.26
(m, 2H)
MS (ESI, m/z) 414 (M+H)+
1H NMR of 61d
COSY of 61d
180
 Deprotected Cyclic Lysine – Glycine Mimic 61e
CO
HN
HN
CO
N
HNO
N
N
61e
NH
Compound 64e was deprotected from an ethanol solution.
1H NMR (DMSO-d6) 9.23 (t, 1H, J = 9.0 Hz), 9.10 (t, 1H, J = 6.0 Hz), 8.01 (t, 1H, J =
6.0 Hz), 7.79 (s, 1H), 7.77 (d, 1H, J = 8.5 Hz), 7.65 (t, 1H, J = 8.5 Hz), 7.56 (m, 1H ),
7.56 (m, 1H),  7.48 (d, 1H, J = 6.0 Hz), 4.42 (dd, 1H, J = 15.5 Hz, 6.0 Hz), 4.36 (m,
1H)), 4.30 (dd, 1H, J = 15.5 Hz, 6.0 Hz), 3.89 (m, 1H), 3.28 (m,1H), 2.41 (q, 2H, J = 7.0
Hz), 2.32 (t, 2H, J = 7.0 Hz), 1.62 (m, 2H), 1.37 (m, 2H), 1.26 (m, 2H), 0.92 (t, 3H, J =
7.0 Hz)
MS (ESI, m/z) 414 (M+H)+
1H NMR of 61e
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COSY of 61e
Deprotected Cyclic Glycine – Serine Mimic 61f
61f
CO
HN
HN
CO
N
HNO
N
N
OH
1H NMR (DMSO-d6) 9.35 (t, 1H, J = 6.0 Hz), 8.65 (d, 1H, J = 7.5), 8.18 (dd, 1H, J =
7.5 Hz, 5.5 Hz), 7.81 (s, 1H), 7.77 (d, 1H, J = 7.5 Hz), 7.57 (dd, 1H, J = 7.5 Hz, 1.0 Hz),
7.53 (m, 1H), 4.98 (b, 1H), 4.57 (dd, 1H, J = 15.5 Hz, 7.0 Hz), 4.20 (dd, 1H, 14.0 Hz, 7.5
Hz), 4.11 (m, 2H), 3.71 (m, 1H)
MS (ESI, m/z) 345 (M+H)+
182
1H NMR of 61f
COSY of 61f
183
Deprotected Cyclic Serine – Glycine Mimic 61g
61g
CO
HN
HN
CO
N
HNO
N
N
HO
1H NMR (DMSO-d6) 9.39 (t, 1H, J = 6.0 Hz), 8.69 (d, 1H, J = 7.5), 8.22 (dd, 1H, J =
7.0 Hz, 5.0 Hz), 7.82 (s, 1H), 7.82 (dd, 1H, J = 7.5 Hz, 1.0 Hz), 7.67 (m, 1H), 7.58 (m,
1H), 7.54 (dd, 1H, J = 7.5, 1.5 Hz), 5.02 (b, 1H), 4.58 (dd, 1H, J = 15.5 Hz, 7.0 Hz), 4.21
(dd, 1H, 14.0 Hz, 7.5 Hz), 4.11 (m, 2H), 3.73 (m, 1H)
MS (ESI, m/z) 367 (M+Na)+
1H NMR of 61g
184
COSY of 61g
Deprotected Cyclic Tyrosine – Serine Mimic 61h
61h
CO
HN
HN
CO
N
HNO
N
N
OH
OH
1H NMR (DMSO-d6) 9.28 (b, 1H), 8.61 (d, 1H, J = 8.5 Hz), 8.43 (dd, 1H, J = 8.0 Hz,
4.0 Hz), 8.01 (d, 1H, J = 9.0 Hz), 7.88 (s, 1H), 7.77 (m, 1H), 7.67 (m, 1H), 7.57 (m, 1H),
7.21 (dd, 1H, J = 7.5 Hz, 1.5 Hz), 7.06 (d, 2H, J = 7.5 Hz), 6.73 (d, 2H, J = 7.5 Hz), 7.71
(dd, 1H, J = 15.5 Hz, 8.0 Hz), 4.34 (m, 1H), 4.10 (m, 1H), 4.00 (dd, 1H, J = 15.5 Hz, 9.5
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Hz), 3.79 (dd, 1H, J = 10.5 Hz, 8.5 Hz), 2.91 (dd, 1H, J = 14.0 Hz, 6.0 Hz), 2.84 (dd, 1H,
J = 14.0 Hz, 9.5 Hz)
MS (ESI, m/z) 473 (M+Na)+
1H NMR of 61h
COSY of 61h
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Preparation of Compoounds 66 and 67
N
H
H
N
O
O
BocHN
(i) AcCl, MeOH
(ii) Boc-Orn(N3)-OH,
EDC, HOBt
OBn
(i) AcCl, MeOH
(ii)Boc-Lys(Cbz)-OH,    
EDC, HOBt N
H
H
N
O
OH
N
OBn
BocHN
O
NHCbz
CO
HN
HN
CO
HN
OC
O
BocHN
NH
N3
CbzHN
OBn
63c 68
66
Scheme A1. Synthesis of Linear Lys-Thr-Gly Mimic.
Preparation of Lysine – Threonine – Glycine Derivative 68. (Scheme A1)  To a 5 ml
solution of 63c (0.5 mmol, 0.20 g) in 20:1 EtOAc/MeOH was added AcCl (2.5 mmol,
0.17 ml, 5 equiv) dropwise and the resulting mixture was stirred at 0 °C for 2 h in a
sealed flask, then warmed to room temperature for another 2h.  Solvent was removed
and the residue was used without further purification. To a suspension of the above
residue (1 equiv) in 10 ml dry CH2Cl2 was added Boc-Lys(Cbz)-OH (0.55 mmol, 0.21 g,
1.1 equiv.) followed by addition of NEt3 (1.25 mmol, 0.14 ml, 2.5 equiv), HOBt (0.55
mmol, 0.07 g, 1.1 equiv) and EDC (0.55 mmol, 0.11 g, 1.1 equiv).  The resulting
suspension was stirred at room temperature for 4 h.  EtOAc (20 ml) was added to the
reaction and extracted with 5% HCl, H2O, 5% Na2CO3 and brine. The organic layer was
dried with Na2SO4 and concentrated to dryness. Recrystallization with EtOAc and
hexanes provided 0.15 g (45%) 68 as a white solid.
1H NMR (CDCl3) 7.70 (s, 1H), 7.39-7.28 (m, 10H), 7.03 (s, 1H), 6.79 (s, 1H), 5.75 (s,
1H), 5.14 (s, 2H), 5.01 (s, 1H), 4.56 (dd, 2H, J = 41.1 Hz, 11.7 Hz), 4.42 (d, 1H, J = 7.5
187
Hz), 4.35 (m, 1H), 4.14 (t, 1H, J = 7.2 Hz), 4.03 (m, 1H), 3.96 (m, 2H), 3.80 (m, 1H),
3.23 (m, 2H), 2.18 (t, 1H, J = 2.6 Hz), 1.93-1.43 (m, 6H), 1.36 (s, 9H), 1.25 (d, 3H, J =
6.6 Hz)
1H NMR of 68
Preparation of Linear Lysine – Threonine – Glycine Mimic 66. To a 3 ml solution of 68
(0.23 mmol, 0.15 g) in 20:1 EtOAc/MeOH was added AcCl (1.1 mmol, 0.08 ml, 5
equiv) dropwise and the resulting mixture was stirred at 0 °C for 2 h in a sealed flask,
then warmed to room temperature for another 2h.  Solvent was removed and the residue
was used without further purification. To a suspension of the above residue (1 equiv) in
10 ml dry CH2Cl2 was added (0.39 mmol, 0.10 g, 1.1 equiv.) of N-_-Boc protected
ornithine azide (prepared from required amine via azido transfer using TfN3, see
Lundquist, J. T.; Pelletier, J. C. Org. Lett. 2001, 3, 781-783) followed by addition of
NEt3 (0.68 mmol, 0.1 ml, 2.5 equiv), HOBt (0.39 mmol, 0.05 g, 1.1 equiv) and EDC
(0.39 mmol, 0.07 g, 1.1 equiv).  The resulting suspension (0.075 M) was stirred at room
temperature for 4 h. EtOAc was added to the reaction and extracted with 5% HCl, H2O,
5% Na2CO3 and brine. The organic layer was dried with Na2SO4 and concentrated to
dryness. Recrystallization with EtOAc and hexanes provided 0.15 g (83%) 66 as a
slightly yellow solid.
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1H NMR (CDCl3) 7.39-7.22 (m, 10H), 7.21 (s, 1H), 7.01 (s, 1H), 6.82 (s, 1H), 5.13 (dd,
2H, J = 14.1 Hz, 7.5 Hz), 4.56 (dd, 2H, J = 31.8 Hz, 7.2 Hz), 4.52 (m, 1H), 4.27 (m, 2H),
4.07 (m, 2H), 3.99 (m, 2H), 3.85 (m, 1H), 3.24 (m, 4H), 2.17 (t, 1H, J = 1.5 Hz), 1.91-
1.54 (m, 10 H), 1.44 (s, 9H), 1.16 (d, 3H, J = 3.9 Hz)
MS (ESI, m/z) 806 (M+H)+
1H NMR of 66
N
H
H
N
O
O
BocHN
(i) AcCl, MeOH
(ii) 2-N3C6H4COCl,
NEt3, DMAP
(i) AcCl, MeOH
(ii)Boc-Asp(Bn)-OH,    
EDC, HOBt
N
H
H
N
O
OH
N
BocHN
O
NHCbz NHCbz
COOBn
CO
HN
HN
CO
HN
OC
O
NH
BnOOC
NHCbzN3
63a 69
67
Scheme A2. Synthesis of Linear Asp-Ile-Lys Mimic.
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Preparation of Aspartic acid – Isoleucine – Lysine Derivative 69. (Scheme A2)  To a 5
ml solution of 63a (1.0 mmol, 0.48 g) in 20:1 EtOAc/MeOH was added AcCl (5.0mmol,
0.34 ml, 5 equiv) dropwise and the resulting mixture was stirred at 0 °C for 2 h in a
sealed flask, then warmed to room temperature for another 2h.  Solvent was removed
and the residue was used without further purification. To a suspension of the above
residue (1 equiv) in 20 ml dry CH2Cl2 was added Boc-Asp(Bn)-OH (1.1 mmol, 0.36 g,
1.1 equiv.) followed by addition of NEt3 (2.5 mmol, 0.27 ml, 2.5 equiv), HOBt (1.1
mmol, 0.15 g, 1.1 equiv) and EDC (1.1 mmol, 0.21 g, 1.1 equiv).  The resulting
suspension was stirred at room temperature for 4 h.  EtOAc (40 ml) was added to the
reaction and extracted with 5% HCl, H2O, 5% Na2CO3 and brine. The organic layer was
dried with Na2SO4 and concentrated to dryness. Recrystallization with EtOAc and
hexanes provided 0.68 g (97%) 69 as a white solid.
1H NMR (CDCl3) 7.39-7.31 (m, 10H), 6.90 (m, 3H), 5.35 (d, 1H, J = 7.2 Hz), 5.12 (s,
2H), 5.09 (dd, 2H, J = 23.4 Hz, 6.0 Hz), 4.95 (m, 1H), 4.43 (m, 2H), 4.23 (dd, 1H, J =
6.5 Hz, 5.0 Hz), 4.10 (m, 1H), 3.90 (m, 1H), 3.18 (m, 2H), 2.86 (m, 2H), 2.15 (t,. 1H, J =
2.6 Hz), 2.05 (m, 2H), 1.69 (m, 4H), 1.56 (m, 2H), 1.45 (s, 9H), 1.17 (m, 1H), 0.95 (m,
6H)
1H NMR of 69
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Preparation of Linear Aspartic Acid – Isoleucine – Lysine Mimic 67. To a 5 ml solution
of 69 (0.5 mmol, 0.34g) in 20:1 EtOAc/MeOH was added AcCl (2.5 mmol, 0.18 ml, 5
equiv) dropwise and the resulting mixture was stirred at 0 °C for 2 h in a sealed flask,
then warmed to room temperature for another 2h.  Solvent was removed and the residue
was used without further purification. Triethylamine (1.3 mmol, 0.17 ml, 2.5 equiv) was
added to a solution of deprotected 69 (1 equiv) in 5 ml dry THF. The resulting mixture
was stirred for 10 min and treated with DMAP (0.35 mmol, 0.04 g, 0.7 equiv). Freshly
prepared 2-azido-benzoyl chloride (from 1 equiv.of 2-azidobenzoic acid) in 1 ml dry
THF was added dropwise to the solution and the resulting mixture was stirred for 2h at
room temperature. The reaction mixture was poured into ice water and the white
precipitate was filtered with a fine frit funnel and rinsed with small portions of water
three times. The precipitate was dried under vacuum and recystallized with EtOAc and
hexanes afforded 0.32 g (86%) 67 as a slightly yellow solid.
1H NMR (CDCl3) 8.30 (d, 1H, J = 7.8 Hz), 8.10 (dd, 1H, J = 7.8 Hz, 1.5 Hz), 7.58 (m,
1H), 7.40-7.31 (m, 10H), 7.22 (m, 2H), 6.91 (m, 2H), 5.17 (m, 4H), 5.01 (m, 1H), 4.46
(m, 1H), 4.28 (dd, 1H, J = 6.3 Hz, 4.8 Hz), 4.13 (m, 1H), 3.92 (m, 1H), 3.19 (m, 2H),
3.01 (m, 2H), 2.18 (t, 1H, J = 2.7 Hz), 2.07 (m, 2H), 1.76 (m, 2H), 1.53 (m, 2H), 1.43
(m, 2H), 1.27 (m, 1H), 0.96 (m, 6H)
13C NMR (CDCl3) 172.0, 171.9, 171.5, 171.1, 165.5, 156.9, 137.7, 136.9, 135.4, 133.3,
132.3, 128.9, 128.7, 128.5, 128.3, 128.1, 125.6, 123.3, 118.8, 79.8, 71.5, 67.5, 66.8,
59.4, 53.3, 50.5, 40.7, 36.5, 35.6, 30.9, 29.6, 29.3, 24.9, 23.1, 15.9, 11.9
MS (ESI, m/z) 781 (M+H)+
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1H NMR of 67
13C NMR of 67
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Conformational Analyses of Compounds 61a, 61b and 61c
NMR studies. NMR spectra recorded for conformation analyses of compounds 61a, 61b
and 61c were conducted on an Inova500 spectrometer. Proton NMR assignments were
made via COSY, TOCSY and ROESY experiments.  The concentration of each sample
was approximately 4mM in DMSO-d6 throughout. Temperature coefficients of amide
protons were measured via several 1D experiments in the range of 25-55 oC adjusted in 5
oC increments with an equilibration time of approximately 30 min after successive
temperature steps. H/D exchange data was measured via addition of 10 µl of CD3OD to
the DMSO solution. H/D exchange data was recorded at 25 oC.
Through-bond connectivities were elucidated by COSY and TOCSY, and through-space
interactions were identified by ROESY spectra. ROESY experiments were performed
using mixing times of 100, 200 and 300 ms; normally a mixing time of 300 ms was
superior. The intensities of ROESY cross peaks were assigned as strong, medium, weak
and/or not obs. (not observed) from the magnitude of their volume integrals.
CD studies. CD measurements were obtained on an Aviv (Model 202 DS) spectrometer.
For these experiments the cyclic peptidomimetics were dissolved in 80:20
water/methanol (v:v) (c = 0.1 mg/ml, 0.1 cm path length). The CD spectra were recorded
at 25 oC.
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Molecular simulations. QUANTA2000 (Molecular Simulations Inc.) was used to build
the residue topologies files (RTF) for all the peptidomimetics. Quenched molecular
Dynamics simulations were performed using CHARMm standard parameters. All three
molecules were modeled in a dielectric continuum of 45 (simulating DMSO). The
starting conformers were minimized using 1000 steps of steepest descent and 3000 steps
of the Adopts Basis Newton-Paphson method.  The minimized structures were subjected
to heating, equilibration and dynamitic simulation. Throughout, SHAKE was used to
constrain all bond lengths containing polar hydrogens. Each molecule was heated to
1000 K over 10 ps and equilibrated at 1000 K for another 10 ps, and then molecular
dynamics were performed for a total time of 600 ps with trajectories saved per ps. The
resulting 600 structures were minimized and about 100 structures were selected for
further analysis.
QUANTA2000 was used again to classify the selected structures in conformational
groups. The grouping method was based on calculation of RMS deviation of a subset of
ring backbone atoms. The lowest energy conformer from each family was considered as
the typical representative. Inter-proton distance and dihedral angles of the lowest energy
conformer from each family were calculated for comparison with the ROE data.
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Conformational Studies of Compound 61a
Table A1.  Important Chemical Shifts and Coupling Constants of Compound 61a.
sequence proton δ (ppm) J (Hz)
Ile NH 8.65(d) 8.5
CaH 4.06(m)
Lys NH 8.04(d) 8.5
CaH 4.06(m)
NH_ 7.70(b)
PPA NH 8.35(t) 7.0
CH 4.67(dd) 15.0, 7.0
CH 4.06(m)
Ar H1 7.52(dd) 7.5, 1.5
H2 7.61(m)
H3 7.69(m)
H4 7.78(d) 7.5
H5 7.85(s)
CO
HN
HN
CO
N
HNO
N
N
61a
NH2
H H
H1
H2
H3 H4
H5
lysHαIleHα
H
H
PPAHα
NHε
i+1
i+2
i+3
* PPA: propargyl amine derived fragment
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Table A2. Data From Conformational Ananlysis of Peptidomimetics 61a.
 QMD Data
 Residue
dihedral angels for lowest energy conformers
(degrees)
family 1 family 2 family 3 family 4
      
 Ile Φ -81.09 -84.44 67.18 69.75
Ψ 121 -121.2 -99.91 114.6
Lys Φ 62.1 -77.74 -101.5 62.58
Ψ 84.57 92.39 105.1 63.13
number in family 17 28 61 3
Lowest energy conformer
(kcal· mol-1) 30.1002 30.5227 30.5442 31.9028
COi  – NHi+3 distance
 (Å) 4.252 5.114 4.912 5.984
      
 Fit of Lowest Conformers with NMR Data
contracts/characteristic ROE
intensity
calc. dist. from QMD
(Å)
  family 1 family 2 family 3 family 4
(Ile)NH – (Aryl)H1 medium 2.318 4.052 2.338 4.012
(Ile)NH – (Lys)NH medium 4.436 3.822 4.293 3.700
(Ile)CαH – (Lys)NH strong 2.069 3.313 3.501 2.066
(Lys)NH – (PPA)NH weak 3.212 4.108 4.205 2.755
(Aryl)H5 – (PPA)NH strong 3.458 2.943 3.009 3.800
(Aryl)H5 – (Aryl)H4 weak 4.556 4.558 4.564 4.605
(Aryl)H5 – (Ile)NH strong 3.446 3.158 3.405 3.107
 
3Jobs (Hz)       3Jcalc (Hz)
 
(Ile) CαH – NH 8.5 6.9 7.3 6.9 6.7
(Lys) CαH – NH 8.5 6.9 6.4 9.0 6.9
(PPA) CαH – NH 7.0 5.8 6.1 6.9 4.3
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family 1                                                              family 2
                     
family 3                                                                   family 4
C          N        O        H
Figure A1.  Backbone Conformation of the Lowest Energy Structures for Compound
61a.
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Conformational Studies of Compound 61b
Table A3.  Important Chemical Shifts and Coupling Constants of Compound 61b.
sequence proton δ (ppm) J (Hz)
Glu NH 8.69(d) 8.0
CaH 4.21(dd) 15.0, 8.0
COOH 12.28(b)
Lys NH 8.24(d) 8.5
CaH 4.16(dd) 15.5, 8.5
NH_ 8.60(b), 7.81(b)
PPA NH 8.41(dd) 8.0, 4.5
CH 4.70(dd) 15.0, 8.0
CH 4.02(dd) 15.0, 4.5
Ar H1 7.61(d) 4.0
H2 7.61(d) 4.0
H3 7.69(m)
H4 7.78(d) 8.0
H5 7.89(s)
CO
HN
HN
CO
N
HNO
N
N
61b
HOOC
NH2
H H
H1
H2
H3 H4
H5
lysHαGluHα
H
H
PPAHα
NHε
i+1
i+2
i+3
* PPA: propargyl amine derived fragment
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Table A4.  Data From Conformational Ananlysis of Peptidomimetics 61b.
 QMD Data
 Residue
dihedral angels for lowest energy conformers
(degrees)
family 1 family 2 family 3 family 4
      
Glu Φ -140.3 -96.25 -65.35 70.45
Ψ 123.8 106.8 -74.63 114.3
Lys Φ 59.79 71.97 -96.95 61.09
Ψ 58.88 -83.17 94.64 64.91
number in family 61 25 21 3
Lowest energy conformer
(kcal· mol-1) 27.9018 28.0635 28.1124 29.3325
COi  – NHi+3 distance
 (Å) 5.175 5.669 4.441 6.024
      
 Fit of Lowest Conformers with NMR Data
contracts/characteristic ROE
intensity
calc. dist. from QMD
(Å)
  family 1 family 2 family 3 family 4
(Glu)NH – (Aryl)H1 strong 4.081 3.899 2.530 3.999
(Glu)NH – (Lys)NH strong 4.159 4.225 3.026 3.687
(Glu)CαH – (Lys)NH medium 2.071 2.088 3.583 2.079
(Lys)NH – (PPA)NH weak 2.764 4.063 4.101 2.813
(Aryl)H5 – (PPA)NH medium 2.907 3.672 3.274 3.832
(Aryl)H5 – (Aryl)H4 weak 4.579 4.612 4.548 4.067
(Aryl)H5 – (Glu)NH medium 3.065 3.229 3.166 3.129
 
3Jobs (Hz)       3Jcalc (Hz)
 
(Glu) CαH – NH 8.0 8.9 8.5 4.8 7.0
(Lys) CαH – NH 8.5 5.9 6.7 8.6 5.9
(PPA) CαH – NH 7.5 6.0 7.7 6.2 4.3
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 family 1                                                                         family 2
         family 3                                                                         family 4
        
C          N        O        H
Figure A2. Backbone Conformation of the Lowest Energy Structures for Compound
61b.
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Conformational Studies of Compound 61c
Table A5.  Important Chemical Shifts and Coupling Constants of Compound 61c.
sequence proton δ (ppm) J (Hz)
Thr NH 9.64(d) 7.5
CaH 4.19(t) 7.5
Gly NH 8.05(t) 6.5
CaH1 3.88(dd) 14.0, 6.5
CaH2 3.35(dd) 14.0, 6.5
PPA NH 9.20(t) 6.0
CaH1 4.36(m)
CaH2 4.36(m)
Ar H1 7.56(m)
H2 7.56(m)
H3 7.66(m)
H4 7.75(d) 7.5
H5 7.84(s)
CO
HN
HN
CO
N
HNO
N
N
H
61c
H H
H1
H2
H3 H4
H5
lysHαGluHα
H
H
PPAHα
i+1
i+2
i+3
HO
* PPA: propargyl amine derived fragment
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Table A6.  Data From Conformational Ananlysis of Peptidomimetics 61c.
QMD Data
 Residue  
dihedral angels for lowest energy conformers
(degrees)
  family 1 family 2 family 3
Thr Φ -71.12 -82.16 -140.3
Ψ 117.60 108.0 120.7
Gly Φ 87.73 74.73 68.21
Ψ -106.6 85.20 53.58
number in family 33 55 11
Lowest energy conformer
(kcal· mol-1) 31.8227 32.2123 32.4951
COi  – NHi+3 distance
 (Å) 4.979 4.274 5.107
     
 Fit of Lowest Conformers with NMR Data
contracts/characteristic
ROE
intensity
calc. dist. from QMD
(Å)
  family 1 family 2 family 3
(Thr)NH – (Aryl)H1 strong 2.373 2.316 4.040
(Thr)NH – (Gly)NH weak 4.462 4.317 4.413
(Thr)CaH – (Gly)NH strong 2.104 2.119 2.090
(Gly)NH – (PPA)NH weak 4.299 3.107 2.595
(Aryl)H5 – (PPA)NH medium 2.999 3.486 2.959
(Aryl)H5 – (Aryl)H4 not obs. 4.551 4.557 5.597
(Aryl)H5 – (Thr)NH medium 3.379 3.445 3.096
3Jobs (Hz)       3Jcalc (Hz)
(Thr) CαH – NH 7.5 6.5 7.1 6.0
(Gly) CαH – NH 6.0 5.7 5.7 5.6
(PPA) CαH – NH 6.5 6.8 8.9 6.9
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 family 1                                                                family 2
                   
         family 3
C          N        O        H
Figure A3.  Backbone Conformation of the Lowest Energy Structures for Compound
61c.
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Table A7.  Temperature Coefficients (-ΔδK[ppb/K]), H-D Exchange Data for 61a-c.
 -Δδ/K[ppb/K]/H-D
compound AA i+1 AA i+2 AA i+3
a 3.8/ M 4.6/ F  5.3/F
b 1.5/S 3.8/F 6.6/F
c  7.0/M 6.0/M 6.4/M
* For H-D exchange, F: Fast, M: medium, S: slow
Temperature Coefficients for Compound 61a in DMSO-d6
----- y = -0.0038x + 9.7676 R2 = 0.9803
----- y = -0.0053x + 9.9235 R2 = 0.999
----- y = -0.0046x + 9.4138 R2 = 0.9991
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Temperature Coefficients for Compound 61b in DMSO-d6
----- y = -0.0015x + 9.1561 R2 = 0.9985
----- y = -0.0038x + 9.3662 R2 = 0.9987
-----  y = -0.0066x + 10.365R2 = 0.9997
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Temperature Coefficients for Compound 61c in DMSO-d6
----- y = -0.007x + 11.094 R2 = 0.9998
----- y = -0.006x + 10.652 2 = 0.9999
----- y = -0.0064x + 9.7856R2 = 0.9938
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H-D Exchange Data for 61a in 10% CD3OD/DMSO-d6
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H-D Exchange Data for 61b in 10% CD3OD/DMSO-d6
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H-D Exchange Data for 61c in 10% CD3OD/DMSO-d6
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Table A 8.  OD values of Compounds 61a, b, d.
OD ValueTreatments
Mean SD
 SFM 0.083 0.004
5% Serum 0.477 0.013
Low NGF 0.166 0.001
 High NGF 0.317 0.015
a (10 uM) 0.107 0.009
b (10 uM) 0.092 0.006
d (10 uM) 0.090 0.006
a (1 uM) 0.086 0.004
b (1 uM) 0.086 0.004
d (1 uM) 0.083 0.007
50% DMSO 0.079 0.002
SFM
10% DMSO 0.089 0.004
a (10 uM) 0.181 0.002
b (10 uM) 0.176 0.003
d (10 uM) 0.175 0.010
a (1 uM) 0.169 0.007
b (1 uM) 0.166 0.002
d (1 uM) 0.166 0.009
50% DMSO 0.171 0.004
Low NGF
10% DMSO 0.179 0.004
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Table A 9.  OD values of Compounds 61e, g, h.
OD ValueTreatments
Mean SD
 SFM 0.079 0.004
5% Serum 0.492 0.015
Low NGF 0.145 0.003
 High NGF 0.296 0.004
e (10 uM) 0.093 0.013
g (10 uM) 0.097 0.004
h (10 uM) 0.092 0.001
e (1 uM) 0.092 0.004
g (1 uM) 0.088 0.009
h (1 uM) 0.086 0.01
40% DMSO 0.083 0.005
SFM
30% DMSO 0.082 0.007
e (10 uM) 0.174 0.003
g (10 uM) 0.192 0.006
h (10 uM) 0.177 0.018
e (1 uM) 0.169 0.008
g (1 uM) 0.160 0.012
h (1 uM) 0.174 0.006
40% DMSO 0.174 0.002
Low NGF
30% DMSO 0.158 0.002
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APPENDIX B
EXPERIMENTAL ON CHAPTER III
General Methods.  All chemicals were obtained from commercial suppliers and used
without further purification. Dichloromethane was obtained anhydrous by distillation
over calcium hydride and THF was distilled over sodium metal and benzophenone.
Analytical HPLC analyses were carried out on 25 x 0.46 cm C-18 column using gradient
conditions (5 – 95% B).  The eluents used were: solvent A (H2O with 0.1% TFA) and
solvent B (CH3CN with 0.1% TFA).  The flow rate used was 1.0 mL/min.  NMR spectra
were recorded at 300 MHz if otherwise indicated.  NMR chemical shifts were expressed
in ppm relative to internal solvent peaks, and coupling constants were measured in Hz.
All calculations were performed at the semi-empirical level of theory with the AM1
(Austin model 1) method as implemented in the MOPAC module in Cerius2 (4.10).  The
standard type I β-turn was used without optimization of the geometry and the triazole
molecule was optimized and modified to match the conformation of the type I β-turn by
twisting the torsion angles of the carboxylic acid group.  The overlay of the fully
optimized structure and the modified one is shown in Figure B1.  The single point
energy of both molecules was calculated with high convergence criteria.  The
electrostatic potential was mapped on the density with an isodensity value of 0.1.
Figure B1.  Overlay of the fully optimized triazole molecule (blue) and the modified one
(yellow).
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Preparation of Compound 73a-f
Method A.  The free amino acids were transformed into azides 73a-f with copper(I)-
catalyzed diazo transfer method followed by a linker coupling reaction.  A representative
synthesis of the amino acid azide derivative 73a is described below.
73a
BocN
N
O
N3
A solution of sodium azide (549.0 mmol, 35.6 g) was dissolved in a 1:1 mixture of H2O
(80 ml) and CH2Cl2 (80 ml) and cooled using an ice bath.  Triflic anhydride (111.0
mmol, 18.6 ml) was added over 5 min and the solution was then stirred at 0 °C for a
further 2 h.  The CH2Cl2 phase was separated, and the aqueous portion was extracted
with CH2Cl2 (2 x 80 mL).  The organic fractions were combined, washed once with
saturated Na2CO3, and the solution used without further purification (this is to avoid
risks with the triflic azide in the solution).  Isoleucine (55.8 mmol, 7.3 g) was combined
with K2CO3 (83.6 mmol, 11.6 g), CuSO4 · 5H2O (0.56 mmol, 0.14 g), H2O (180 ml) and
CH3OH (360 ml).  The CH2Cl2 solution of triflyl azide prepared above was added in one
portion, and the mixture was stirred at 25 oC for 14 h.  The organic solvents were then
removed under reduced pressure, giving an aqueous slurry that was diluted with H2O
(500 ml) and the pH was adjusted to 6 with concentrated HCl.  The solution was
extracted with EtOAc (4 x 200 ml) and the organic layers were separated.  The pH of the
aqueous phase was adjusted to 2 and extracted with EtOAc (3 X 300 ml).  The organic
extracts were combined, dried (NaSO4), and evaporated to dryness giving the Isoleucine
azide, which was used without further purification.
Boc-piperazine (1.0 mmol, 0.19 g) was added to a suspension of the above Isoleucine
azide (1.0 mmol, 0.19 g) in CH2Cl2 (to give a 0.2 M solution) at 0 oC.  N-
Methylmorpholine (2.0 mmol, 0.22 ml) was added to the above suspension followed by
HOBt (1.1 mmol, 0.15 g) and EDC (1.1 mmol, 0.22 g).  The resulting solution was
stirred at 0 °C for 1 h and warmed to 25 oC and stirred for another 3 h.  Ethyl acetate (ca
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20 ml) was added to the reaction mixture, and the resulting suspension was washed with
5% HCl, H2O, 5% Na2CO3 and brine.  The organic layer was separated, dried with
Na2SO4, and concentrated to afford 73a as clear oil (0.3g g, 95 %).  This sample (and
others in the series 73) was used without further purification.
Method B.  Boc-piperazine (3.0 mmol, 0.56 g) was added to a suspension of Cbz
protected Isoleucine (3.3 mmol, 0.88 g) in dry CH2Cl2 (0.2 M) at 0 oC.  N-
Methylmorpholine (3.3 mmol, 0.36 ml) was added to the above suspension followed by
HOBt (3.3 mmol, 0.45 g) and EDC (3.3 mmol, 0.63 g).  The resulting solution was
stirred at 0 oC for 1 h and warmed to 25 oC and stirred for another 3 h.  Ethyl acetate (ca.
40 ml) was added to the reaction mixture, and the resulting suspension was washed with
5% HCl, H2O, 5% Na2CO3 and brine.  The organic layer was separated, dried with
Na2SO4, and concentrated to afford 75a as clear oil (1.10 g, 85%).
BocN
N
O
NHZ
75a
Data for Compound 75a
1H NMR (CDCl3) δ 7.32 (m, 5H), 5.80 (d, 1H, J = 9 Hz), 5.07 (dd, 2H, J = 9Hz, 7.2
Hz), 4.51 (m, 1H), 3.64-3.01 (m, 8H), 1.71 (m, 1H), 1.47 (s, 9H), 1.11 (m, 1H), 0.93-
0.84 (m, 6H)
13C NMR (CDCl3) δ 171.0, 156.7, 154.7, 136.6, 128.7, 128.3, 128.34, 128.30, 80.6,
67.1, 55.0, 46.0, 44.0, 42.2, 38.2, 28.6, 24.2, 16.1, 11.6
MS (ESI, m/z) 434 (M+H)+
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1H NMR of 75a
13C NMR of 75a
The above residue of compound 75a was dissolved in MeOH (0.2 M) and 10 % Pd/C
(0.4 g) was added.  The suspension was stirred at room temperature with 1 atm H2
overnight and filtered with a pad of Celite and concentrated to dryness. The amines were
transformed into azide 73a with 82 % yield via copper(I)-catalyzed diazo transfer
method as described in method A.
212
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Data for Compound 73a.  Compound 73a was prepared from NH2-Ile-OH as a slightly
yellow oil: (0.9 g, 98%)
1H NMR (CDCl3) δ 3.55 (d, 1H, J = 12.0 Hz), 3.50-3.27 (m, 8H), 1.86 (m, 1H), 1.57
(m, 1H), 1.30 (s, 9H), 1.08 (m, 1H), 1.04-0.74 (m, 6H)
13C NMR (CDCl3) δ 168.5, 154.5, 80.3, 63.2, 45.8, 43.8, 42.1, 36.4, 28.4, 25.3, 15.8,
10.9
MS (ESI, m/z) 332 (M+Li)+
1H NMR of 73a
13C NMR of 73a
213
73b
BocN
N
O
N3
NHBoc
Data for Compound 73b
1H NMR (CDCl3) δ 4.74 (b, 1H), 3.79 (t, 1H, J = 7.2 Hz), 3.64-3.29 (m, 8H), 3.01 (m,
2H), 1.77 (m, 2H), 1.44 (m, 2H), 1.36 (m, 2H), 1.30 (s, 9H), 1.28 (s, 9H)
13C NMR (CDCl3) δ 168.5, 156.3, 154.6, 80.6, 78.3, 58.8, 45.6, 43.8, 42.2, 40.3, 30.5,
29.9, 28.6, 28.5, 23.3
1H NMR of 73b
13C NMR of 73b
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Data for Compound 73c
1H NMR (CDCl3) δ 4.10 (b, 1H), 4.08 (m, 1H), 3.40-3.18 (m, 8H), 1.28(s, 9H), 1.08 (d,
3H, J = 6.6 Hz)
13C NMR (CDCl3) δ 167.7, 154.5, 80.5, 68.6, 62.7, 45.8, 43.6, 42.0, 28.4, 19.5
MS (ESI, m/z) 314 (M+H)+
1H NMR of 73c
13C NMR of 73c
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Data for Compound 73d
1H NMR (CDCl3) δ 4.00 (q, 1H, J = 6.6 Hz), 3.70-3.40 (m, 8H), 1.50 (d, 3H, J = 6.6
Hz), 1.45 (s, 9H)
13C NMR (CDCl3) δ 168.8, 154.7, 80.7, 54.5, 45.7, 43.6, 42.3, 28.6, 16.2
MS (ESI, m/z) 306 (M+Na)+
1H NMR of 73d
13C NMR of 73d
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Data for Compound 73e
1H NMR (CDCl3) δ 7.04 (d, 2H, J = 8.4 Hz), 6.80 (d, 2H, J = 8.4 Hz), 4.00 (t, 1H, J =
7.5 Hz), 3.53-2.87 (m, 10H), 1.43 (s, 9H)
13C NMR (CDCl3) δ 169.0, 156.1, 145.8, 130.6, 127.0, 116.0, 81.1, 59.1, 45.6, 43.4,
42.3, 37.1, 28.6
MS (ESI, m/z) 376 (M+H)+
1H NMR of 73e
13C NMR of 73e
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Data for Compound 73f
1H NMR (CDCl3) δ 3.68-3.44 (m, 9H), 2.24 (m, 1H), 1.47 (s, 9H), 1.08 (d, 3H, J = 6.6
Hz), 0.94 (d, 3H, J = 6.6 Hz)
13C NMR (CDCl3) δ 168.8, 154.7, 80.7, 65.0, 45.9, 43.8, 42.3, 30.6, 28.6, 19.8, 19.2
MS (ESI, m/z) 312 (M+H)+
1H NMR of 73f
13C NMR of 73f
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Preparation of Compound 73g.  Boc-piperazine (3.00 mmol, 0.56 g) was dissolved in
10 ml 5% Na2CO3 and 10 ml of CH2Cl2 was added.  The solution was cooled in ice
water bath and bromoacetyl bromide (3.30 mmol, 0.43 ml) was added.  The resulting
mixture was stirred at 0 oC for 40 min and warmed to 25 oC and stirred for another 2 h.
The reaction mixture was separated and the organic layer was washed with water, 5%
HCl, water and brine.  The CH2Cl2 solution was dried with Na2SO4, concentrated to
dryness and recrystallized to afford Boc-piperazine acetyl bromide (0.91g, 99%) as a
white solid.  The above intermediate (2.9 mmol, 0.91 g) was dissolved in 15 ml of
CH3CN and NaN3 (8.0 mmol, 0.52 g) was added.  The resulting suspension was stirred
and heated to reflux 14 h.  The product was isolated with extraction and recrystallized
(EtOAc and hexanes) to afford 73g (0.76 g, 95%) as a white solid.
1H NMR (CDCl3) δ 3.95 (s, 2H), 3.62-3.35 (m, 8H), 1.46 (s, 9H)
13C NMR (CDCl3) δ 166.1, 154.6, 80.8, 50.9, 45.2, 43.8, 42.1, 28.6
MS (ESI, m/z) 292 (M+Na)+
1H NMR of 73g
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13C NMR of 73g
N
H
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79
Procedure for Preparation of Compound 79.  Boc protected 4-pentynyl amine (10.00
mmol, 1.83 g) was dissolved in a mixture of ethyl acetate and methanol (50 ml, v:v =
10:1) and the solution was cooled to 0 oC.  Acetyl chloride (5ml) was added to the above
solution slowly and the resulting mixture was stirred at 0 oC for 2 h and warmed to room
temperature and kept for 4 h.  The solvent was removed and the residue was redissolved
in 10 ml of dry THF.  tert-Butyl (1H-pyrazol-1-yl)methylenedicarbamate (10.00 mmol,
1.20 g) was added and followed with 1.0 ml of N,N-diisopropalethylammine. The
resulting suspension was stirred at 25 oC for 48 h and the solvent was removed. Flash
chromatography afforded 79 (2.0 g, 62%) as a white solid.
1H NMR (CDCl3) δ 11.50 (s, 1H), 8.39 (s, 1H), 3.60 (m, 2H), 2.27 (m, 2H), 1.97 (t, 1H,
J = 2.4 Hz), 1.81 (m, 2H), 1.49 (s, 18H)
13C NMR (CDCl3) δ 163.8, 156.5, 153.5, 100.2, 83.4, 79.6, 69.5, 40.1, 28.6, 28.3, 28.1,
16.3
MS (ESI, m/z) 326 (M+H)+
220
1H NMR of 79
13C NMR of 79
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General Procedure for Preparation of Triazole Compound 74a-o
BocN
N
O
74a
N
NN
NHBoc
To the 20 ml dry THF solution of 74a (3.0 mmol, 0.98 g) was added Boc protected
hexynyl amine (3.0 mmol, 0.59 g) followed with DIEA (6.0 mmol, 1.0 ml) and CuI (3.0
mmol, 0.57 g).  The resulting mixture was stirred at room temperature under nitrogen for
4 h and the solvent was removed.  Dichloromethane (40 ml) was added to the above
residue and extracted with 20 ml of NH4Cl/NH4OH (9:1).  The organic layer was
separated and the aqueous layer was extracted with CH2Cl2 (2 X 20 ml).  The organic
layers were combined and washed with brine, 5 % HCl and brine and dried with Na2SO4.
Flash cromatagraphy (2 % MeOH in CH2Cl2) afforded compound 5a (1.21 g, 78 %) as a
white solid.
1H NMR (CDCl3) δ 5.42 (d, 1H, J = 10.5 Hz), 5.28 (s, 1H), 4.56 (s, 2H), 3.67-3.29 (m,
12H), 2.36 (m, 1H), 1.04 (s, 18H), 1.02-0.78 (m, 8H)
13C NMR (CDCl3) δ 166.9, 156.2, 154.6, 145.5, 121.7, 80.8, 79.5, 70.0, 64.7, 63.5,
46.3, 43.8, 42.5, 40.5, 38.2, 28.6, 28.5, 24.7, 15.9, 10.6
MS (ESI, m/z) 531 (M+Li)+
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1H NMR of 74a
13C NMR of 74a
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Compound 74b was prepared from compound 4g and Boc protected hexynyl amine.
Flash chromatography (5 % MeOH in CH2Cl2) afforded 5b (1.80 g, 79%) as a white
solid.
1H NMR (CDCl3) δ 7.48 (s, 1H), 5.21 (s, 2H), 4.60 (s, 1H), 3.61-3.52 (m, 8H), 3.12 (m,
2H), 2.75 (t, 2H, J = 7.5 Hz), 1.71 (m, 2H), 1.55 (m, 2H), 1.52 (s, 9H), 1.43 (s, 9H)
13C NMR (CDCl3) δ 164.0, 156.2, 154.6, 148.4, 122.7, 80.9, 79.3, 51.2, 45.3, 44.0,
42.4, 40.5, 29.8, 28.7, 28.6, 26.7, 25.5
MS (ESI, m/z) 467 (M+H)+
1H NMR of 74b
13C NMR of 74b
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Compound 74c was prepared from compound 73a and 4-pentynoic acid.  Flash
Chromatography (5 % MeOH in CH2Cl2) afforded 74c (1.04 g, 80%) as a yellow solid.
1H NMR (CDCl3) δ 8.75 (b, 1H), 7.71 (s, 1H), 5.40 (d, 1H, J = 10.5 Hz), 3.67-3.04 (m,
8H), 3.02 (t, 2H, J = 7.2 Hz), 2.74 (t, 2H, 7.2 Hz), 1.23 (s, 9H), 0.97-0.76 (m, 8H)
13C NMR (CDCl3) δ 176.4, 167.0, 154.8, 147.0, 120.6, 80.9, 63.6, 46.3, 43.9, 42.5,
38.1, 33.6, 28.5, 24.7, 21.1, 15.9, 10.7
MS (ESI, m/z) 422 (M-H)+
1H NMR of 74c
13C NMR of 74c
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Compound 74d was prepared from 73g and 3-butynol. Flash chromatography (5 %
MeOH in CH2Cl2) afforded 74d (1.60 g, 94%) as a white solid.
1H NMR (CD3OD) δ 7.75 (b, 1H), 5.45 (s, 2H), 3.82 (t, 2H, J = 6.3 Hz), 3.60-3.52 (m,
8H), 2.91 (t, 2H, J = 6.3 Hz), 1.47 (s, 9H)
13C NMR (CDCl3) δ 164.1, 154.6, 146.2, 123.7, 80.9, 61.7, 51.1, 45.4, 44.0, 42.4, 31.2,
28.6; MS (ESI, m/z) 340 (M+H)+
1H NMR of 74d
13C NMR of 74d
226
BocN
N
O
74e
N
NN
OH
Compound 74e was prepared from 73g and 4-pentyn-2-ol. Flash chromatography (3 %
MeOH in CH2Cl2) afforded 74e (2.20 g, 96%) as a white solid.
1H NMR (CD3OD) δ 7.74 (s, 1H), 5.49 (s, 2H), 4.00 (m, 1H), 3.60-3.54 (m, 8H), 2.81
(d, 2H, J = 6.3 Hz), 1.47 (s, 9H), 1.20 (d, 3H, J = 6.3 Hz)
13C NMR (CDCl3) δ 164.1, 154.6, 145.8, 123.9, 80.9, 67.3, 51.1, 45.4, 44.0, 42.4, 35.2,
28.6, 23.2
MS (ESI, m/z) 360 (M+Li)+
1H NMR of 74e
13C NMR of 74e
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Compound 74f was prepared from 73f and 4-butynol.  Flash chromatography (3 %
MeOH in CH2Cl2) afforded 74f (1.03 g, 80%) as a white solid.
1H NMR (CDCl3) δ 7.74 (s, 1H), 5.28 (d, 1H, 7.5 Hz), 3.89 (s, 2H), 3.72-3.17 (m, 8H),
2.94 (m, 4H), 2.55 (m, 1H), 1.42 (s, 9H), 0.99 (m, 3H), 0.74 (m, 3H)
13C NMR (CDCl3) δ 166.9, 154.6, 146.2, 120.7, 80.8, 65.1, 61.0, 46.3, 44.2, 43.6, 42.5,
32.2, 28.6, 19.7, 18.6
MS (ESI, m/z) 382 (M+H)+
1H NMR of 74f
13C NMR of 74f
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Compound 74g was prepared from 73c and Boc protected hexynyl amine. Flash
chromatography (3 % MeOH in CH2Cl2) afforded 74g (1.14 g, 71%) as a white solid.
1H NMR (CD3OD) δ 7.98 (s, 1H), 5.74 (d, 1H, J = 5.7 Hz), 4.83 (s, 2H), 4.46 (m, 1H),
3.66-3.12 (m, 8H), 3.05 (t, 2H, J = 6.6 Hz), 2.73 (m, 2H), 1.67 (m, 2H), 1.54 (m, 2H),
1.48 (s, 9H), 1.44 (s, 9H), 1.13 (d, 3H, J = 6.3 Hz)
13C NMR (CD3OD) δ 167.2, 158.3, 156.0, 148.3, 124.0, 81.6, 79.7, 68.3, 66.1, 46.8,
44.0, 43.3, 40.9, 30.3, 28.8, 28.6, 27.6, 25.9, 20.1
MS (ESI, m/z) 511 (M+H)+
1H NMR of 74g
13C NMR of 74g
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Compound 74h was prepared from 73c and tert-Boc protected hexynyl amine. Flash
Chromatography (3 % MeOH in CH2Cl2) afforded 74h (1.28 g, 92%) as a white solid.
1H NMR (CD3OD) δ 7.93 (s, 1H), 5.88 (t, 1H, J = 7.2 Hz), 4.05 (m, 1H), 3.71-3.05 (m,
8H), 2.86 (m, 2H), 2.84 (d, 2H, J = 6.3 Hz), 2.14 (m, 2H), 1.39 (m, 11H), 1.27 (m, 11H),
1.20 (d, 3H, J = 6.3 Hz)
13C NMR (CD3OD) δ 167.5, 157.4, 155.0, 145.2, 122.4, 80.6, 78.7, 66.8, 59.9, 45.6,
44.0, 42.3, 39.6, 35.0, 31.9, 29.2, 27.7, 27.5, 22.7, 21.9
MS (ESI, m/z) 531 (M+Li)+
1H NMR of 74h
13C NMR of 74h
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Compound 74i was prepared from 73d and 79.  Flash chromatography (60 % EtOAc in
hexanes) afforded 74i (1.13 g, 77%) as a white solid.
1H NMR (CD3OD) δ 7.95 (s, 1H), 6.00 (q, 1H, J = 6.6 Hz), 3.68-3.34 (m, 10H), 2.83 (t,
2H, J = 7.5 Hz), 1.80 (m, 2H), 1.76 (d, 3H, J = 6.6 Hz), 1.74 (s, 9H), 1.54 (s, 9H)
13C NMR (CD3OD) δ 168.0, 163.5, 156.5, 155.0, 153.0, 147.2, 121.5, 83.3, 80.6, 79.2,
55.7, 45.4, 44.0, 42.3, 40.0, 28.7, 27.4, 27.1, 22.5, 17.2
MS (ESI, m/z) 609 (M+H)+
1H NMR of 74i
13C NMR of 74i
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Compound 74j was prepared from 73b and n-hexyne. Flash chromatography (40 %
EtOAc in hexanes) afforded 74j (1.89 g, 94%) as a white foam like solid.
1H NMR (CD3OD) δ 7.91 (s, 1H), 5.87 (t, 1H, J = 7.2 Hz), 3.72-3.33 (m, 8H), 3.04 (t,
2H, J = 7.5 Hz), 2.74 (t, 2H, J = 7.2 Hz), 2.18 (m, 2H), 1.69 (2 Hz)
13C NMR (CD3OD) δ 167.4, 157.3, 154.9, 121.3, 80.5, 78.6, 59.9, 47.1, 45.6, 44.0,
42.3, 39.7, 31.9, 31.6, 29.3, 27.8, 27.6, 25.0, 22.7, 22.1, 13.1
MS (ESI, m/z) 523 (M+H)+
1H NMR of 74j
13C NMR of 74j
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Compound 74k was prepared from 73b and 4-pentynoic acid. Flash chromatography (5
% MeOH in CH2Cl2) afforded 74k (1.60 g, 87%) as yellow foam like solid.
1H NMR (CD3OD) δ 7.91 (s, 1H), 5.87 (t, 1H, J = 7.2 Hz), 3.72-3.33 (m, 8H), 3.04 (t,
2H, J = 7.5 Hz), 2.74 (t, 2H, J = 7.2 Hz), 2.18 (m, 2H), 1.69 (2 Hz)
13C NMR (CD3OD) δ 167.4, 157.3, 154.9, 121.3, 80.5, 78.6, 59.9, 47.1, 45.6, 44.0,
42.3, 39.7, 31.9, 31.6, 29.3, 27.8, 27.6, 25.0, 22.7, 22.1, 13.1
MS (ESI, m/z) 537 (M-H)+
1H NMR of 74k
13C NMR of 74k
233
BocN
N
O
N
NN
COOH
74l
Compound 74l was prepared from 73d and 4-pentynoic acid.  Flash chromatography (5
% MeOH in CH2Cl2) afforded 74l (0.80 g, 87%) as yellow foam like solid.
1H NMR (CDCl3) δ 7.62 (b, 1H), 7.27 (s, 1H), 5.81 (q, 1H, J = 7.2 Hz), 3.75-3.20 (m,
8H), 3.03 (t, 2H, J = 7.2 Hz), 2.75 (t, 2H, J = 7.2 Hz), 1.68 (d, 3H, J = 7.2 Hz), 1.43 (s,
9H)
13C NMR (CDCl3) δ 176.4, 167.1, 154.9, 146.9, 120.6, 80.9, 55.4, 45.8, 43.9, 42.6,
33.5, 28.6, 21.1, 18.9
MS (ESI, m/z) 380 (M-H)+
1H NMR of 74l
13C NMR of 74l
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Compound 74m was prepared from 73g and 79.  Flash chromatography (60 % EtOAc in
hexanes) afforded 5m (1.9 g, 86%) as a white solid.
1H NMR (CD3OD) δ 7.89 (s, 1H), 7.79 (s, 1H), 5.44 (s, 2H), 3.56-3.30 (m, 10H), 2.77
(t, 2H, J = 7.5 Hz), 1.94 (m, 2H), 1.52 (s, 9H), 1.46 (s, 18H)
13C NMR (CD3OD) δ 165.3, 163.4, 156.5, 155.0, 153.0, 147.0, 124.2, 83.3, 80.6, 79.2,
50.9, 44.7, 43.5, 42.0, 39.8, 28.8, 27.5, 27.1, 22.4
MS (ESI, m/z) 595 (M+H)+
1H NMR of 74m
13C NMR of 74m
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Compound 74n was prepared from 73e and 4-butynol.  Flash chromatography (40 %
EtOAc in hexanes) afforded 74n (0.30 g, 89%) as a white solid.
1H NMR (CDCl3) δ 7.88 (s, 1H), 6.92 (d, 2H, J = 8.4 Hz), 6.72 (d, 2H, J = 8.4 Hz), 5.88
(t, 1H, J = 7.8 Hz), 3.87 (t, 2H, J = 6.0 Hz), 3.52-3.16 (m, 9H), 2.93 (m, 3H), 1.43 (s,9H)
13C NMR (CDCl3) δ 166.8, 156.6, 154.7, 145.7, 130.6, 125.8, 121.8, 116.1, 81.0, 61.5,
60.6, 46.0, 43.8, 42.5, 39.1, 28.6
MS (ESI, m/z) 446 (M+H)+
1H NMR of 74n
13C NMR of 74n
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Compound 74o was prepared from 73a and 79.  Flash chromatography (40 % EtOAc in
hexanes) afforded 74o (2.00 g, 96%) as a white solid.
1H NMR (CDCl3) δ 11.44 (s, 1H), 8.36 (s, 1H), 7.62 (s, 1H), 5.33 (d, 1H, J = 9.9 Hz),
3.61-3.11 (m, 10H), 2.71 (m, 2H), 2.32 (s, 1H), 1.93 (m, 2H), 1.43 (s, 18H), 1.32 (s, 9H),
0.94(m, 5H), 0.74 (m, 3H)
13C NMR (CDCl3) δ 166.9, 163.7, 156.4, 154.5, 153.4, 147.6, 119.8, 83.2, 80.5, 79.3,
63.4, 53.7, 46.2, 43.8, 42.4, 40.4, 37.9, 28.8, 28.4, 28.2, 24.6, 23.3, 15.9, 10.6
MS (ESI, m/z) 651 (M+H)+
1H NMR of 74o
13C NMR of 74o
237
General Procedure for Preparation of Fluorescent Labeled Monomers.  Boc-
protected monomeric compounds 74a-o (1.0 eq.) were treated with 30% TFA in CH2Cl2,
stirred in sealed glass vials for 4h and solvent was removed. The resulting residue was
dissolved in THF (0.1 M) and DTAF (1.0 equiv.) and K2CO3 (4.0 eq.) were added. The
suspension was stirred for 2 h and solvent was removed. The crude product 76a-o was
used for the next step without further purification.  Analytical HPLC and MALDI MS
were used to check the purities of these crude samples.
N
N N
R2'
R1'
N
O
BocN
i) 30% TFA
ii) 1 eq. DTAF, K2CO3,
THF, 25 oC N N
NN Cl
HN
Fluorescein
N
O
N
NN
R2
R1
74a-o 76a-o
O
COOH
OHO
Fluorescein =
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 Table B1.  Characterization of crude compounds 76a-o.
MALDI-MS HPLC Purity (%)
Comp’d 76 Calc'd Found UV Sedex
a 781 781 94 92
b 725 725 100 100
c 782 782 91 98
d 698 698 91 92
e 712 712 95 100
f 740 740 92 95
g 769 769 92 95
h 783 783 87 92
i 767 767 100 100
j 781 781 91 100
k 797 797 94 100
l 740 740 100 100
m 753 753 93 100
n 804 804 88 100
o 809 809 100 100
Preparation of Fluorescent Labeled Dimers 71 and Monomers 71a’-o’.
Dimerization was carried out in 2 ml glass vials.  The monomeric compounds 74a-o
were treated with 30% TFA/CH2Cl2 for 4 h.  Stock solutions of 76 (0.03 M) and
deprotected 74 (0.03 M) or morpholine (0.33 M) in DMSO were prepared.  One stock
solution of 76 (0.5 ml) and one of deprotected 74 (0.5 ml) or morpholine (0.5 ml) were
added to a glass vial and followed with solid K2CO3 (ca 20 mg).  The reaction vial was
sealed and sonicated for 15 min.  The reaction mixture was agitated at 25 °C for 48 h
then the DMSO was lyophilized.  Aqueous HCl solution (5%, ca 0.5 ml) was added to
the above solid residue and sonicated for 3 min.  Most of the compounds were
precipitated in the acidic aqueous solution and they were transferred to a 15 mL
centrifuge tube and centrifuged for 15 min and the aqueous solution was carefully
removed with a glass pipette.  The solid products were dried under vacuum 14 h to give
the final products 71.  Some of the compounds with monovalent units like g, h and k are
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highly water-soluble.  The aqueous solution of these compounds were lyophilized and
redissolved in 0.5 ml MeOH.  The inorganic salts were precipitated out and removed.
The MeOH solution was then concentrated to give compounds 71. All crude products
were analyzed by analytical HPLC (5-95% B in 30 min) and MALDI-MS.
N N
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71
deprotected 74 or morpholine
K2CO3, DMSO, 25 oC
N N
NN N
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O
71a'-o'
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Data for 71o’
1H NMR (500 MHz, DMSO-d6) δ 9.72 (s, 1H), 8.39 (s, 1H), 8.03 (d, 1H, J = 6.0 Hz),
7.99 (s, 1H), 7.66 (t, 1H, 6.0 Hz), 7.15 (d, 1H, J = 8.5 Hz), 6.67 (d, 2H, J = 2.0 Hz), 6.62
(d, 2H, J = 8.5 Hz), 6.56 (dd, 2H, J = 8.5 Hz, 2.0 Hz), 5.69 (d, 1H, J = 9.0 Hz), 3.99-3.60
(m, 16H), 3.15 (m, 2H), 2.65 (t, 2H, J = 7.5 Hz), 2.30 (m, 1H), 1.80 (m, 2H), 0.95 (m,
5H), 0.77 (t, 3H, J = 7.5 Hz)
13C NMR (500 MHz, DMSO-d6) δ 168.9, 166.3, 164.4, 163.9, 159.5, 157.7, 156.9,
156.8, 151.9, 146.2, 145.0, 142.0, 129.1, 126.8, 124.0, 121.1, 113.3, 112.6, 109.9, 102.2,
66.0, 62.9, 45.2, 43.4, 43.1, 42.9, 41.6, 37.8, 28.2, 24.1, 22.1, 15.0, 10.5
MS (MALDI, m/z) 860 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 16.73 min
Analytical HPLC (Sedex) purity 100%, retention time = 16.78 min
UV HPLC of Compound 71o’
241
1H NMR of Compound 71o’
13C NMR of Compound 71o’
242
TOCSY of Compound 71o’
Data for 71gi
1H NMR (500 MHz, DMSO-d6) δ 9.77 (s, 1H), 8.39 (s, 1H), 8.04 (d, 1H, J= 2.0 Hz),
8.00 (s, 1H), 7.95 (s, 1H), 7.71 (m , 4H), 7.17 (d, 1H, J = 8.5 Hz), 6.67 (d, 2H, J = 2.5
Hz), 6.63 (d, 2H, J = 8.5 Hz), 6.56 (dd, 2H, J = 8.5 Hz, 2.5 Hz), 6.03 (q, 1H, J = 7.0 Hz),
5.80 (d, 1H, J = 5.0 Hz), 4.33 (t, 1H, J = 6.0 Hz), 3.90-3.60 (m, 16H), 3.17 (t, 2H, J = 6.5
Hz), 2.81 (t, 2H, J = 6.5 Hz), 2.65 (m, 4H), 1.80 (m, 2H), 1.64 (m, 5H), 1.61 (m, 2H),
1.05 (d, 3H, J = 6.0 Hz)
13C NMR (500 MHz, DMSO-d6) δ 169.0, 167.3, 165.5, 164.5, 164.0, 159.7, 158.7 (q, J
= 150 Hz, from CF3COO-), 157.0, 152.1, 145.9, 145.8, 145.1, 142.1, 129.3, 126.9, 126.6,
124.2, 122.6, 121.6, 119.2, 116.9, 114.6, 113.6, 112.8, 110.1, 102.3, 66.5, 64.4, 54.8,
45.3, 44.9, 43.1, 42.6, 41.7, 28.3, 26.8, 25.9, 24.6, 22.2, 20.2, 17.9
MS (MALDI, m/z) 1041 (M+H)+
Analytical HPLC (UV) purity 98%, retention time = 8.98 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.02 min
243
UV HPLC of Compound 71gi
1H NMR of Compound 71gi
13C NMR of Compound 71gi
244
COSY of Compound 71gi
Data for 71gm
1H NMR (500 MHz, DMSO-d6) δ 9.77 (s, 1H), 8.41 (s, 1H), 8.05 (d, 2H, J = 2.0 Hz),
7.96 (s, 1H), 7.80 (s, 1H), 7.71 (bs, 2H), 7.17 (d, 1H, J = 8.5 Hz), 6.66 (d, 2H, J = 2.5
Hz), 6.63 (d, 2H, J = 8.5 Hz), 6.56 (dd, 2H, J = 8.5 Hz, 2.5 Hz), 5.81 (d, 1H, J = 6.0 Hz),
5.48 (s, 2H), 4.33 (m, 1H), 4.04-3.57 (m, 16H), 3.18 (dd, 2H, J = 6.0 Hz, 7.0 Hz), 2.83
(t, 2H, J = 7.0 Hz), 2.67 (m, 4H), 1.82 (m, 2H), 1.67 (m, 2H), 1.62 (m, 2H), 1.06 (d, 3H,
J = 6.0 Hz)
13C NMR (500 MHz, DMSO-d6) δ 169.0, 165.5, 164.7, 164.5, 164.0, 159.7, 158.7 (q, J
= 150 Hz, from CF3COO-), 157.0, 152.1, 145.8, 145.7, 145.1, 142.1, 129.3, 126.9, 126.7,
124.2, 123.9, 122.6, 119.2, 117.0, 114.7, 113.6, 112.8, 110.1, 102.3, 66.5, 64.4, 50.7,
45.3, 44.1, 42.7, 41.7, 41.4, 28.4, 26.7, 25.9, 24.6, 22.1, 20.2
MS (MALDI, m/z) 1027 (M+H)+
245
Analytical HPLC (UV) purity 100%, retention time = 12.42 min
Analytical HPLC (Sedex) purity 100%, retention time = 12.47 min
UV HPLC for Compound 71gm
1H NMR of Compound 71gm
246
13C NMR of Compound 71gm
COSY of Compound 71gm
247
Data for 71gn
1H NMR (500 MHz, DMSO-d6) δ 9.75 (s, 1H), 8.37 (s, 1H), 8.02 (m, 3H), 7.96 (s, 1H),
7.68 (bs, 2H), 7.17 (d, 1H, J = 9.0 Hz), 7.03 (d, 2H, J = 8.5 Hz), 6.67 (d, 2H, J = 2.0 Hz),
6.63 (m, 3H), 6.55 (d, 2H, J = 8.5 Hz), 6.06 (m, 1H), 5.79 (d, 1H, J = 6.0 Hz), 4.33 (m,
1H), 3.90-3.60 (m, 18H), 3.31 (m, 1H), 3.21 (m, 1H), 2.82 (dd, 2H, J = 6.5 Hz, 6.0 Hz),
2.75 (t, 2H, J = 7.0 Hz), 2.66 (t, 2H, J = 7.0 Hz), 1.65 (m, 2H), 1.61 (m, 2H), 1.06 (d,
3H, J = 6.0 Hz)
13C NMR (500 MHz, DMSO-d6) δ 169.0, 166.3, 165.5, 164.5, 164.4, 163.9, 159.8,
158.7 (q, J = 150 Hz, from CF3COO-), 156.4, 152.2, 145.8, 145.0, 142.1, 130.5, 129.3,
126.9, 126.6, 125.8, 124.3, 122.6, 122.2, 119.2, 116.7, 115.2, 114.6, 113.7, 112.9, 110.2,
102.3, 66.6, 64.5, 60.5, 59.8, 45.3, 45.1, 43.2, 42.8, 41.8, 37.3, 29.3, 26.8, 25.9, 24.6,
20.2
MS (MALDI, m/z) 1078 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 13.20 min
Analytical HPLC (Sedex) purity 100%, retention time = 13.24 min
UV HPLC of Compound 71gn
248
1H NMR of Compound 71gn
13C NMR of Compound 71gn
249
COSY of Compound 71gn
Data for 71gj
1H NMR (500 MHz, DMSO-d6) δ 9.76 (s, 1H), 8.39 (s, 1H), 8.03 (m, 1H), 7.96 (s, 1H),
7.95 (s, 1H), 7.72 (bs, 2H), 7.17 (d, 1H, J = 8.5 Hz), 5.86 (m, 1H), 5.81 (d, 1H, J = 5.0
Hz), 4.32 (m, 1H), 3.90-3.50 (m, 16H), 2.82 (dd, 2H, J = 13.0 Hz, 6.5 Hz), 2.75 (m, 2H),
2.66 (t, 2H, J = 7.5 Hz), 2.63 (t, 2H, J = 7.5 Hz), 2.05 (m, 2H), 1.68 (m, 2H), 1.57 (m,
6H), 1.30 (m, 4H), 1.06 (d, 3H, J = 6.0 Hz), 0.87 (t, 3H, J = 7.0 Hz)
13C NMR (500 MHz, DMSO-d6) δ 169.0, 166.4, 165.5, 164.6, 164.1, 159.7, 158.7(q, J
= 150 Hz, from CF3COO-), 152.0, 147.1, 145.8, 145.2, 142.1, 129.2, 126.9, 126.6, 124.1,
122.5, 121.2, 119.8, 117.2, 114.9, 113.5, 112.7, 110.0, 102.3, 66.5, 64.4, 58.7, 45.2,
44.9, 43.1, 42.6, 41.8, 38.7, 31.4, 31.1, 26.7, 26.6, 25.9, 24.8, 24.6, 22.2, 21.7, 20.1, 13.7
MS (MALDI, m/z) 1055 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 13.78 min
Analytical HPLC (Sedex) purity 100%, retention time = 13.93 min
250
UV HPLC of Compound 71gj
1H NMR of Compound 71gj
13C NMR of Compound 71gj
251
COSY of Compound 71gj
Data for 71ek
1H NMR (300 MHz, DMSO-d6) δ 10.10 (s, 1H), 8.40 (s, 1H), 8.05 (m, 2H), 8.02 (s,
2H), 7.80 (s, 1H), 7.20 (d, 1H, J = 8.4 Hz), 6.74 (d, 2H, J = 1.8 Hz), 6.66 (d, 2H, J = 8.4
Hz), 6.59 (dd, 2H, J = 8.4.Hz, 1.8 Hz), 5.90 (m, 1H), 5.5 (s, 2H), 3.90-3.60 (m, 14H),
2.86  (t, 2H, J = 7.5 Hz), 2.70 (m, 2H), 2.59 (t, 2H, J = 7.5 Hz), 2.03 (m, 2H), 1.57 (m,
2H), 1.30 (m, 1H), 1.06 (d, 3H, J = 8.4 Hz)
MS (MALDI, m/z) 1015 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.78 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.93 min
252
1H NMR of 71ek
COSY NMR of 71ek
253
Data for 71hn
1H NMR (300 MHz, DMSO-d6) δ 9.91 (s, 1H), 8.36 (s, 1H), 8.03 (s, 2H), 7.91 (s, 2H),
7.18 (d, 1H, J = 8.4 Hz), 7.01 (d, 2H, J = 8.7 Hz), 6.73 (d, 2H, J = 2.1 Hz), 6.64 (d, 4H, J
= 8.7), 6.61 (dd, 2H, J = 8.4 Hz, 2.1 Hz), 6.07 (t, 1H, J = 6.0 Hz), 5.89 (t, 1H, J = 6.0
Hz), 3.80-3.58 (m, 19H), 3.27 (m, 2H), 2.68 (m, 4H), 2.06 (m, 2H), 1.54 (m, 2H), 1.33
(m, 1H), 1.04 (m, 1H), 1.03 (d, 3H, J = 6.3 Hz)
MS (MALDI, m/z) 1093 (M+H)+
Analytical HPLC (UV) purity 92%, retention time = 9.82 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.97 min
1H NMR of 71hn
254
COSY NMR of 71hn
Data for 71en
1H NMR (300 MHz, DMSO-d6) δ 9.95 (s, 1H), 8.38 (s, 1H), 8.04 (s, 2H), 8.02 (s, 1H),
7.74 (s, 1H), 7.18 (d, 1H, J = 8.4 Hz), 7.02 (d, 2H, J = 8.7 Hz), 6.71 (d, 2H, J = 2.1 Hz),
6.56 (d, 4H, J = 8.7 Hz), 6.58 (dd, 2H, J = 8.4 Hz, 2.1 Hz), 6.07 (t, 1H, J = 6.0 Hz), 5.49
(s, 2H), 3.90-3.58 (m, 19H), 3.28 (m, 2H), 2.75 (m, 3H), 2.64 (dd, 1H, J = 14.4 Hz, 6.3
Hz), 1.06 (d, 3H, J = 6.3 Hz)
MS (MALDI, m/z) 1021 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 12.24 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.40 min
255
1H NMR of 71en
COSY NMR of 71en
256
Data for 71jo
1H NMR (300 MHz, DMSO-d6) δ 9.80 (s, 1H), 8.37 (s, 1H), 8.06 (d, 1H, J = 8.4 Hz),
8.04 (s, 1H), 8.00 (s, 1H), 7.90 (b, 2H), 7.16 (d, 1H, J = 8.4 Hz), 6.70 (d, 2H, J = 2.1
Hz), 6.65 (d, 2H, J = 8.7 Hz), 6.55 (dd, 2H, J = 8.7 Hz, 2.1 Hz), 5.99 (t, 1H, J = 7.2 Hz),
5.68 (d, 1H, J = 9.6 Hz), 3.89-3.39 (m, 16H), 3.15 (m, 2H), 2.67 (m, 4H), 2.31 (m, 1H),
2.05 (m, 2H), 1,78 (m, 2H), 1,57 (m, 4H), 1.31 (m, 2H), 1.09 (m, 1H), 0.96 (m, 5H),
0.85 (t, 3H, J = 7.2 Hz), 0.78 (t, 3H, J = 7.2 Hz)
MS (MALDI, m/z) 1096 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 13.83 min
Analytical HPLC (Sedex) purity 98%, retention time = 13.98 min
1H NMR of 71jo
257
COSY NMR of 71jo
Data for 71ab
1H NMR (300 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.05 (s, 4H), 7.97 (s, 1H), 7.80 (s, 1H),
7.18 (d, 1H, J = 8.4 Hz), 6.75 (s, 2H), 6.65 (d, 2H, J = 8.7 Hz), 6.59 (d, 2H, J = 8.7 Hz),
5.68 (d, 1H, J = 7.2 Hz), 5.50 (s, 2H), 3.89-3.49 (m, 16H), 2.70 (m, 4H), 2.60 (m, 4H),
2.31 (m, 1H), 1.63 (m, 8H), 0.94 (m, 5H), 0.78 (t, 3H, J = 7.2 Hz)
MS (MALDI, m/z) 1012 (M+H)+
Analytical HPLC (UV) purity 86%, retention time = 9.85 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.01 min
258
1H NMR of 71ab
COSY NMR of 71ab
259
Data for 71no
1H NMR (300 MHz, DMSO-d6) δ 9.80 (s, 1H), 9.36 (s, 1H), 8.05 (s, 1H), 8.03 (s, 1H),
8.00 (s, 1H), 7.76 (t, 1H, J = 7.2 Hz), 7.15 (d, 1H, J = 8.4 Hz), 7.01 (d, 2H, J = 8.7 Hz),
6.70 (d, 2H, J = 2.1 Hz), 6.22 (d, 4H, J = 8.7 Hz), 6.56 (dd, 2H, J = 8.7 Hz, 2.1 Hz), 6.07
(t, 1H, J = 7.2 Hz), 5.68 (d, 1H, J = 7.2 Hz), 3.89-3.58 (m, 18 Hz), 3.28 (m, 2H), 3.15
(m, 2H), 2.75 (t, 2H, J = 6.9 Hz), 2.67 (t, 2H, J = 7.2 Hz), 2.31 (m, 1H), 1.80 (m, 2H),
0.94 (m, 5H), 0.78 (t, 3H, J = 7.2 Hz)
MS (MALDI, m/z) 1119 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 12.72 min
Analytical HPLC (Sedex) purity 100%, retention time = 12.87 min
1H NMR of 71no
260
COSY NMR of 71no
Data for 71ai
1H NMR (500 MHz, DMSO-d6) δ 9.99 (s, 1H), 8.38 (s, 1H), 7.99 (m, 5H), 7.17 (d, 1H,
J = 8.5 Hz), 6.74 (s, 2H), 6.64 (d, 2H, J = 8.5 Hz), 6.59 (d, 2H, J = 8.5 Hz), 6.02 (q, 1H, J
= 6.5 Hz), 5.69 (d, 1H, J = 9.0 Hz), 3.89-3.55 (m, 16 Hz), 3.17 (, 2H), 2.78 (m, 2H), 2.68
(t, 2H, J = 7.5 Hz), 2.63 (t, 2H, J = 7.5 Hz), 2.40 (m, 1H), 1.82 (m, 2H), 1.64 (m, 4H,
0.94 (m, 5H), 0.78 (t, 3H, J = 7.5 Hz)
MS (MALDI, m/z) 1054 (M+H)+
Analytical HPLC (UV) purity 93%, retention time = 10.77 min
Analytical HPLC (Sedex) purity 91%, retention time = 10.92 min
261
1H NMR of 71ai
COSY NMR of 71ai
262
Data for 71de
1H NMR (500 MHz, DMSO-d6) δ 9.94 (s, 1H), 8.40 (s, 1H), 8.05 (d, 1H, J = 8.5 Hz),
7.79 (s, 1H), 7.77 (s, 1H), 7.17 (d, 1H, J = 8.5 Hz), 6.72 (s, 2H), 6.64 (d, 2h, J = 8.5 Hz),
6.58 (d, 2H, J = 8.5 Hz), 5.48 (s, 4H), 3.90-3.57 (m, 18H), 2.79 (t, 2H, J = 7.0 Hz), 2.74
(dd, 1H, J = 14.5 Hz, 6.5 Hz), 2.65 (dd, 1H, J = 14.5 Hz, 6.0 Hz), 1.05 (d, 3H, J = 6.0
Hz)
MS (MALDI, m/z) 916 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 9.77 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.92 min
1H NMR of 71de
263
COSY NMR of 71de
Data for 71fg
1H NMR (300 MHz, DMSO-d6) δ 10.21 (s, 1H), 8.38 (s, 1H), 8.02 (b, 2H), 7.99 (s,
1H), 7.97 (s, 1H), 7.20 (d, 1H, J = 8.4 Hz), 6.76 (s, 2H), 6.68 (d, 2H, J = 8.4 Hz), 6.61
(d, 2H, J = 8.4 Hz), 5.81 (d, 1H, J = 6.0 Hz), 5.65 (d, 1H, J = 9.0 Hz), 4.33 (m, 1H),
3.76-3.59 (m, 18H), 2.77 (t, 4H, J = 6.9 Hz), 2.66 (t, 2H, J = 6.6 Hz), 1.63 (m, 4H), 1.05
(d, 3H, J = 6.0 Hz), 0.97 (d, 3H, J = 6.0 Hz), 0.66 (d, 3H, J = 6.0 Hz)
MS (MALDI, m/z) 1015 (M+H)+
Analytical HPLC (UV) purity 96%, retention time = 10.12 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.37min
264
1H NMR of 71fg
COSY NMR of 71fg
265
Data for 71fo
1H NMR (300 MHz, DMSO-d6) δ 10.04 (s, 1H), 8.69 (s, 1H), 8.07 (s, 1H), 8.04 (s, 1H),
8.01 (s, 1H), 7.96 (s, 1H), 7.18 (d, 1H, J = 8.4 Hz), 6.75 (s, 2H), 6.65 (d, 2H, J = 8.4 Hz),
6.59 (d, 2H, J = 8.4 Hz), 5.68 (m, 2H), 3.89-3.59 (m, 18H), 3.14 (m, 2H), 2.78 (t, 2H, J =
6.9 Hz), 2.67 (t, 2H, J = 7.5 Hz), 2.31 (m, 1H), 1.79 (m, 2H), 0.96 (m, 7H), 0.78 (t, 3H, J
= 7.2 Hz), 0.67 (d, 3H, J = 6.6 Hz)
MS (MALDI, m/z) 1055 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 11.35 min
Analytical HPLC (Sedex) purity 100%, retention time = 11.50 min
1H NMR of 71fo
266
COSY NMR of 71fo
Data for 71mn
1H NMR (500 MHz, DMSO-d6) δ 10.24 (s, 1H), 8.38 (s, 1H), 8.06 (s, 1H), 8.01 (m,
2H), 7.84 (s, 1H), 7.21 (d, 1H, J = 8.5 Hz), 7.01 (d, 2H, J = 8.5 Hz), 6.78 (s, 2H), 6.66
(m, 4H), 6.09 (s, 1H), 5.51 (s, 2H), 3.90-3.49 (m, 18H), 3.36 (m, 2H), 3.19 (m, 2H), 2.75
(t, 2H, J = 6.5 Hz), 2.70 (t, 2H, J = 7.0 Hz), 1.81 (m, 2H)
MS (MALDI, m/z) 1063 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 12.82 min
Analytical HPLC (Sedex) purity 100%, retention time = 12.97 min
267
1H NMR of 71mn
COSY NMR of 71mn
268
Data for 71mo
1H NMR (300 MHz, DMSO-d6) δ 9.99 (s, 1H), 8.39 (s, 1H), 8.05 (d, 1H, J = 8.4 Hz),
8.01 (s, 1H), 7.95 (t, 2H, J = 5.7 Hz), 7.82 (s, 1H), 7.18 (d, 1H, J = 8.4 Hz), 6.74 (d, 2H,
J = 2.1 Hz), 6.34 (d, 2H, J = 8.4 Hz), 6.58 (dd, 2H, J = 8.4 Hz, 2.1 Hz), 5.70 (d, 1H, J =
9.0 Hz), 5.50 (s, 2H), 3.89-3.58 (m, 16H), 3.16 (m, 4H), 2.67 (m, 2H), 2.31 (m, 1H),
1.81 (m, 4H), 0.94 (m, 5H), 0.78 (t, 3H, J = 7.2 Hz)
MS (MALDI, m/z) 1068 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 13.45 min
Analytical HPLC (Sedex) purity 100%, retention time = 13.60 min
1H NMR of 71mo
269
COSY NMR of 71mo
Data for 71kl
1H NMR (300 MHz, DMSO-d6) δ 10.40 (s, 1H), 8.37 (s, 1H), 8.04 (s, 2H), 8.00 (s, 1H),
7.98 (s, 1H), 7.19 (d, 1H, J =8.4 Hz), 6.77 (s, 2H), 6.68 (d, 2H, J = 8.7 Hz), 6.10 (d, 2H,
J = 8.7 Hz), 6.02 (q, 1H, J = 7.2 Hz), 5.91 (t, 1H, J = 7.2 Hz), 3.90-3.54 (m, 16H), 3.05
(t, 4H, J = 7.2 Hz), 2.71 (m, 2H), 2.59 (t, 2H, J = 7.2 Hz), 2.04 (m, 2H), 1.62 (d, 3H, J =
7.2 Hz), 1.58 (m, 2H), 1.31 (m, 1H), 1.06 (m, 1H)
MS (MALDI, m/z) 1043 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 9.15 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.30 min
270
1H NMR of 71kl
COSY NMR of 71kl
271
Data for 71ln
1H NMR (300 MHz, DMSO-d6) δ 9.85 (s, 1H), 8.35 (s, 1H), 8.05 (s, 1H), 8.03 (s, 1H),
7.95 (s, 1H), 7.17 (d, 1H, J = 8.4 Hz), 7.01 (d, 2H, J = 8.4 Hz), 6.71 (d, 2H, J = 2.1 Hz),
6.63 (d, 2H, J = 8.4 Hz), 6.57 (dd, 2H, J = 8.4 Hz, 2.1 Hz), 6.02 (m, 2H), 3.90-3.58 (m,
18H), 3.32 (m, 2H), 2.85 (t, 2H, J = 7.2 Hz), 2.75 (t, 2H, J = 7.2 Hz), 2.54 (t, 2H, J = 7.5
Hz), 1.61 (d, 3H, J = 7.2 Hz)
MS (MALDI, m/z) 1050 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.02 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.17 min
1H NMR of 71ln
272
COSY NMR of 71ln
Data for 71ho
1H NMR (300 MHz, DMSO-d6) δ 9.95 (s, 1H), 8.36 (s, 1H), 8.00 (m, 5H), 7.16 (d, 1H, J
= 8.4 Hz), 6.71 (s, 2H), 6.62 (d, 2H, J = 8.4 Hz), 6.57 (d, 2H, J = 8.4 Hz), 5.89 (t, 1H, J =
7.2 Hz), 5.68 (d, 1H, J = 10.5 Hz), 3.95-3.61 (m, 17H), 3.15 (m, 2H), 2.69 (m, 6H), 2.31
(m, 1H), 2.05 (m, 2H), 1.79 (m, 2H), 1.57 (m, 2H), 1.31 (m, 1H), 1.00 (m, 1H), 1.04 (d,
3H, J = 6.0 Hz), 0.94 (m, 5H), 0.78 (t, 3H, J = 7.2 Hz)
MS (MALDI, m/z) 1098 (M+H)+
Analytical HPLC (UV) purity 96%, retention time = 10.25 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.40 min
273
1H NMR of 71ho
COSY NMR of 71ho
274
Data for 71bi
1H NMR (300 MHz, DMSO-d6) δ 9.88 (s, 1H), 8.39 (s, 1H), 8.06 (m, 6H), 7.79 (s, 1H),
6.71 (d, 2H, J = 2.1 Hz), 6.63 (d, 2H, J = 8.4 Hz), 6.56 (dd, 2H, J = 8.4 Hz, 2.1 Hz), 5.89
(t, 1H, J = 7.2 Hz), 5.49 (s, 2H), 3.89-3.50 (m, 16H), 2.81 (m, 2H), 2.73 (m, 2H), 2.64
(m, 4H), 2.06 (m, 2H), 1.61 (m, 8H), 1.31 (m, 3H), 1.13 (m, 1H), 0.87 (t, 3H, J = 7.2 Hz)
MS (MALDI, m/z) 998 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 9.02 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.17 min
1H NMR of 71bi
275
COSY NMR of 71bi
Data for 71fn
1H NMR (300 MHz, DMSO-d6) δ 9.95 (s, 1H), 8.36 (s, 1H), 8.07 (s, 1H), 8.04 (s, 1H),
7.96 (s, 1H), 7.31 (d, 1H, J = 8.4 Hz), 7.02 (d, 2H, J = 8.4 Hz), 6.62 (d, 2H, J = 2.1 Hz),
6.64 (d, 4H, J = 8.4 Hz), 6.60 (dd, 2H, J = 8.4 Hz, 2.1 Hz), 6.07 (t, 1H, J = 7.2 Hz), 5.63
(d, 1H, J = 9.0 Hz), 3.89-3.44 (m, 18H), 3.30 (m, 2H), 2.77 (m, 2H), 1.28 (m, 1H), 0.94
(d, 3H, J = 7.2 Hz), 0.78 (d, 3H, J = 7.2 Hz)
MS (MALDI, m/z) 1050 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.37 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.52 min
276
1H NMR of 71fn
COSY NMR of 71fn
277
Data for 71oo
1H NMR (300 MHz, DMSO-d6) δ 9.82 (s, 1H), 8.36 (s, 1H), 8.06 (d, 1H, J = 8.4 Hz),
8.04 (s, 2H), 7.85 (t, 2H, J = 8.1 Hz), 7.23 (d, 1H, J = 8.4 Hz), 6.70 (d, 2H, J = 2.1 Hz),
6.63 (d, 2H, J = 8.4 Hz), 6.56 (dd, 2H, J = 8.4 Hz, 2.1 Hz), 5.67 (d, 2H, J = 10.2 Hz),
3.89-3.58 (m, 16 Hz), 3.15 (m, 4H), 2.67 (m, 4H), 2.30 (m, 2H), 1.80 (m, 4H), 0.95 (m,
10H), 0.78 (t, 6H, J = 7.2 Hz)
MS (MALDI, m/z) 1124 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 9.75 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.90 min
1H NMR of 71oo
278
COSY NMR of 71oo
Data for 71gg
1H NMR (500 MHz, DMSO-d6) δ 9.99 (s, 1H), 8.38 (s, 1H), 8.05 (s, 6H), 7.98 (s, 2H),
7.17 (d, 1H, J = 8.5 Hz), 6.74 (s, 2H), 6.65 (d, 2H, J = 8.5 Hz), 6.60 (d, 2H, J = 8.5 Hz),
5.79 (d, 2H, J = 10.0 Hz), 4.31 (m, 2H), 3.84-3.56 (m, 16H), 2.76 (m, 4H), 2.54 (m, 4H),
1.65 (m, 8H), 1.07 (d, 6H, J = 7.5 Hz)
MS (MALDI, m/z) 1044 (M+H)+
Analytical HPLC (UV) purity 86%, retention time = 8.78 min
Analytical HPLC (Sedex) purity 100%, retention time = 8.93 min
279
1H NMR of 71gg
COSY NMR of 71gg
280
Data for 71dd
1H NMR (500 MHz, DMSO-d6) δ 9.98 (s, 1H), 8.40 (s, 1H), 8.05 (d, 1H, J = 7.0 Hz),
7.79 (s, 2H), 7.18 (d, 1H, J = 8.5 Hz), 6.73 (s, 2H), 6.64 (d, 2H, J = 8.5 Hz), 6.58 (d, 2H,
J = 8.5 Hz), 5.49 (s, 4H), 3.90 (m, 20H), 2.79 (t, 4H, J = 7.0 Hz)
MS (MALDI, m/z) 902 (M+H)+
Analytical HPLC (UV) purity 92%, retention time = 10.07 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.22 min
1H NMR of 71dd
281
COSY NMR of 71dd
Data for 71n’
1H NMR (300 MHz, DMSO-d6) δ 9.57 (s, 1H), 8.41 (s, 1H), 8.02 (s, 1H), 7.90 (s, 1H),
7.06 (d, 1H, J = 8.4 Hz), 7.01 (d, 2H, J = 8.4 Hz), 6.56 (m, 4H), 6.49 (s, 2H), 6.42 (d,
2H, J = 8.4 Hz), 6.05 (t, 1H, J = 7.5 Hz), 3.87-3.47 (m, 18H), 3.29 (m, 2H), 2.74 (t, 2H, J
= 6.9 Hz)
MS (MALDI, m/z) 1114 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.57 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.72 min
282
1H NMR of 71n’
COSY NMR of 71n’
283
Data for 71l’
1H NMR (300 MHz, DMSO-d6) δ 9.61 (s, 1H), 8.44 (s, 1H), 7.88 (s, 1H), 7.06 (d, 1H, J
= 8.4 Hz), 6.63 (d, 2H, J = 8.4 Hz), 6.52 (s, 2H), 6.47 (d, 2H, J = 8.4 Hz), 5.94 (q, 1H, J
= 6.0 Hz), 3.88-3.67 (m, 16 Hz), 2.79 (t, 2H, J = 7.2 Hz), 2.38 (t, 2H, J = 7.2 Hz), 1.57
(d, 3H, J = 6.0 Hz)
MS (MALDI, m/z) 986 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.75 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.90 min
1H NMR of 71l’
284
COSY NMR of 71l’
Data for 71c’
1H NMR (300 MHz, DMSO-d6) δ 9.65 (s, 1H), 8.41 (s, 1H), 7.96 (d, 1H, J = 8.4 Hz),
7.88 (s, 1H), 7.09 (d, 1H, J = 8.4 Hz), 6.63 (d, 2H, J = 8.4 Hz), 6.60 (s, 2H), 6.48 (d, 2H,
J = 8.4 Hz), 5.60 (d, 1H, J = 10.2 Hz), 3.87-3.42 (m, 16 Hz), 2.80 (t, 2H, J = 7.2 Hz),
2.40 (t, 2H, J = 7.2 Hz), 2.75 (m, 1H), 0.94 (m, 5H), 0.75 (t, 3H, J = 7.2 Hz)
MS (MALDI, m/z) 1070 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.58 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.73 min
285
1H NMR of 71c’
COSY NMR of 71c’
286
Further Coupling Selectivity Evidence
TOCSY Spectra of 71gg, 71oo and their monomeric fragments 70g, 70o are analyzed to
indicate that monochloro- and dichloro- triazine derivatives couple to the amine of
piperazine linker residue selectively over other active sites in the deprotected monomeric
fragments.  Compared to the spectra of 70g and 70o, the piperazine NH is absent and the
chemical shifts of piperzine ring have changed in that of 71gg and 71oo.
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General Procedure for Preparation of Biotin Labeled Bivalent Compounds 72 and
Monovalent Compounds 72a’-o’
Boc-protected monomeric compounds 74a-o (1.0 eq.) were treated with 30% TFA in
CH2Cl2, stirred in sealed glass vials for 4h and solvent was removed. The resulting
residue was dissolved in DMSO (0.05 M) and DTAF (1.0 equiv.) and K2CO3 (4.0 eq.)
were added. The suspension was stirred for 2 h. The crude product 78a-o was used for
the next step without further purification.  Analytical HPLC and MALDI MS were used
to check the purities of these crude samples.
Dimerization was carried out in 2 ml glass vials.  The monomeric compounds 74a-o
were treated with 30% TFA/CH2Cl2 for 4 h.  Stock solutions of 78 (0.05 M) and
deprotected 74 (0.05 M) or morpholine (0.05 M) in DMSO were prepared.  One stock
solution of 7 (0.5 ml) and one of deprotected 74 (0.5 ml) or morpholine (0.5 ml) were
added to a glass vial and followed with solid K2CO3 (ca 20 mg).  The reaction vial was
sealed and sonicated for 15 min.  The reaction mixture was agitated at 25 °C for 48 h
then the DMSO was lyophilized.  Aqueous HCl solution (5%, ca 0.5 ml) was added to
the above solid residue and sonicated for 3 min.  The aqueous solution of these
compounds were lyophilized and redissolved in 0.5 ml MeOH.  The inorganic salts were
precipitated out and removed.  The MeOH solution was then concentrated to give
compounds 73.  All crude products were analyzed by analytical HPLC (5-95% B in 30
min) and MALDI-MS.
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Preparation of Biotin Labeled Linker 77.  To the ice-water bath cooled CHCl3
solution (5 ml) of cyanuric chloride (0.52 mmol, 0.10 g) was added norbiotin amine
hydrochloride salt (0.4 mmol, 0.10 g) and N,N-diisopropyl ethyl amine (1.00 mmol, 0.17
ml).  The resulting mixture was stirred at 0 ºC for 2 h.  The white solid precipitate was
filtered, washed with cooled CHCl3 (5 ml), H2O (5 ml), and dried under vacumm for 14
h to give compound 77 (0.10 g, 71 %).
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Data for Biotin Labeled Bivalent Compounds 72
72bm
1H NMR (500 MHz, CD3OD) δ 7.77 (s, 1H), 7.72 (s, 1H), 4.48 (dd, 1H, J = 7.5 Hz, 4.5
Hz), 4.29 (dd, 1H, J = 7.5 Hz, 4.0 Hz), 3.98-3.52 (m, 18H), 3.06 (t, 2H, J = 7.0 Hz), 3.00
(m, 1H), 2.88 (m, 2H), 2.81 (m, 2H), 1.75 (m, 2H), 1.68 (m, 3H), 1.62 (m, 2H), 1.52 (m
2H), 1.46 (m, 2H)
MS (MALDI, m/z) 852  (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 8.65 min
Analytical HPLC (Sedex) purity 100%, retention time = 8.80 min
1H NMR of 72bm
293
gCOSY NMR of 72bm
72lm
1H NMR (500 MHz, CD3OD) δ 7.83 (s, 1H), 7.76 (s, 1H), 5.96 (s, 2H), 5.92 (q, 1H, J =
7.0 Hz), 4.48 (dd, 1H, J = 7.5 Hz, 4.5 Hz), 4.29 (dd, 1H, J = 7.5 Hz, 4.5 Hz), 3.89-3.51
(m, 16H), 3.33 (t, 2H, J = 7.0 Hz), 3.28 (m, 1H), 3.19 (t, 2H, J = 7.0 Hz), 3.17 (m, 1H),
2.98 (m, 2H), 2.70 (t, 2H, J = 7.5 Hz), 1.96 (m, 2H), 1.69 (d, 3H, J = 7.0 Hz), 1.58 (m,
2H), 1.46 (m, 2H)
MS (MALDI, m/z) 867 (M+H)+
Analytical HPLC (UV) purity 94%, retention time = 9.27 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.41 min
294
1H NMR of 72lm
gCOSY NMR of 72lm
295
72ci
1H NMR (500 MHz, CD3OD) δ 7.91 (s, 1H), 7.89 (s, 1H), 6.01 (q, 1H, J = 7.0 Hz), 5.59
(d, 1H, J = 9.5 Hz), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.29 (dd, 1H, J = 7.5 Hz, 4.5 Hz),
3.87-3.35 (m, 16H), 3.19 (m, 2H), 3.17 (m, 1H), 2.92 (t, 2H, J = 7.0 Hz), 2.89 (m, 1H),
2.79 (t, 2H, J = 7.5 Hz), 2.65 (t, 2H, J =7.0 Hz), 2.48 (m, 2H), 1.95 (m, 2H), 1.72 (d, 3H,
J = 7.0 Hz), 1.71 (m, 2H), 1.57 (m, 2H), 1.03 (m, 5H), 0.82 (m, 3H)
MS (MALDI, m/z) 923 (M+H)+
Analytical HPLC (UV) purity 96%, retention time = 10.58 min
Analytical HPLC (Sedex) purity 97%, retention time = 10.73 min
1H NMR of 72ci
296
gCOSY NMR of 72ci
72kl
1H NMR (500 MHz, CD3OD) δ 7.87 (s, 1H), 7.85 (s, 1H), 5.96 (q, 1H, J = 7.5 Hz), 5.79
(t, 1H, J = 7.5 Hz), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.28 (dd, 1H, J = 7.5 Hz, 4.0 Hz),
3.88-3.46 (m, 16H), 2.98 (m, 1H), 2.78 (t, 4H, J = 7.5 Hz), 2.69 (m, 1H), 2.64 (m, 2H),
2.61 (m, 2H), 2.58 (t, 4H, J = 7.5 Hz), 2.14 (m, 2H), 1.75 (d, 3H, J = 7.5 Hz), 1.62 (m,
2H), 1.54 (m, 4H), 1.33 (m, 1H), 1.02 (m, 1H)
MS (MALDI, m/z) 911 (M+H)+
Analytical HPLC (UV) purity 92%, retention time = 9.18 min
Analytical HPLC (Sedex) purity 92%, retention time = 9.35 min
297
1H NMR of 72kl
gCOSY NMR of 72kl
298
72ae
1H NMR (500 MHz, CD3OD) δ 7.94 (s, 2H), 5.68 (d, 1H, J = 10.0 Hz), 5.66 (s, 2H),
4.49 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.29 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 3.87-3.38 (m, 16H),
3.19 (m, 2H), 2.90 (m, 2H), 2.68 (m, 3H), 2.39 (m, 2H), 1.73 (m, 1H), 1.65 (m, 7H),
1.51 (m, 2H), 1.07 (m, 5H), 0.84 (m, 3H)
MS (MALDI, m/z) 867 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 8.93 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.08 min
1H NMR of 72ae
299
gCOSY NMR of 72ae
72ad
1H NMR (500 MHz, CD3OD) δ 7.95 (s, 2H), 5.69 (d, 1H, J = 10.0 Hz), 5.51 (s, 2H),
4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 3.98-3.38 (m, 16H),
3.19 (m, 2H), 2.95 (t, 2H, J = 8.0 Hz), 2.90 (t, 2H, J = 8.0 Hz), 2.69 (m, 2H), 1.75 (m,
7H), 1.52 (m, 2H), 1.37 (m, 4H), 1.09 (m, 5H), 0.84 (m, 3H)
MS (MALDI, m/z) 853 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.95 min
Analytical HPLC (Sedex) purity 100%, retention time = 11.11 min
300
1H NMR of 72ad
gCOSY NMR of 72ad
301
72cn
1H NMR (500 MHz, CD3OD) δ 7.99 (s, 1H), 7.89 (s, 1H), 6.92 (d, 2H, J = 8.0 Hz), 6.59
(d, 2H, J = 8.0 Hz), 6.02 (t, 1H, J = 7.0 Hz), 5.61 (d, 1H, J = 10.0 Hz), 4.48 (dd, 1H, J =
7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 3.79 (t, 2H, J = 7.0 Hz), 3.75-3.38 (m,
18H), 3.01 (t, 2H, J = 7.0 Hz), 2.95 (t, 2H, J = 8.0 Hz), 2.92 (m, 1H), 2.56 (t, 2H, J = 8.0
Hz), 2.42 (m, 2H), 1.73 (m, 1H), 1.60 (m, 2H), 1.55 (m, 2H), 1.28 (m, 5H), 0.87 (m, 3H)
MS (MALDI, m/z) 960 (M+H)+
Analytical HPLC (UV) purity 93%, retention time = 11.38 min
Analytical HPLC (Sedex) purity 90%, retention time = 11.55 min
1H NMR of 72cn
302
gCOSY NMR of 72cn
72co
1H NMR (500 MHz, CD3OD) δ 7.93 (s, 1H), 7.87 (s, 1H), 5.64 (d, 1H, J = 10.0 Hz),
5.56 (d, 1H, J = 9.5 Hz), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5 Hz, 5.0
Hz), 3.75-3.38 (m, 16H), 3.23 (t, 2H, J = 7.0 Hz), 2.97 (t, 2H, J = 8.0 Hz), 2.89 (m, 1H),
2.78 (t, 2H, J = 8.0 Hz), 2.49 (m, 2H), 2.44 (m, 2H), 1.93 (m, 2H), 1.72 (m, 1H), 1.58
(m, 2H), 1.45 (m, 2H), 1.08 (m, 10H), 0.86 (m, 6H)
MS (MALDI, m/z) 965 (M+H)+
Analytical HPLC (UV) purity 93%, retention time = 10.80 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.95 min
303
1H NMR of 72co
gCOSY NMR of 72co
304
72bo
1H NMR (500 MHz, CD3OD) δ 7.95 (s, 1H), 7.74 (s, 1H), 5.67 (d, 1H, J = 10.0 Hz),
4.82 (s, 2H), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 3.78-
3.38 (m, 16H), 3.20 (t, 2H, J = 7.0 Hz), 2.78 (m, 1H), 2.74 (t, 2H, J = 8.0 Hz), 2.71 (m,
2H), 2.69 (m, 2H), 2.42 (m, 2H), 1.93 (m, 2H), 1.72 (m, 2H), 1.63 (m, 1H), 1.60 (m,
4H), 1.50 (m, 2H), 1.05 (m, 5H), 0.87 (m, 3H)
MS (MALDI, m/z) 908 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.03 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.19 min
1H NMR of 72bo
305
gCOSY NMR of 72bo
72jm
1H NMR (500 MHz, CD3OD) δ 7.97 (s, 1H), 7.84 (s, 1H), 5.86 (t, 1H, J = 7.5 Hz), 4.82
(s, 2H), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5 Hz, 4.0 Hz), 3.75-3.38
(m, 16H), 3.20 (t, 2H, J = 7.0 Hz), 2.93 (m, 1H), 2.82 (m, 1H), 2.70 (t, 2H, J = 8.0 Hz),
2.61 (t, 2H, J = 8.0 Hz), 2.14 (m, 2H), 1.89 (m, 2H), 1.73 (m, 1H), 1.66 (m, 4H), 1.58
(m, 2H), 1.46 (m, 2H), 1.35 (m, 2H), 0.93 (t, 3H, J = 7.0 Hz)
MS (MALDI, m/z) 908 (M+H)+
Analytical HPLC (UV) purity 94%, retention time = 10.11 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.27 min
306
1H NMR of 72jm
gCOSY NMR of 72jm
307
72fo
1H NMR (500 MHz, CD3OD) δ 7.94 (s, 1H), 7.91 (s, 1H), 5.64 (d, 1H, J = 10.0 Hz),
5.56 (d, 1H, J = 9.5 Hz), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5 Hz, 4.0
Hz), 3.75-3.38 (m, 18H), 3.24 (t, 2H, J = 7.0 Hz), 3.22 (m, 1H), 2.92 (t, 2H, J = 8.0 Hz),
2.78 (m, 3H), 2.56 (m, 1H), 2.40 (m, 2H), 1.92 (m, 1H), 1.61 (m, 2H), 1.56 (m, 2H),
1.06 (m, 6H), 1.08 (m, 5H), 0.84 (m, 3H)
MS (MALDI, m/z) 923 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 11.12 min
Analytical HPLC (Sedex) purity 94%, retention time = 11.27 min
1H NMR of 72fo
308
gCOSY NMR of 72fo
72jo
1H NMR (500 MHz, CD3OD) δ 7.95 (s, 1H), 7.87 (s, 1H), 5.86 (t, 1H, J = 7.5 Hz), 5.66
(d, 1H, J = 10.0 Hz), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5 Hz, 4.5 Hz),
3.91-3.38 (m, 16H), 3.02 (t, 2H, J = 7.0 Hz), 3.02 (m, 1H), 2.75 (m, 1H), 2.66 (t, 2H, J =
8.0 Hz), 2.59 (t, 2H, J = 8.0 Hz), 2.11 (m, 1H), 1.75 (m, 2H), 1.65 (m, 2H), 1.58 (m, 1H),
1.53 (m, 4H), 1.39 (m, 2H), 1.34 (m, 2H), 1.20 (m, 1H0, 1.06 (t, 3H, J = 7.0 Hz), 1.03
(m, 5H), 0.86 (m, 3H)
MS (MALDI, m/z) 964 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 11.25 min
Analytical HPLC (Sedex) purity 100%, retention time = 11.39 min
309
1H NMR of 72jo
gCOSY NMR of 72jo
310
72dn
1H NMR (500 MHz, CD3OD) δ 7.99 (s, 1H), 7.78 (s, 1H), 7.02 (d, 2H, J = 8.5 Hz), 6.86
(d, 2H, J = 8.5 Hz), 6.05 (m, 2H), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5
Hz, 5.0 Hz), 3.89 (m, 4H), 3.75-3.38 (m, 16H), 3.36 (m, 2H), 3.21 (m, 2H), 2.92 (m,
4H),
1.72 (m, 1H), 1.60 (m, 2H), 1.45 (m, 2H)
MS (MALDI, m/z) 876 (M+H)+
Analytical HPLC (UV) purity 92%, retention time = 9.62 min
Analytical HPLC (Sedex) purity 100%, retention time = 9.77 min
1H NMR of 72dn
311
gCOSY NMR of 72dn
72cm
1H NMR (500 MHz, CD3OD) δ 7.88 (s, 1H), 7.77 (s, 1H), 5.59 (d, 1H, J = 10.0 Hz),
4.82 (s, 2H), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 3.87-
3.38 (m, 16H), 3.20 (t, 2H, J = 7.0 Hz), 3.18 (m, 1H), 2.96 (t, 2H, J = 7.5 Hz), 2.90 (m,
1H), 2.82 (t, 2H, J = 7.0 Hz), 2.59 (t, 2H, J = 8.0 Hz), 2.49 (m, 1H), 2.41 (m, 2H), 1.73
(m, 1H), 1.61 (m, 2H), 1.49 (m, 2H), 1.08 (m, 5H), 0.86 (m, 3H)
MS (MALDI, m/z) 909 (M+H)+
Analytical HPLC (UV) purity 96%, retention time = 10.67 min
Analytical HPLC (Sedex) purity 95%, retention time = 10.83 min
312
1H NMR of 72cm
gCOSY NMR of 72cm
313
72m’
1H NMR (500 MHz, CD3OD) δ 7.77 (s, 1H), 4.84 (s, 2H), 4.49 (dd, 1H, J = 7.5 Hz, 5.0
Hz), 4.30 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 3.89-3.68 (m, 16H), 3.64 (t, 2H, J = 7.0 Hz), 3.44
(t, 2H, J = 7.0 Hz), 3.29 (m, 2H), 2.93 (m, 1H), 1.97 (m, 2H), 1.72 (m, 1H), 1.62 (m,
2H), 1.48 (m, 2H)
MS (MALDI, m/z) 672 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.38 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.54 min
1H NMR of 72m’
314
gCOSY NMR of 72m’
72n’
1H NMR (500 MHz, CD3OD) δ 7.99 (s, 1H), 6.97 (d, 2H, J = 8.0 Hz), 6.63 (d, 2H, J =
8.0 Hz), 6.03 (t, 1H, J = 7.5 Hz), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5
Hz, 4.0 Hz), 3.80-3.38 (m, 18H), 3.37 (t, 2H, J = 7.0 Hz), 3.28 (m, 2H), 3.20 (t, 2H, J =
7.0 Hz), 2.92 (m, 1H), 1.73 (m, 1H), 1.59 (m, 2H), 1.46 (m, 2H)
MS (MALDI, m/z) 723 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.30 min
Analytical HPLC (Sedex) purity 100%, retention time = 10.47 min
315
1H NMR of 72n’
gCOSY NMR of 72n’
316
72cc
1H NMR (500 MHz, CD3OD) δ 7.90 (s, 2H), 5.61 (d, 2H, J = 10.0 Hz), 4.49 (dd, 1H, J
= 7.5 Hz, 5.0 Hz), 4.29 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 3.85-3.38 (m, 16H), 3.19 (m, 2H),
2.95 (t, 4H, J = 8.0 Hz), 2.90 (m, 1H), 2.68 (t, 4H, J = 8.0 Hz), 2.39 (m, 2H), 1.75 (m,
1H), 1.61 (m, 2H), 1.47 (m, 2H), 1.09 (m, 10H), 0.84 (m, 6H)
MS (MALDI, m/z) 938 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 12.28 min
Analytical HPLC (Sedex) purity 87%, retention time = 12.41 min
1H NMR of 72cc
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gCOSY NMR of 72cc
72ll
1H NMR (500 MHz, CD3OD) δ 7.89 (s, 1H), 7.79 (s, 1H), 6.01 (s, 1H), 5.14 (q, 2H, J =
7.5 Hz), 4.51 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.31 (dd, 1H, J = 7.5 Hz, 4.0 Hz), 3.89-3.76
(m, 16 H), 3.22 (m, 1H), 3.05 (m, 1H), 2.98 (m, 4H), 2.95 (m, 1H), 2.92 (m, 2H), 2.53
(m, 4H), 1.76 (d, 6H, J = 7.5 Hz), 1.62 (m, 2H), 1.54 (m, 2H)
MS (MALDI, m/z) 854 (M+H)+
Analytical HPLC (UV) purity 91%, retention time = 9.65 min
Analytical HPLC (Sedex) purity 89%, retention time = 9.79 min
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1H NMR of 72ll
gCOSY NMR of 72ll
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72jj
1H NMR (500 MHz, CD3OD) δ 7.88 (s, 2H), 5.86 (m, 2H), 4.48 (dd, 1H, J = 7.5 Hz,
5.0 Hz), 4.29 (dd, 1H, J = 7.5 Hz, 4.0 Hz), 3.98-3.32 (m, 16H), 3.20 (m, 1H), 2.92 (m,
1H), 2.79 (m, 2H), 2.15 (m, 4H), 1.64 (m, 4H), 1.59 (m, 2H), 1.53 (m, 2H), 1.38 (m,
4H), 1.95 (t, 6H, J = 7.5 Hz)
MS (MALDI, m/z) 936 (M+H)+
Analytical HPLC (UV) purity 90%, retention time = 11.10 min
Analytical HPLC (Sedex) purity 92%, retention time = 11.25 min
1H NMR of 72jj
320
gCOSY NMR of 72jj
72ff
1H NMR (500 MHz, CD3OD) δ 8.00 (s, 1H), 7.96 (s, 1H), 5.60 (d, 2H, J = 4.5 Hz), 4.51
(dd, 1H, J = 7.5 Hz, 5.5 Hz), 4.31 (dd, 1H, J = 8.0 Hz, 4.5 Hz), 3.98-3.36 (m, 18H), 3.20
(m, 1H), 2.95 (t, 4H, J = 7.0 Hz), 2.72 (m, 2H), 2.54 (m, 1H), 1.63 (m, 2H), 1.47 (m,
2H), 1.08 (d, 3H, J = 7.0 Hz), 1.07 (d, 3H, J = 7.0 Hz), 0.79 (d, 3H, J = 7.0 Hz), 0.76 (d,
3H, J = 7.0 Hz)
MS (MALDI, m/z) 854 (M+H)+
Analytical HPLC (UV) purity 100%, retention time = 10.78 min
Analytical HPLC (Sedex) purity 99%, retention time = 10.93 min
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1H NMR of 72ff
gCOSY NMR of 72ff
322
72aa
1H NMR (500 MHz, CD3OD) δ 7.92 (s, 2H), 5.60 (d, 1H, J = 9.0 Hz), 5.54 (d, 1H, J =
9.0 Hz), 4.48 (dd, 1H, J = 7.5 Hz, 5.5 Hz), 4.29 (dd, 1H, J = 7.5 Hz, 4.0 Hz), 3.86-3.38
(m, 20H), 3.18 (m, 1H), 3.07 (m, 2H), 2.89 (m, 1H), 2.73 (m, 4H), 2.43 (m, 2H), 1.73
(m, 4H), 1.56 (m, 2H), 1.45 (m, 6H), 1.81 (m, 6H), 1.05 (m, 6H), 0.96 (m, 4H)
MS (MALDI, m/z) 936 (M+H)+
Analytical HPLC (UV) purity 93%, retention time = 10.88 min
Analytical HPLC (Sedex) purity 100%, retention time = 11.95 min
1H NMR of 72aa
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gCOSY NMR of 72aa
72ii
1H NMR (500 MHz, CD3OD) δ 7.94 (s, 1H), 7.82 (s, 1H), 6.01 (q, 1H, J = 7.5 Hz), 5.15
(q, 1H, J = 7.5 Hz), 4.48 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.29 (q, 1H, J = 7.5 Hz, 4.5 Hz),
3.87-3.43 (m, 16H), 3.29 (t, 4H, J = 7.5 Hz), 3.23 (m, 1H), 3.19 (t, 4H, J = 7.0 Hz), 2.62
(m, 4H), 1.95 (d, 6H, J = 7.5 Hz), 1.74 (m, 2H,) 1.48 (m, 2H)
MS (MALDI, m/z) 908 (M+H)+
Analytical HPLC (UV) purity 91%, retention time = 9.10 min
Analytical HPLC (Sedex) purity 95%, retention time = 9.24 min
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1H NMR of 72ii
gCOSY NMR of 72ii
325
72nn
1H NMR (500 MHz, CD3OD) δ 8.08 (s, 2H), 6.91 (d, 4H, J = 8.0 Hz), 6.56 (d, 4H, J =
8.0 Hz), 6.04 (t, 2H, J = 7.5 Hz), 4.95 (dd, 1H, J = 7.5 Hz, 5.0 Hz), 4.30 (dd, 1H, J = 7.5
Hz, 4.5 Hz), 3.80 (t, 4H, J = 6.5 Hz), 3.74-3.34 (m, 16H), 3.32 (m, 4H), 3.19 (t, 4H, J =
6.5 Hz), 3.15 (m, 2H), 2.80 (m, 2H), 1.76 (m, 1H), 1.67 (m, 2H), 1.48 (m, 2H)
MS (MALDI, m/z) 982 (M+H)+
Analytical HPLC (UV) purity 96%, retention time = 10.28 min
Analytical HPLC (Sedex) purity 96%, retention time = 10.42 min
1H NMR of 72nn
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gCOSY NMR of 72nn
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Preparation of Aliphatic Hydrocarbon Chain Labeled Bivalent Compounds 81
N N
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Cu/CuSO4, THF/H2O
8 h, 25 oC
Alkyne labeled Compounds 80 were prepared by another member in our group.
Compounds 80 (ca 10.0 mg) were dissolved in 1.0 ml THF/H2O (v:v = 1:1) and CuSO4
solution (1.0 M, 10 µl) was added to the above solution and followed by Cu powder (1.0
mg).  The azidooctadecane in THF solution (0.1 mmol, 0.2 ml) was then added and the
resulting suspension was stirred at 25 oC for 24 h and filtered through a glass pipette
filled with silica gel with 30 % methanol in CH2Cl2 as eluent.  The solution was dried
and concentrated to give compounds 81.
Compounds 81 were originally analyzed by HPLC with CH3CN/H2O as eluents but the
compounds couldn’t pass through the column.  The eluents later used were: solvent A
(20% H2O, 5% THF and 75% MeOH with 0.1% TFA) and solvent B (20% H2O, 5%
MeOH and 75% THF with 0.1% TFA).  Analytical HPLC analyses were carried out on
25 x 0.46 cm C-18 column using gradient conditions (5 – 95% B) for 30 minutes.
However, the peaks of the HPLC spectra were still broad.  The HPLC data of
compounds 81 was not obtained at this stage.
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Luciferase Assay for Compounds 81 on cancer cell lines
Luciferase assay was performed on the hydrocarbon chain labeled compounds 81
by Professor Nancy Templeton’s group at Rice University.  The purpose of this
experiment is to scan compounds that increase the transfection efficiency of Dr.
Templeton’s patented complexes for specific cell lines.  Using a luciferase assay,
compounds that result in a significant increase of light emitted relative to transfection of
complexes without compound coating will be identified.
The compounds were first dissolved in water at 50 oC with sonication and then
coated on the liposomes at different concentrations [3, 1.6, 0.3, -1 log (pg compound/ug
DNA)] by mixing and incubation overnight.  The transfection efficiency of each
compound at different concentration was measured using luciferase assay.  Of the 108
compounds that have been screened (the other 27 compounds contain large chunky or
overly gelatinous material and they were not tested), the following showed significant
increase (about 1.5 to 3 fold) post-transfection of the lung cancer (Figure B2) and breast
cancer cell lines (Figure B3).
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a.
Concentration 3 1.6 0.3 -1
norm error norm error norm error norm error
81ae 1.66 0.73 2.49 0.71 0.42 0.25 0.69 0.17
81ag 2.68 1.21 1.46 0.12 1.35 0.41 1.94 0.77
81bg 0.80 0.21 0.46 0.05 0.94 0.30 2.07 0.36
81dm 2.06 0.51 0.83 0.09 1.12 0.55 0.80 0.32
81en 1.04 0.55 1.16 0.46 2.96 0.25 0.67 0.31
81ij 0.82 0.14 0.56 0.32 0.54 0.21 1.76 0.74
      ∗ the concentration is measured by log (pg compound/ug DNA)
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Figure B 2.  (a) Data of the positive “hits” from lung cancer cell lines and (b) the
corresponding graph presentation..
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a.
Concentration 3 1.6 0.3 -1
norm error norm error norm error norm error
81m’ 2.40 0.01 1.05 0.15 1.03 0.24 0.90 0.04
81mn 2.15 0.21 0.80 0.12 0.94 0.26 0.84 0.12
81mk 1.88 0.45 0.83 0.07 0.85 0.23 0.67 0.22
81bj 1.81 0.03 2.25 0.69 0.90 0.17 1.02 0.27
81ab 2.31 0.46 1.54 0.39 0.60 0.11 0.97 0.28
81bd 3.03 0.36 1.43 0.29 0.86 0.04 0.89 0.39
∗ the concentration is measured by log (pg compound/ug DNA)
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Figure B 3.  (a) Data of the positive “hits” from lung cancer cell lines and (b) the
corresponding graph presentation..
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APPENDIX C
EXPERIMENTAL ON CHAPTER IV
General Methods.  All chemicals were obtained from commercial suppliers and used
without further purification. Analytical HPLC analyses were carried out on 25 x 0.46 cm
C-18 column using gradient conditions (5 – 95% B) for 30 minutes.  The eluents used
were: solvent A (H2O with 0.1% TFA) and solvent B (CH3CN with 0.1% TFA).  The
flow rate used was 1.0 ml/min.  Flash chromatography was performed using silica gel
(230-600 mesh).  NMR spectra were recorded at 500 MHz if otherwise indicated.  NMR
chemical shifts were expressed in ppm relative to internal solvent peaks, and coupling
constants were measured in Hz.  Through bond connectivities were elucidated by COSY
spectra, which were recorded with 256 t1 increments and 8 scans per t1 increments.
General Procedure for Preparation of Compounds 84a, 84b and 84f.  The
preparation of compounds 84a, 84b and 84f was accomplished as shown in Scheme C1.
The short linker N was attached to the scaffold 3-iodobenzoic acid by the activation of
the acid group with diphenylphosphoryl azide (DPPA) followed by the addition of N.
Sonogashira coupling of the resulting intermediate with corresponding akynes afforded
target molecules with good yields.
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(i) DPPA, NEt3, 
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N
O
N NBoc
O NHBoc
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Pd(PPh3)4, CuI, 
NEt3, THF
85a
84b
84f
86
Scheme C1.  Preparation of compounds 84a, 84b and 84f.
333
Data for Compound 84a
1H NMR (300 MHz, CDCl3) δ 7.41 (s, 1H), 7.32 (d, 1H, J = 4.5 Hz), 7.20 (t, 1H, J = 4.5
Hz), 7.10 (d, 1H, J = 4.5 Hz), 6.87 (bs, 1H), 4.71 (q, 1H, J = 3.9 Hz), 3.44 (m, 8H), 1.72
(s, 1H), 1.53 (d, 3H, J = 3.9 Hz), 1.48 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 155.8, 155.0, 139.4, 129.0, 126.7, 124.2, 123.4, 121.2,
91.8, 83.6, 80.7, 58.6, 28.6, 24.6
MS (ESI, m/z) 373 (M+H)+
1H NMR of 84a
13C NMR of 84a
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Data for Compound 84b
1H NMR (300 MHz, CDCl3) δ 7.37 (s, 1H), 7.31 (d, 1H, J = 7.8 Hz), 7.19 (t, 1H, J = 7.8
Hz), 7.07 (d, 1H, J = 7.8 Hz), 4.41 (s, 2H), 3.43 (m, 8H), 1.47 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 155.6, 155.1, 139.4, 129.0, 126.7, 124.3, 123.3, 121.3,
88.2, 85.1, 80.7, 15.3, 28.6
MS (ESI, m/z) 359 (M+H)+
1H NMR of 84b
13C NMR of 84b
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Data for Compound 84f
1H NMR (300 MHz, CDCl3) δ 7.45 (s, 1H), 7.39 (d, 1H, J = 7.5 Hz), 7.27 (t, 1H, J = 7.5
Hz), 7.12 (d, 1H, J = 7.5 Hz), 6.71 (bs, 1H), 4.98 (bs, 1H), 4.35 (s, 2H), 3.63 (t, 2H, J =
5.4 Hz), 3.48 (m, 8H), 3.36 (t, 2H, J = 5.4 Hz), 1.48 (s, 9H), 1.47 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 156.3, 155.5, 154.8, 139.5, 128.9, 126.5, 123.6, 122.9,
120.9, 86.6, 84.8, 80.5, 79.5, 69.2, 60.6, 59.1, 44.0, 40.5, 28.6
MS (ESI, m/z) 502 (M+H)+
1H NMR of 84f
13C NMR of 84f
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Procedure for Preparation of Compound 86.  To a solution of N-(2-Hydroxyethyl)
phthalimide (0.38 g, 2.0 mmol) in 10 ml dry THF was added 0.1 g of NaH (60% w.t. in
minoral oil) and the resulting suspension was stirred at 25 oC for 15 min.  Tetra-
nbutyliodide (0.15 g, 0.4 mmol) in 10 ml THF was added to the above suspension
followed by propargyl bromide (0.45 ml, 4.0 mmol).  The reaction mixture was heated to
reflux for 8 h, cooled to 25 oC and concentrated.  The residue was extracted with ethyl
acetate and brine and the organic layer was concentrated and purified by flash
chromatography (25% ethyl acetate in hexanes). Compound 86 was isolated as a white
solid with the yield of 52%.
1H NMR (300 MHz, CDCl3) δ 7.85 (dd, 2H, J = 5.4 Hz, 2.1 Hz), 7.71 (dd, 2H, J = 5.4
Hz, 2.4 Hz), 4.17 (d, 2H, J = 2.4 Hz), 3.90 (t, 2H, J = 4.8 Hz), 3.82 (t, 2H, J = 4.8 Hz),
2.38 (t, 1H, J = 2.4 Hz)
13C NMR (300 MHz, CDCl3) δ 168.5, 134.2, 132.4, 132.6, 79.5, 75.1, 66.6, 58.1, 37.5
MS (ESI, m/z) 230 (M+H)+
1H NMR of 86
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13C NMR of 86
General Procedure for Preparation of Compounds 84c and 84j.  Synthesis of 84c
and 84j is very straightforward.  Short and long linkers were attached to the 4-
aminobenzoylalcohol directly by EDC coupling reaction (Scheme C2).  The
benzoylalcohol is a mimic of serine side chain and the proton on the score structure is
mimicking glycine side chain.  The alkyne is used in this case is for the synthetic
convenience.
HO
NH2 P, EDC, HOBt, 
NMM, CH2Cl2
HN
O
O N
O
NBoc
HO
84j
O, EDC, HOBt, 
NMM, CH2Cl2
HO
HN
O
NBoc
84c
Scheme C2.  Preparation of compounds 84c and 84j.
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Data for 84c
1H NMR (300 MHz, CDCl3) δ 7.50 (d, 2H, J = 8.4 Hz), 7.32 (d, 2H, J = 8.4 Hz), 4.66
(s, 2H), 4.20 (d, 2H, J = 13.2 Hz), 2.78 (t, 2H, J = 13.2 Hz), 2.93 (m, 1H), 2.14 (s, 1H),
1.91 (m, 2H), 1.75 (m, 2H), 1.49 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 173.3, 155.0, 137.42, 137.37, 127.9, 120.6, 80.1, 64.7,
44.0, 28.7
MS (ESI, m/z) 335 (M+H)+
1H NMR of 84c
13C NMR of 84c
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Data for 84j
1H NMR (300 MHz, CDCl3) δ 9.91 (s, 1H), 7.65 (d, 2H, J = 8.4 Hz), 7.32 (d, 2H, J =
8.4 Hz), 4.44 (d, 2H, J = 3.6 Hz), 4.37 (s, 2H), 4.19 (s, 2H), 3.45-3.29 (m, 8H), 2.16 (t,
1H, J = 3.6 Hz), 1.47 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 168.1, 167.9, 154.7, 137.4, 137.2, 128.0, 120.2, 80.9,
72.8, 70.2, 64.9, 44.3, 41.9, 28.6
MS (ESI, m/z) 430 (M+Na)+
1H NMR of 84j
13C NMR of 84j
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Sonogashira coupling of 3-iodonitrobenzene with carboxylic acid functionalized
alkynes afforded acid intermediates that were converted to amides by the oxalyl chloride
activation and ammonia addition.  The nitro groups of the resulting amides were reduced
by zinc dust and the short or long linker was attached to give compounds 84d, 84e, 84k
and 84l (Scheme C3).
NO2
CONH2
HN
CONH2
O
NBoc
(i) Zn, AcOH, EtOH
(ii) O, EDC, HOBt, 
NMM, CH2Cl2
n = 2  84d
n = 1  84e
n
n
HN
CONH2
O
O N
O
NBoc
(i) Zn, AcOH, EtOH
(ii) P, EDC, HOBt,
 NMM, CH2Cl2
n = 2  84k
n = 1  84l
n
Scheme C3.  Preparation of compounds 84d, 84e, 84k and 84l.
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Data for 84d
1H NMR (300 MHz, CDCl3) δ 7.69 (s, 1H), 7.54 (d, 1H, J = 2.1 Hz), 7.32 (dd, 1H, J =
8.4 Hz, 2.1 Hz), 7.10 (d, 1H, J = 8.4 Hz), 5.90 (s, 1H), 5.57 (s, 1H), 4.18 (d, 2H,  J =
12.0 Hz), 2.76 (t, 2H, J = 12.0 Hz), 2.52 (t, 2H, J = 6.6 Hz), 2.42 (t, 2H, J = 6.6 Hz), 2.34
(m, 4H), 1.96 (m, 2H), 1.84 (m, 2H), 1.68 (m, 2H), 1.46 (s, 9H)
13C NMR (300 MHz, CD3OD) δ 177.2, 174.6, 155.2, 136.3, 135.6, 129.5, 124.0, 123.3,
119.8, 93.1, 80.0, 79.7, 43.6, 34.3, 28.5, 27.6, 24.9, 19.2, 18.6
MS (ESI, m/z) 400 (M+H)+
1H NMR of 84d
13C NMR of 84d
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Data for 84e
1H NMR (500 MHz, CDCl3) δ 7.89 (s, 1H), 7.49 (d, 1H, J = 2.0 Hz), 7.36 (dd, 1H, J =
8.0 Hz, 2.0 Hz), 7.08 (d, 1H, J = 8.0 Hz), 6.17 (s, 1H), 5.79 (s, 1H), 4.14 (m, 2H), 2.75
(t, 4H, J = 7.0 Hz), 2.51 (t, 2H, J = 7.0 Hz), 2.38 (m, 1H), 2.32 (s, 3H), 1.83 (m, 2H),
1.71 (m, 2H), 1.46 (s, 9H)
13C NMR (500 MHz, CDCl3) δ 174.3, 173.5, 154.6, 135.7, 135.6, 129.6, 123.5, 123.3,
120.0, 92.3, 79.8, 79.6, 43.5, 34.8, 28.4, 28.3, 19.9, 15.7
MS (ESI, m/z) 414 (M+H)+
1H NMR of 84e
13C NMR of 84e
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Data for 84k
1H NMR (300 MHz, CDCl3) δ 9.77 (s, 1H), 7.69 (s, 1H), 7.46 (d, 1H, J = 7.5 Hz), 7.10
(d, 1H, J = 7.5 Hz), 6.02 (s, 1H), 5.80 (s, 1H), 4.34 (s, 2H), 4.16 (s, 2H), 3.62-3.42 (m,
8H), 2.54 (t, 2H, J = 6.6 Hz), 2.43 (t, 2H, J = 6.6 Hz), 2.40 (s, 3H), 1.93 (m, 2H), 1.46 (s,
9h)
13C NMR (300 MHz, CDCl3) δ 175.4, 167.8, 154.7, 136.1, 135.5, 130.0, 124.1, 123.3,
119.7, 93.4, 80.9, 80.5, 73.0, 70.4, 44.4, 42.0, 34.7, 28.6, 24.5, 20.4, 19.2
MS (ESI, m/z) 473 (M+H)+
1H NMR of 84k
13C NMR of 84k
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Data for 84l
1H NMR (300 MHz, CDCl3) δ 9.78 (s, 1H), 7.71 (d, 1H, J = 1.8 Hz), 7.51 (dd, 1H, J =
8.1 Hz, 1.8 Hz), 7.16 (d, 1H, J = 8.1 Hz), 5.80 (s, 1H), 5.69 (s, 1H), 4.38 (s, 2H), 4.21 (s,
2H), 3.67-3.34 (m, 8H), 2.81 (t, 2H, J = 7.2 Hz), 2.57 (t, 2H, J = 7.2 Hz), 2.37 (t, 3H),
1.50 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 174.2, 167.8, 154.6, 136.2, 135.5, 130.0, 123.7, 123.3,
119.9, 92.5, 80.9, 80.5, 73.0, 70.4, 44.4, 42.0, 35.3, 28.6, 20.4, 16.1
MS (ESI, m/z) 487 (M+H)+
1H NMR of 84l
13C NMR of 84l
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Compound 84g was prepared from 3-iodo-4-methylbenzoic acid.  Amide bond
coupling followed with Sonogashira reaction with 5-hexynic acid afforded 84g (Scheme
C4).
I
COOH
(i) (COCl)2, CH2Cl2
(ii) O, EDC, HOBt, 
NMM, CH2Cl2
I
NO NBoc
Pd(PPh3)4, CuI, 
NEt3, THF
COOH
NO NBoc
COOH
84g
Scheme C4.  Preparation of compound 84g.
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Data for 84g
1H NMR (500 MHz, CDCl3) δ 7.40 (s, 1H), 7.22 (m, 2H), 3.80-3.43 (m, 8H), 2.56 (m,
4H), 2.43 (s, 3H), 1.95 (m, 2H), 1.47 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 177.7, 170.5, 154.9, 142.3, 132.7, 130.7, 129.8, 126.5,
124.2, 94.3, 80.7, 79.7, 48.2, 43.9, 33.0, 28.6, 24.0, 20.9, 19.1
MS (ESI, m/z) 415 (M+H)+
13C NMR of 84g
13C NMR of 84g
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Compound 84h and 84i were prepared from 3-iodonitrobenzene in parallel
(Scheme C5).  Sonogashira coupling with corresponding alkynes gave the phenyl
acetylene intermediate which was reduced with zinc dust and the short linker was
attached by coupling reactions.
I
NO2
OH
Pd(PPh3)4, CuI, 
NEt3, THF NO2
OH
HN
OH
O
O N
O
NBoc
(i) Zn, AcOH, EtOH
(ii) P, EDC, HOBt,
 NMM, CH2Cl2
R
R
R
R = CH3,  84h
R = H,  84i
Scheme C5.  Preparation of compound 84h and 84i.
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Data for 84h
1H NMR (300 MHz, CDCl3) δ 10.00 (s, 1H), 7.79 (d, 1H, J = 1.8 Hz), 7.64 (dd, 1H, J =
7.8 Hz, 1.8 Hz), 7.27 (m, 1H), 7.15 (dd, 1H, J = 6.6 Hz, 1.2 Hz), 4.76 (q, 1H, J = 6.6
Hz), 4.37 (s, 2H), 4.20 (s, 2H), 3.65-3.31 (m, 8H), 1.55 (d, 3H, J = 6.6 Hz), 1.48 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 168.3, 168.2, 154.7, 138.1, 129.1, 127.7, 123.6, 123.1,
120.3, 92.0, 83.5, 80.9, 72.7, 70.1, 58.6, 44.3, 41.9, 28.6, 24.5
MS (ESI, m/z) 446 (M+H)+
1H NMR of 84h
13C NMR of 84h
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Data for 84i
1H NMR (300 MHz, CDCl3) δ 10.06 (s, 1H), 7.80 (d, 1H, J = 1.8 Hz), 7.66 (dd, 1H, J =
7.8 Hz, 1.8 Hz), 7.27 (m, 1H), 7.15 (dd, 1H, J = 6.6 Hz, 1.5 Hz), 4.49 (s, 2H), 4.37 (s,
2H), 4.20 (s, 2H), 3.65-3.30 (m, 8H), 1.48 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 168.2, 154.7, 138.1, 129.2, 127.7, 123.5, 123.1, 120.3,
88.2, 85.1, 81.0, 73.0, 70.3, 51.5, 44.3, 42.0, 28.6
MS (ESI, m/z) 432 (M+H)+
1H NMR of 84i
13C NMR of 84i
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As shown in Scheme C6, Sonogashira coupling of 3-iodonitrobenzene with
alkyne 86 gave the phthalimide protected intermediate, which was reduced with zinc and
linker P was attached.  The following deprotection of phthalimide group with
methylamine and the reprotection with Boc anhydride afforded 84m in good yield.
Pd(PPh3)4, CuI, 
NEt3, THF NO2
O N CO
OC
I
NO2
86
(i) Zn, AcOH, EtOH
(ii) P, EDC, HOBt,
 NMM, CH2Cl2
HN
O
O
O N
O
NBoc
N C
O
OC
(i) NH2Me, EtOH
(ii) (Boc)2O, aq NaOH, 
dioxane/H2O
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O
O
O N
O
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Scheme C6.  Preparation of compound 84m.
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Data for 84m
1H NMR (300 MHz, CDCl3) δ 10.02 (s, 1H), 7.80 (s, 1H), 7.65 (d, 1H, J = 8.4 Hz), 7.28
(t, 1H, J = 8.4 Hz), 7.18 (d, 1H, J = 8.4 Hz), 4.38 (s, 4H), 4.20 (s, 2H), 3.65 (t, 4H, J =
8.4 Hz), 3.66-3.12 (m, 8H), 1.48 (s, 9H), 1.44 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 168.2, 168.0, 156.2, 154.6, 138.1, 129.1, 127.8, 123.3,
123.0, 120.3, 86.5, 85.1, 80.9, 79.5, 73.3, 70.5, 69.4, 59.3, 44.4, 42.0, 40.6, 28.6, 28.5
MS (ESI, m/z) 575 (M+H)+
1H NMR of 84m
13C NMR of 84m
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Preparation of compound 84n started from the commercially available 3-iodo-4-
methyl-nitrobenzene (Scheme C7).  Sonogashira coupling with 5-hexynoic acid gave the
acid intermediate which was protected with t-butyl group.  The resulting nitro compound
was reduced and long linker was attached to produce compound 84n.
NO2
COOH EDC, DMAP,
tBuOH, CH2Cl2
NO2
COOtBu (i) Zn, AcOH, EtOH
(ii) P, EDC, HOBt,
 NMM, CH2Cl2 HN
O
O N
O
NBoc
COOtBu
NO2
I
Pd(PPh3)4, CuI, NEt3, THF
COOH
84n
Scheme C7.  Preparation of compound 84n.
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Data for 84n
1H NMR (300 MHz, CDCl3) δ 9.68 (s, 1H), 7.65 (d, 1H, J = 2.1 Hz), 7.52 (dd, 1H, J =
6.9 Hz, 2.1 Hz), 7.14 (d, 1H, J = 6.9 Hz), 4.37 (s, 2H), 4.19 (s, 2H), 3.65-3.32 (m, 8H),
2.50 (t, 2H, J = 6.9 Hz), 2.42 (t, 2H, J = 7.5 Hz), 2.37 (s, 3H), 1.89 (m, 2H), 1.48 (s, 9H),
1.46 (s, 9H)
13C NMR (300 MHz, CDCl3) δ 172.9, 168.0, 167.7, 154.6, 136.2, 135.5, 129.9, 124.2,
123.2, 119.7, 93.5, 80.9, 80.6, 80.1, 72.9, 70.3, 44.4, 42.0, 34.7, 28.6, 28.4, 24.5, 20.4,
19.2
MS (ESI, m/z) 457 (M+H)+
1H NMR of 84n
13C NMR of 84n
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General Procedure for preparation of Dimers 85.  Boc-protected monomeric
compounds 84a-n (1.0 eq.) were treated with 30% TFA in CH2Cl2, stirred in sealed glass
vials for 4h and solvent was removed. The resulting residue was dissolved in THF (0.1
M) and DTAF (1.0 equiv.) and K2CO3 (4.0 eq.) were added. The suspension was stirred
for 2 h and solvent was removed. The crude product was used for the next step without
further purification.  Analytical HPLC was used to check the crude purity at this stage
and 95% is the cutoff of the satisfactory purity.
Dimerization was carried out in 2 ml glass vials.  Stock solutions of the above crude
material (0.03 M) and deprotected 84 (0.03 M) in DMSO were prepared.  One stock
solution of the crude material (0.5 ml) and one of deprotected 84 (0.5 ml) were added to
a glass vial and followed with solid K2CO3 (ca 20 mg).  The reaction vial was sealed and
sonicated for 15 min. The reaction mixture was agitated at room temperature for 48 h
and DMSO was lyophilized.  Aqueous HCl solution (1%, ca 0.5 ml) was added to the
above solid residue and the suspension was transferred to a 5ml centrifuge tube and
centrifuged for 15 min and the aqueous solution was carefully decanted. The solid
products were dried under vacuum overnight to give the final products 85.  All crude
products were analyzed by analytical HPLC (5-95% B in 30 min) and MALDI-MS.
85
N N
N
NHF*
peptidomimetic
 linker A, B or C
peptidomimetic
 linker A, B or C
85an
1H NMR (300 MHz, DMSO-d6) δ 10.40 (s, 1H), 9.92 (s, 1H), 8.81 (s, 1H), 8.44 (s, 1H),
8.01 (d, 1H, J = 8.4 Hz), 7.21 (d, 1H, J = 1.8 Hz), 7.64 (t, 1H, J = 1.8 Hz), 7.47 (dd, 2H,
J = 8.4 Hz, 1.8 Hz), 7.18 (m, 3H), 6.92 (d, 1H, J = 8.4 Hz), 6.71 (d, 2H, J = 2.4 Hz), 6.63
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(d, 2H, J = 9.0 Hz), 6.57 (dd, 2H, J = 9.0 Hz, 2.4 Hz), 4.58 (q, 1H, J = 6.6 Hz), 4.19-3.48
(m, 22H), 2.39 (t, 2H, J = 7.8 Hz), 2.29 (s, 3H), 1.77 (m, 2H), 1.36 (d, 3H, J = 6.6 Hz)
LRMS (MALDI) calc’d for [M+H]+ 1097, found 1097
Analyticl HPLC purity = 94%, retention time = 19.6 min
1H NMR of 85an
COSY NMR of 85an
356
85fn
1H NMR (300 MHz, DMSO-d6) δ 10.71 (s, 1H), 9.46 (s, 1H), 9.15 (s, 1H), 8.45 (s, 1H),
7.79 (d, 1H, J = 8.4 Hz), 7.67 (m, 2H), 7.46 (m, 2H), 7.20 (t, 1H, J = 8.1 Hz), 7.15 (d,
1H, J = 8.1 Hz), 6.97 (d, 1H, J = 8.4 Hz), 6.90 (d, 2H, J = 8.4 Hz), 6.71 (d, 2H, J = 9.6
Hz), 6.14 (d, 2H, J = 9.6 Hz), 6.05 (s, 2H), 4.41 (s, 1H), 4.34 (s, 2H), 4.14 (s, 2H), 3.76-
3.44 (m, 22H), 2.43 (t, 2H, J = 7.2 Hz), 2.27 (s, 3H), 2.08 (t, 2H, J = 7.2 Hz), 1.70 (m,
2H),
LRMS (MALDI) calc’d for [M+H]+ 1067, found 1067
Analyticl HPLC purity = 90%, retention time = 17.5 min
1H NMR of 85fn
357
COSY NMR of 85fn
85dn
1H NMR (300 MHz, DMSO-d6) δ 10.40 (s, 1H), 10.07 (s, 1H), 8.44 (s, 1H), 7.98 (d,
1H, J = 7.8 Hz), 7.71 (d, 2H, J = 7.2 Hz), 7.46 (m, 2H), 7.24 (m, 4H), 6.75 (d, 2H, J =
2.1 Hz), 6.62 (d, 2H, J = 8.4 Hz), 6.59 (dd, 2H, J = 8.4 Hz, 2.1 Hz), 4.72 (d, 2H, J = 10.2
Hz), 4.49 (s, 2H), 4.18 (s, 2H), 3.92-3.48 (m, 16H), 3.06 (m, 2H), 2.72 (t, 2H, J = 7.2
Hz), 2.45 (t, 2H, J = 7.2 Hz), 2.41 (t, 2H, J = 7.5 Hz), 2.39 (s, 6H), 2.24 (t, 2H, J = 7.5
Hz), 1,93 (d, 2H, J = 10.2 Hz), 1.77 (m, 4H), 1.64 (m, 2H)
LRMS (MALDI) calc’d for [M+H]+ 1151, found 1151
Analyticl HPLC purity = 95%, retention time = 19.1 min
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1H NMR of 85dn
COSY NMR of 85dn (300 MHz)
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85hn
1H NMR (300 MHz, DMSO-d6) δ 10.58 (s, 1H), 10.42 (s, 1H), 9.93 (s, 1H), 8.41 (s,
1H), 8.05 (d, 1H, J = 8.4 Hz), 7.84 (s, 1H), 7.73 (d, 1H, J = 1.8 Hz), 7.60 (d, 1H, J = 6.3
Hz), 7.48 (dd, 1H, J = 8.4 Hz, 2.1 Hz), 7.32 (t, 1H, J = 8.4 Hz), 7.10 (m, 2H), 7.09 (d,
1H, J = 8.1 Hz), 6.73 (d, 2H, J =2.4 Hz), 6.64 (d, 2H, J = 9.0 Hz), 6.57 (dd, 2H, J = 9.0
Hz, 2.4 Hz), 4.58 (q, 1H, J = 6.6 Hz), 4.49 (s, 2H), 4.48 (s, 2H), 4.21 (s, 2H), 4.18 (s,
2H), 3.82-3.48 (m, 16H), 2.43 (t, 2H, J = 7.8 Hz), 2.31 (s, 3H), 1.77 (m, 2H), 1.39 (d,
3H, J = 6.6 Hz)
LRMS (MALDI) calc’d for [M+H]+ 1068, found 1069
Analyticl HPLC purity = 90%, retention time = 18.7 min
1H NMR of 85hn
360
COSY NMR of 85hn
85in
1H NMR (300 MHz, DMSO-d6) δ 10.58 (s, 1H), 10.42 (s, 1H), 10.05 (s, 1H), 8.40 (s,
1H), 8.04 (d, 1H, J = 7.2 Hz), 7.84 (s, 1H), 7.73 (d, 1H, J = 1.8 Hz), 7.60 (d, 1H, J = 9.3
Hz), 7.48 (dd, 1H, J = 8.4 Hz, 1.8 Hz), 7.33 (t, 1H, J = 8.4 Hz), 7.20 (d, 2H), 7.12 (d, 1H,
J = 7.8 Hz), 6.73 (d, 2H, J =2.4 Hz), 6.67 (d, 2H, J = 9.0 Hz), 6.57 (dd, 2H, J = 9.0 Hz,
2.4 Hz), 4.49 (s, 2H), 4.48 (s, 2H), 4.30 (s, 2H), 4.21 (s, 2H), 4.17 (s, 2H), 3.91-3.49 (m,
16H), 2.43 (t, 2H, J = 7.2 Hz), 2.30 (s, 3H), 1.77 (m, 2H)
LRMS (MALDI) calc’d for [M+H]+ 1155, found 1155
Analyticl HPLC purity = 95%, retention time = 17.9 min
361
1H NMR of 85in
COSY NMR of 58in
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85jn
1H NMR (300 MHz, DMSO-d6) δ 10.35 (s, 1H), 10.01 (s, 1H), 8.41(s, 1H), 8.03 (d,
1H), 8.05 (d, 1H, J = 8.4 Hz), 7.72 (s, 1H), 7.65 (d, 2H, J = 8.4 Hz), 7.49 (d, 1H, J = 10.2
Hz), 7.27 (d, 2H, J = 8.4 Hz), 7.20 (d, 2H, J = 8.4 Hz), 6.73 (d, 2H, J = 1.8 Hz), 6.65 (d,
2H, J = 9.0 Hz), 6.58 (dd, 2H, J =9.0 Hz, 1.8 Hz), 4.48 (s, 2H), 4.47 (s, 2H), 4.44 (s, 2H),
4.18 (s, 4H), 3.90-3.40 (m, 16H), 2.43 (t, 2H, J = 7.2 Hz), 2.37 (s, 3H), 1.77 (m, 2H),
LRMS (MALDI) calc’d for [M+H]+ 1131, found 1131
Analyticl HPLC purity = 98%, retention time = 18.2 min
1H NMR of 85jn
363
COSY NMR of 85jn (300 MHz)
85ik
1H NMR (300 MHz, DMSO-d6) δ 10.70 (s, 1H), 10.51 (s, 1H), 9.49 (s, 1H), 8.51 (s,
1H), 7.84 (s, 2H), 7.74 (d, 1H, J = 1.8 Hz), 7.61 (d, 1H, J = 8.1 Hz), 7.46 (dd, 1H, J = 8.4
Hz, 2.1 Hz), 7.41 (s, 1H), 7.33 (t, 1H, J = 8.1 Hz), 7.18 (d, 1H, J = 8.4 Hz), 7.11 (d, 1H, J
=7.8 Hz), 6.98 (d, 2H, J = 8.4 Hz), 6.79 (s, 1H), 6.73 (d, 2H, J = 9.0 Hz), 6.22 (s, 2H),
6.17 (d, 2H, J = 9.0 Hz), 4.47 (s, 4H), 4.31 (s, 2H), 4.21 (s, 2H), 4.18 (s, 2H), 3.89-3.48
(m, 16H), 2.47 (t, 2H, J = 7.2 Hz), 2.31 (s, 3H), 2.24 (t, 2H, J = 7.2 Hz), 1.74 (m. 2H)
LRMS (MALDI) calc’d for [M+H]+ 1054, found 1054
Analyticl HPLC purity = 89%, retention time = 17.7 min
364
1H NMR of 85ik
COSY NMR of 85ik (300 MHz)
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85ai
1H NMR (500 MHz, DMSO-d6) δ 10.58 (s, 1H), 9.78 (s, 1H), 8.73 (s, 1H), 8.45 (s, 1H),
8.01 (d, 1H, J = 7.5 Hz), 7.83 (s, 1H), 7.63 (s,1H), 7.59 (d, 1H, J = 7.0 Hz), 7.45 (d, 1H,
J = 8.5 Hz), 7.33 (t, 1H, J = 7.5 Hz), 7.23 (t, 1H, J = 7.5 Hz), 7.16 (d, 1H, J = 8.0 Hz),
7.12 (d, 1H, J = 7.5 Hz), 6.96 (d, 1H, J = 7.5 Hz), 6.68 (d, 2H, J = 2.0 Hz), 6.62 (d, 2H, J
= 9.0 Hz), 6.58 (dd, 2H, J = 9.0 Hz, 2.0 Hz), 4.56 (q, 1H, J = 6.5 Hz), 4.48 (s, 2H), 4.30
(s, 2H), 4.19 (s, 2H),  3.82-3.48 (m, 16H), 1.37 (d, 3H, J = 6.5 Hz)
 LRMS (MALDI) calc’d for [M+H]+ 1027, found 1027
Analyticl HPLC purity = 99%, retention time = 18.9 min
1H NMR of 85ai
366
COSY NMR of 85ai
85dj
1H NMR (500 MHz, DMSO-d6) δ 10.48 (s, 1H), 9.98 (s, 1H), 9.83 (s, 1H), 8.46 (s, 1H),
8.01 (d, 1H, J = 8.0 Hz), 7.68 (d, 1H, J = 2.0 Hz), 7.60 (d, 2H, J = 8.5 Hz), 7.42 (dd, 1H,
J = 8.5 Hz, 2.0 Hz), 7.32 (s, 1H), 7.25 (d, 2H, J = 8.5 Hz), 7.16 (t, 2H, J = 8.5 Hz), 6.76
(s, 1H), 6.69 (d, 2H, J = 2.0 Hz), 6.63 (d, 2H, J = 9.0 Hz), 6.58 (dd, 2H, J = 9.0 Hz, 2.4
Hz), 4.71 (d, 2H, J = 7.0 Hz), 4.48 (s, 2H), 4.43 (s, 2H), 4.17 (s, 2H), 3.80-3.49 (m, 8H),
2.99 (m, 2H), 2.67 (m, 1H), 2.46 (t, 2H, J = 7.5 Hz), 2.32 (s, 3H), 2.22 (t, 2H, J = 7.5
Hz), 1.89 (d, 2H, J = 10.0 Hz), 1.76 (m, 2H), 1.58 (m, 2H)
LRMS (MALDI) calc’d for [M+H]+ 1057, found 1057
Analyticl HPLC purity = 99%, retention time = 18.5 min
367
1H NMR of 85dj
COSY NMR of 85dj
368
85fj
1H NMR (500 MHz, DMSO-d6) δ 10.39 (s, 1H), 9.89 (s, 1H), 9.83 (s, 1H), 8.91 (s, 1H),
8.45 (s, 1H), 8.08 (s, 2H), 8.01 (d, 1H, J = 8.0 Hz), 7.74 (s, 1H), 7.60 (d, 2H, J = 8.5 Hz),
7.51 (s, 1H, J = 8.0 Hz), 7.28 (m, 3H), 7.22 (d, 1H, J = 9.0 Hz), 7.03 (d, 1H, J = 9.0 Hz),
6.72 (d, 2H, J = 2.4 Hz), 6.59 (d, 2H, J = 9.0 Hz), 6.56 (dd, 2H, J = 9.0 Hz, 2.4 Hz), 4.51
(s, 2H), 4.48 (s, 2H), 4.46 (s, 2H), 3.82-3.49 (m, 20H), 3.03 (m, 2H)
LRMS (MALDI) calc’d for [M+H]+ 1033, found 1033
Analyticl HPLC purity = 90%, retention time = 17.8 min
1H NMR of 85fj
369
COSY NMR of 85fj
85bj
1H NMR (500 MHz, DMSO-d6) δ 10.50 (s, 1H), 9.94 (s, 1H), 8.83 (s, 1H), 8.44 (s, 1H),
8.01 (d, 1H, J = 8.5 Hz), 7.66 (d, 1H, J = 1.5 Hz), 7.60 (d, 2H, J = 9.0 Hz), 7.49 (d, 1H, J
= 9.0 Hz), 7.24 (m, 3H), 7.19 (d, 1H, J = 8.5 Hz), 6.98 (d, 1H, J = 7.5 Hz), 6.72 (d, 2H, J
= 2.0 Hz), 6.58 (d, 2H, J = 9.0 Hz), 6.57 (dd, 2H, J = 9.0 Hz, 2.4 Hz), 4.49 (s, 2H), 4.44
(s, 2H), 4.29 (s, 2H), 4.17 (s, 2H), 3.83-3.57 (m, 16H)
LRMS (MALDI) calc’d for [M+H]+ 989, found 989
Analyticl HPLC purity = 88%, retention time = 18.8 min
370
1H NMR of 85bj
COSY NMR of 85bj
371
85jl
1H NMR (300 MHz, DMSO-d6) δ 10.39 (s, 1H), 9.85 (s, 1H), 8.40 (s, 1H), 8.06 (d, 1H,
J = 8.4 Hz), 7.71 (d, 1H, J = 1.8 Hz), 7.60 (d, 2H, J = 9.0 Hz), 7.43 (m, 3H), 7.25 (d, 2H,
J = 8.4 Hz), 7.18 (d, 1H, J = 4.2 Hz), 7.16 (d, 1H, J = 4.2 Hz), 6.91 (s, 1H), 6.70 (d, 2H, J
= 2.4 Hz), 6.60 (d, 2H, J = 9.0 Hz), 6.56 (dd, 2H, J = 9.0 Hz, 2.4 Hz), 4.49 (s, 2H), 4.48
(s, 2H), 4.44 (s, 2H), 4.19 (s, 2H), 4.17 (s, 2H), 3.81-3.48 (m, 16H), 2.65 (t, 2H, J = 7.5
Hz), 2.37 (t, 3H, J = 7.5 Hz), 2.29 (s, 3H)
LRMS (MALDI) calc’d for [M+H]+ 1116, found 1116
Analyticl HPLC purity = 85%, retention time = 18.7 min
1H NMR of 85jl
372
COSY NMR of 85jl
85dl
1H NMR (300 MHz, DMSO-d6) δ 10.87 (s, 1H), 9.98 (s, 1H), 9.83 (s, 1H), 8.45 (s, 1H),
7.99 (d, 1H, J = 8.4 Hz), 7.68 (dd, 1H, J = 8.4 Hz, 1.8 Hz), 7.39 (m, 4H), 7.17 (m, 4H),
6.68 (d, 2H, J = 2.4 Hz), 6.61 (d, 2H, J = 9.0 Hz), 6.58 (dd, 2H, J = 9.0 Hz, 2.4 Hz), 4.69
(d, 2H, J = 12.0 Hz), 4.46 (s, 2H), 4.18 (s, 2H), 3.79-3.48 (m, 8H), 2.93 (m, 3H), 2.51 (t,
2H, J = 7.5 Hz), 2.48 (t, 3H, J = 7.5 Hz), 2.38 (t, 2H, J = 7.5 Hz), 2.36 (s, 6H), 2.23 (t,
2H, J = 7.5 Hz), 1.84 (m, 2H), 1.72 (m, 2H) 1.58 (m,2H)
LRMS (MALDI) calc’d for [M+H]+ 1136, found 1136
Analyticl HPLC purity = 85%, retention time = 18.5 min
373
1H NMR of 85dl
COSY NMR of 85dl (300 MHz)
374
85cd
1H NMR (500 MHz, DMSO-d6) δ 9.99 (s, 1H), 9.97 (s, 1H), 9.49 (s, 1H), 7.96 (dd, 1H,
J = 8.5 Hz, 2.0 Hz), 7.68 (d, 1H, J = 2.0 Hz), 7.63 (d, 1H, J = 8.5 Hz), 7.56 (d, 1H, J =
8.5 Hz), 7.41 (dd, 1H, J = 8.5 Hz, 2.0 Hz), 7.35 (d, 1H, J = 8.5 Hz), 7.21 (d, 1H, J = 8.5
Hz), 7.19 (d, 1H, J = 8.5 Hz), 7.15 (d, 1H, J = 8.5 Hz), 6.69 (d, 2H, J = 2.0 Hz), 6.63 (d,
2H, J = 9.0 Hz), 6.56 (dd, 2H, J = 9.0 Hz, 2.0 Hz), 4.59 (m, 4H), 4.42 (s, 2H), 3.02 (m,
4H), 2.69 (m, 2H), 2.46 (t, 2H, J = 7.0 Hz), 2.29 (s, 3H), 2.22 (t, 2H, J = 7.0 Hz), 1.91
(m, 4H), 1.75 (m, 2H), 1.62 (m, 4H)
LRMS (MALDI) calc’d for [M+H]+ 970, found 970
Analyticl HPLC purity = 99%, retention time = 17.8 min
1H NMR of 85cd
375
COSY NMR of 85cd
85ce
1H NMR (500 MHz, DMSO-d6) δ 9.90 (s, 1H), 9.88 (s, 1H), 9.65 (s, 1H), 8.54 (s, 1H),
7.98 (d, 1H, J = 8.5 Hz), 7.66 (s, 1H), 7.54 (d, 2H, J = 8.5 Hz), 7.40 (s, 1H), 7.38 (s, 1H),
7.22 (d, 2H, J = 8.5 Hz), 7.15 (m, 2H), 6.88 (s, 1H), 6.66 (d, 2H, J = 2.0 Hz), 6.64 (d,
2H, J = 9.0 Hz), 6.56 (dd, 2H, J = 9.0 Hz, 2.0 Hz), 4.74 (d, 4H, J = 11.5 Hz), 4.42 (s,
2H), 2.97 (m, 4H), 2.63 (m, 4H), 2.34 (t, 2H, J = 7.5 Hz), 2.29 (s, 3H), 1.89 (m, 4H),
1.60 (m, 2H)
LRMS (MALDI) calc’d for [M+H]+ 956, found 956
Analyticl HPLC purity = 94%, retention time = 17.4 min
376
1H NMR of 85ce
COSY NMR of 85ce
377
85hl
1H NMR (300 MHz, DMSO-d6) δ 10.55 (s, 1H), 10.39 (s, 1H), 9.89 (s, 1H), 8.40 (s,
1H), 8.04 (d, 1H, J = 9.0 Hz), 7.83 (s, 1H), 7.71 (d, 1H, J = 1.8 Hz), 7.59 (d, 1H, J = 8.4
Hz), 7.46 9dd, 2H, J = 8.4 Hz, 1.8 Hz), 7.32 (t, 1H, J = 7.8 Hz), 7.17 (dd, 2H, J = 8.4 Hz,
3.0 Hz), 7.10 (d, 1H, J = 7.8 Hz), 6.91 (s, 1H), 6.72 (d, 2H, J = 2.4 Hz), 6.64 (d, 2H, J =
9.0 Hz), 6.58 (dd, 2H, J = 9.0 Hz, 2.4 Hz), 4.58 (q, 1H, J = 6.6 Hz), 4.48 (s, 2H), 4.46 (s,
2H), 4.19 (s, 2H), 4.18 (s, 2H), 3.81-3.48 (m, 16H), 2.67 (t, 2H, J = 7.5 Hz), 2.37 (t, 2H,
J = 7.5 Hz), 2.29 (s, 3H), 1.39 (d, 3H, J = 6.6 Hz)
LRMS (MALDI) calc’d for [M+H]+ 1154, found 1154
Analyticl HPLC purity = 89%, retention time = 18.2 min
1H NMR of 85hl
378
COSY NMR of 85hl (300 MHz)
379
APPENDIX D
EXPERIMENTAL ON CHAPTER V
General Methods.  All chemicals were obtained from commercial suppliers and used
without further purification. Analytical HPLC analyses were carried out on 25 x 0.46 cm
C-18 column using gradient conditions (50 – 95% B).  The eluents used were: solvent A
(H2O with 0.1% TFA) and solvent B (CH3CN with 0.1% TFA).  The flow rate used was
1.0 ml/min.  NMR spectra were recorded at 500 MHz if otherwise indicated.  NMR
chemical shifts were expressed in ppm relative to internal solvent peaks, and coupling
constants were measured in Hz.
Optimization of Bistriazole Formation.
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380
a. Base Screening.  The alkyne (1.0 mmol, 1.0 equiv) was added to a mixture of azide
(1.0 equiv) in acetonitrile (1.5 ml) and base solution (1.5 ml).  Copper sulfate (1.0 M, 0.1
ml) was added to the above suspension followed by copper powder (64.0 mg, 1.0 equiv).
The resulting suspension was stirred at 25 oC for 18 h and 10 µl of the solution was
taken and dissolved in 1.0 ml of methanol.  Analytical HPLC (sedex) data with different
bases is shown in Table D1.
Table D1.  Product distribution with different bases.
product distribution
entry base concentration(mol/l) 88a
(%) 89 (%) 90 (%)
1 NaHCO3 0.2 0 100 0
2 NaHCO3 1.5 12 88 0
3 K2CO3 0.5 92 3 4
4 K2CO3 1.0 95 2 3
5 K2CO3 1.5 95 2 3
6 K2CO3 2.0 93 3 4
7 K2CO3 3.0 86 5 7
8 K2CO3 4.0 84 2 13
9 K2CO3 5.0 60 11 28
10 Li2CO3 Sat. 42 58 0
11 Na2CO3 2.0 95 3 2
12 Cs2CO3 4.0 85 1 13
13 (NH4)2CO3 2.0 0 100 0
14 LiOH 1.5 33 57 10
15 KOH 5.0 50 0 50
16 K3PO4 4.0 56 38 6
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b. Atmosphere Effect.  The alkyne (1.0 mmol, 1.0 equiv) was added to a mixture of
azide (1.0 equiv) in acetonitrile (1.5 ml) and base solution or water (1.5 ml).  Copper
sulfate (1.0 M, 0.1 ml) was added to the above suspension followed by copper powder
(64.0 mg, 0.1 equiv).  The resulting suspension was stirred at 25 oC for 18 h and 10 µl of
the solution was taken and dissolved in 1.0 ml of methanol.  Analytical HPLC (sedex)
data is showed in Table S2.
Table D2.  Product distribution under different atmosphere.
product distribution
entry base atmosphere
88a 89 90
1 1.5 M K2CO3 air 95 2 3
2 1.5 M K2CO3 N2 17 82 1
3 no base air 3 97 0
4 no base N2 0 100 0
5* no base O2 0 100 0
* Large amount of starting material was left and only small amount of 89 was formed
382
General Preparation For Syntheses of Compound 88a-k.  The alkyne (1.0 mmol, 1.0
equiv) was added to a mixture of azide (1.0 equiv) in acetonitrile (1.5 ml) and aqueous
Na2CO3 solution (2.0 M, 1.5 ml).  Copper sulfate (1.0 M, 0.1 ml) was added to the above
suspension followed by copper powder (64.0 mg, 1.0 equiv).  The resulting suspension
was stirred at 25 oC for 18 h and passed through a pad of Celite.  The filtrate was
extracted with ethyl acetate and brine and the organic layer was dried and concentrated.
Flash chromatography afforded the bistriazole product 88a-k.
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Bistriazole 88a was prepared from benzyl azide and 2-bromo-4-nitro-1-(prop-2-
ynyloxy)benzene.  Flash chromatography (hexane/EtOAc = 3:2) afforded 88a as a white
solid (0.35 g, 87 %).
1H NMR (CDCl3) δ 8.32 (m, 2H), 8.11 (m, 2H), 7.32 (m, 2H), 7.26 (m, 4H), 6.92 (m,
6H), 5.16 (d, 2H, J = 15.0 Hz), 4.85 (d, 2H, J = 12.0 Hz), 4.52 (d, 2H, J = 15.0 Hz), 4.40
(d, 2H, J = 12.0 Hz)
13C NMR (CDCl3) δ 159.1, 144.5, 142.2, 133.8, 129.5, 129.33, 129.28, 128.4, 124.9,
122.5, 112.3, 111.7, 62.8, 53.3
MS (ESI, m/z): (M+H)+ calcd for C32H25Br2N8O6 777.0243, found 777.2166
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Bistriazole 88b was prepared from tert-butyl 4-(2-azidoacetyl)piperazine-1-carboxylate
and 2-bromo-4-nitro-1-(prop-2-ynyloxy)benzene. Flash chromatography (hexane/EtOAc
= 3:2) afforded 88b as a white solid (0.37 g, 72 %).
1H NMR (CDCl3) δ 8,34 (d, 2H, J = 3.0 Hz), 78.20 (dd, 2H, J = 9.5 Hz, 3.0 Hz), 7.25
(d, 2H, J = 9.5 Hz), 5.51 (d, 2H, J = 15.0 Hz), 5.41 (d, 2H, J = 12.0 Hz), 5.19 (d, 2H, J =
12.0 Hz), 5.03 (d, 2H, J = 15.0 Hz), 3.46-3.39 (m, 16H), 1.47 (s, 18H)
13C NMR (CDCl3) δ 163.8, 159.3, 154.5, 144.2, 142.2, 129.2, 125.1, 124.5, 112.9,
111.6, 81.0, 62.8, 50.3, 45.3, 42.4, 28.6
MS (MALDI, m/z): (M+Na)+ calcd for C40H48Br2N12NaO12 1071.1759, found
1070.8820
1H NMR of 88b
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Bistriazole 88c was prepared from tert-butyl 2-azidoacetate and (prop-2-
ynyloxy)benzene.  Flash chromatography (hexane/EtOAc = 9:1) afforded 88c as a clear
oil (0.13 g, 47 %).
1H NMR (CDCl3) δ 7.22 (t, 4H, J = 8.0 Hz), 6.94 (t, 2H, J = 7.5 Hz), 6.75 (d, 4H, J =
8.0 Hz), 5.12 (d, 2H, J = 12.0 Hz), 5.05 (d, 2H, J = 17.5 Hz), 4.92 (d, 2H, J = 17.5 Hz),
4.78 (d, 2H, J = 12.0 Hz), 1.40 (s, 18H)
13C NMR (CDCl3) δ 165.3, 157.5, 129.5, 121.5, 114.6, 84.1, 60.8, 50.3, 27.8 (two C not
observed as distinct peaks)
MS (ESI, m/z): (M+H)+ calcd for C30H37N6O6 577.2775, found 577.2754
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Bistriazole 88d was prepared from benzyl azide and phenyl propargyl ether.  Flash
chromatography (hexane/EtOAc = 9:1) afforded 88d as a white solid (0.18 g, 69 %).
1H NMR (CDCl3) δ 7.32-7.18 (m, 10H), 6.95-6.70 (m, 6H), 6.64-6.62 (m, 4H), 4.98 (d,
2H, J = 14.5 Hz), 4.58-4.55 (m, 4H), 4.35 (d, 2H, J = 12.5 Hz)
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13C NMR (CDCl3) δ 157.4, 145.8, 133.7, 129.4, 129.0, 128.8, 128.0, 122.1, 121.3,
114.3, 60.7, 52.5
MS (ESI, m/z): (M+H)+ calcd for C32H29N6O2 529.2352, found 529.2317.
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Bistriazole 88e was prepared from benzyl azide and phenyl acetylene.  Flash
chromatography (hexane/EtOAc = 4:1) afforded 88e as a white solid (0.08 g, 37 %).
1H NMR (CDCl3) δ 7.45 (m, 4H), 7.28-7.20 (m, 6H), 7.14 (m, 2H), 7.09 (m, 4H), 6.81
(d, 4H, J = 8.0 Hz), 4.70 (d, 2H, J = 14.5 Hz), 4.64 (d, 2H, J = 14.5 Hz)
13C NMR (CDCl3) δ 147.8, 132.9, 129.2, 128.9, 128.8, 128.74, 128.68, 128.1, 125.8,
119.8, 52.6
MS (ESI, m/z): (M+H)+ calcd for C30H25N6 469.2141, found 469.1979
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Bistriazole 88f was prepared from tert-butyl 2-azidoacetate and phenyl acetylene.  Flash
chromatography (hexane/EtOAc = 9:1) afforded 88f as a clear oil (0.06 g, 23 %).
1H NMR (CDCl3) δ 7.63-7.61 (m, 4H), 7.37-7.33 (m, 6H), 4.87 (d, 2H, J = 18.0 Hz),
4.50 (d, 2H, J = 18.0 Hz), 1.28 (s, 18H)
13C NMR (CDCl3) δ 164.5, 147.2, 129.2, 129.1, 128.8, 126.1, 120.5, 83.8, 49.8, 27.7;
MS (ESI, m/z): (M+H)+ calcd for C28H33N6O4 517.2563, found 517.2067
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Bistriazole 88g was prepared from benzyl azide and 1-butynol.  Flash chromatography
(CH2Cl2/MeOH = 19:1) afforded 88g as a white solid (0.08 g, 34 %).
1H NMR (CD3OD) δ 7.50 (s, 2H), 7.35-7.29 (m, 6H), 6.96-6.92 (m, 4H), 5.18 (d, 2H, J
= 15.0 Hz), 4.87 (d, 2H, J = 15.0 Hz), 3.62 (m, 4H), 2.28 (t, 1H, J = 6.5 Hz), 2.25 (t, 1H,
J = 6.5 Hz), 2.17 (t, 1H, J = 6.5 Hz), 2.14 (t, 1H, J = 6.5 Hz)
13C NMR (CDCl3) δ 148.0, 134.6, 129.0, 128.8, 128.0, 121.6, 60.1, 52.5, 27.8
MS (APCI, m/z) 405 (M+H)+
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Bistriazole 88h was prepared from benzyl azide and trimethylsilyl-acetylene.  Flash
chromatography (hexane/EtOAc = 4:1) afforded 88h as a white solid (0.06 g, 25 %).
1H NMR (CDCl3) δ 7.50 (s, 2H), 7.31-7.29 (m, 6H), 6.93 (m, 4H), 5.10 (s, 4H)
13C NMR (CDCl3) δ 135.9, 134.1, 129.1, 128.8, 127.3, 123.6, 52.3
MS (APCI, m/z): (M+H)+ calcd for C18H17N6 317.1515, found 317.1200
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Bistriazole 88i was prepared from benzyl azide and trimethyl(thiophen-3-
ylethynyl)silane.  Flash chromatography (hexane/EtOAc = 9:1) afforded 88i as a white
solid (0.09 g, 38 %).
1H NMR (CDCl3) δ 7.19-7.11 (m, 10H), 7.04 (m, 2H), 6.86 (m, 4H), 4.78 (d, 2H, J =
15.0 Hz), 4.65 (d, 2H, J = 15.0 Hz)
13C NMR (CDCl3) δ 145.2, 133.2, 130.3, 129.10, 129.05, 128.5, 126.8, 125.5, 122.7,
119.2, 53.1
MS (ESI, m/z): (M+H)+ calcd for C26H21N6S2 481.1269, found 481.1297
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With the same condition that prepared the above compounds, (S)-tert-butyl 4-(2-
azidopropanoyl)piperazine-1-carboxylate (1.0 mmol) and phenyl propargyl ether (1.0
mmol) gave two diastereomers in a ratio of 3:2 as measured by HPLC analysis of the
crude product mixture.
Flash chromatography (hexane/EtOAc = 1:1) afforded bistriazole 88j (major
diastereomer) as a colorless oil (0.18 g, 42%).  [α]D25 = + 41.1 (c = 1.0, CH2Cl2).
1H NMR (CDCl3) δ 7.17 (m, 4H), 6.90 (m, 2H), 6.74 (d, 4H, J = 8.0 Hz), 6.16 (bs, 2H),
4.85 (s, 4H), 3.66-3.10 (m, 16H), 1.65 (d, 6H, J = 5.5 Hz), 1.44 (s, 18H)
13C NMR (CDCl3) δ 167.8, 157.8, 154.1, 145.5, 129.3, 122.9, 121.2, 114.5, 80.4, 60.5,
56.4, 45.4, 42.1, 28.2, 15.6
MS (ESI, m/z): (M+H)+ calcd for C42H57N10O8 829.4361, found 829.4454
1H NMR of 88j
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Flash chromatography (hexane/EtOAc = 1:1) afforded bistriazole 88j’ (minor
diastereomer) as a colorless oil (0.06 g, 14%).  [α]D25 = + 76.6 (c = 1.0, CH2Cl2).
1H NMR (CDCl3) δ 7.30 (m, 4H), 7.01 (m, 2H), 6.92 (m, 4H), 5.41 (q, 2H, J = 7.0 Hz),
5.26 (d, 2H, J = 13.0 Hz), 4.80 (d, 2H, J = 13.0 Hz), 3.47-2.91 (m, 16H), 1.84 (d, 6H, J =
7.0 Hz), 1.45 (s, 18H)
13C NMR (CDCl3) δ 166.9, 157.8, 154.1, 143.5, 129.3, 122.9, 121.2, 114.5, 80.4, 60.5,
54.4, 45.4, 42.1, 28.2, 15.6
MS (ESI, m/z): (M+Na)+ calcd for C42H56N10NaO8 851.4180, found 851.4316
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Bistriazoles 88k and 88k’ were prepared from 2-ethynylpyridine (1.0 mmol) and (R)-(1-
azidoethyl)benzene (1.0 mmol).
Diasteromeric ratio of 88k to 88k’ is 2:1 from the 1H NMR of the crude material.
Bistriazole 88k was isolated by column chromatography (40 % ethyl acetate in hexanes)
in 8 % yield.
1H NMR (CDCl3) δ 8.38 (d, 2H, J = 4.5 Hz), 8.30 (d, 2H, J = 8.0 Hz), 7.76 (m, 2H),
7.16 (m, 2H), 7.01 (m, 2H), 6.89 (m, 4H), 6.90 (m, 4H), 6.83 (m, 4H), 5.18 (q, 2H, J =
7.0 Hz), 1.83 (d, 6H, J = 7.0 Hz)
13C NMR (CDCl3) δ 150.2, 149.4, 145.3, 139.5, 136.6, 128.5, 127.7, 125.9, 123.2,
122.9, 121.2, 59.4, 23.2
MS (ESI, m/z): (M+H)+ calcd for C30H27N8 499.24, found 499.13
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Bistriazole 88k’ was isolated by column chromatography (40 % ethyl acetate in
hexanes) in 16 % yield.
1H NMR (CDCl3) δ 7.91 (m, 2H), 7.73 (d, 2H, J = 7.5 Hz), 7.42 (m, 2H), 7.04 (m, 10
H), 6.87 (m, 2H), 5.12 (q, 2H, J = 7.0 Hz), 1.85 (d, 7.0 Hz)
13C NMR (CDCl3) δ 149.22, 149.19, 147.4, 138.5, 135.7, 128.3, 128.0, 126.8, 122.8,
122.3, 120.6, 59.8, 22.1
MS (ESI, m/z): (M+H)+ calcd for C30H27N8 499.24, found 499.14
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Bistriazoles 88l were prepared from (R)-tert-butyl 4-(2-azidopropanoyl)piperazine-1-
carboxylate (1.0 mmol) and phenyl propargyl ether (1.0 mmol).  The ratio of the major
and minor diastereomers was 3:2 as measured by HPLC analysis of the crude product
mixture.
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Flash chromatography (hexane/EtOAc = 1:1) afforded bistriazole 88l (major
diastereomer) as a colorless oil (0.22 g, 54%).  [α]D25 = - 43.7 (c = 1.0, CH2Cl2).
1H NMR (CDCl3) δ 7.18 (m, 4H), 6.90 (t, 2H, J = 7.0 Hz), 6.75 (d, 4H, J = 8.0 Hz), 6.16
(bs, 2H), 4.86 (s, 4H), 3.67-3.11 (m, 16H), 1.65 (d, 6H, J = 6.0 Hz), 1.45 (s, 18H)
13C NMR (CDCl3) δ 167.9, 157.8, 154.1, 145.5, 129.4, 123.0, 121.2, 114.5, 80.4, 60.5,
56.4, 45.4, 42.1, 28.2, 15.6
MS (ESI, m/z): (M+H)+ calcd for C42H57N10O8 829.4361, found 829.4391
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Flash chromatography (hexane/EtOAc = 1:1) afforded bistriazole 88l’ (minor
diastereomer) as a colorless oil (0.10 g, 24%).  [α]D25 = - 74.4 (c = 0.3, CH2Cl2).
1H NMR (CDCl3) δ 7.28 (m, 4H), 7.00 (t, 2H, J = 7.0 Hz), 6.91 (m, 4H), 5.41 (q, 2H, J
= 7.0 Hz), 5.25 (d, 2H, J = 13.0 Hz), 4.82 (d, 2H, J = 13.0 Hz), 3.46-2.90 (m, 16H), 1.83
(d, 6H, J = 7.0 Hz), 1.43 (s, 18H)
13C NMR (CDCl3) δ 166.9, 157.4, 154.2, 143.1, 129.9, 122.9, 121.9, 114.4, 80.2, 61.3,
54.8, 45.1, 42.2, 28.3, 16.6
MS (ESI, m/z): (M+Na)+ calcd for C42H56N10NaO8 851.4180, found 851.4269
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Variable Temperature NMR Experiments for Compounds 88e and 88g.  To study
the rotation barrier around the C-C bond that connects the two triazole rings, the variable
temperature NMR experiments were conducted on compounds 17e and 17g in DMSO-d6
at the concentration of 5mg/ml.  The chemical shift difference between the Ha and Hb
was calculated and plotted in Figure D1.
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Figure D1.  Chemical shift difference between Ha and Hb.
N
N
N
N N
N Ph
Ph
R
R
88e  R = Ph 
88g  R = CH2CH2OH
Ha Hb
410
CD Experiment for Compounds 88j and 88l.  The CD spectra were recorded at 25 oC.
For these experiments diastereomers were dissolved in 5:1 methanol/water (v:v) (c = 0.2
mg/ml, 0.1 cm path length).
-120
-80
-40
0
40
80
120
195 205 215 225 235 245 255 265 275 285
Wavelength (nm)
M
ol
ar
 E
lli
pt
ic
ity
 (1
06
 d
eg
.c
m
2 .d
m
ol
-1
)
88j (major diastereomer)
88l (minor diastereomer)
88l (major diastereomer)
88j (minor diastereomer)
Figure D2.  CD spectra of compounds 88j and 88l in 5:1 methanol/water at 0.2 mg/ml.
411
VITA
Name: Yu Li Angell
Permanent Address: Pinyun #3, Yiling Street
                                                            YiChang, Hubei, China
Education: 2001-present Ph.D. Chemistry
Texas A&M University
College Station, TX 77843
Advisor: Dr. Kevin Burgess
1996-2001 B. S. Chemistry
Wuhan University
Wuhan
China
Advisor: Dr. Lingzhi Meng
1999-2000 Exchange Student
Osaka University
Osaka
Japan
Advisor: Dr. Takashi Norisuye
